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In 1959 Rosenkrantz et al., first described the effect of the indoleamine serotonin on
aldosterone secretion from the adrenal gland. To date numerous studies have reported
this steroidogenic effect, describing the second messenger system utilised and in some
species the receptor type involved. However the full physiological and
pathophysiological role of serotonin in the control of mineralocorticoid secretion still
remains to be elucidated.
Classically serotonin has always been thought to be the major indoleamine involved in
the modulation of aldosterone secretion from the zona glomerulosa, a fact that has not
been proven. To resolve this, numerous indoleamines, both naturally occurring and
synthetic congeners, were studied in isolated rat zona glomerulosa cells for their ability
to induce aldosterone secretion, as compared to serotonin. Of the compounds tested,
5-methoxytryptamine, tryptamine, N-methyltryptamine, 5-methyltryptamine, 6-
methoxytryptamine and 5-hydroxytryptophan (5-HTP) stimulated, to various degrees
aldosterone secretion, from the zona glomerulosa. Of those compounds tested that
produced comparable stimulation of aldosterone as that produced by serotonin, cAMP
output was also investigated and it was observed that all compounds stimulated cAMP
output also, to varying degrees. The study allowed specific structural requirements,
required for stimulation of aldosterone secretion, to be characterised, namely that the 5-
hydroxyl grouping was not required for full agonist activity, but ring substitutions at
other positions compromise agonist activity. The basicity of the terminal amine group
is important also in receptor binding. This study will aid in the search for specific
agonists and antagonists, required for the research into the serotonin receptor present
within the zona glomerulosa.
Unlike the cardiovascular and CNS, where specific receptors have been identified and
categorised, specific receptors within the rat zona glomerulosa for serotonin have not
yet been fully characterised. The second study of this thesis aimed at characterising the
receptors found within rat zona glomerulosa by utilising an array of serotonin agonists
and antagonists. The antagonists ketanserin and mesulergine were found to inhibit
serotonin induced aldosterone secretion, and the agonists 5-methoxytryptamine and 5-
carboxamidotryptamine, produced identical stimulation of aldosterone from rat zona
glomerulosa, as that produced with serotonin. This effect was also found to be affected
by sodium status. These results taken together with previous studies and preliminary
studies with a 5-HT7 probe in sections of rat adrenal gland would suggest the presence
of a 5-HT7 receptor in rat zona glomerulosa, although the presence of other serotonin
receptors can not be ruled out.
For serotonin to have a physiological role in aldosterone secretion, a local source of
serotonin would be required. In consideration of this the role of the enzyme L-
aromatic amino acid decarboxylase (L-AAAD) in the local production of serotonin and
dopamine was investigated in rat adrenal zona glomerulosa, in animals maintained on
varying sodium diets. The presence of L-AAAD was located, via
immunohistochemistry, in the zona glomerulosa, zona fasciculata and the medulla.
Conversion of 5-HTP to serotonin and L-DOPA to dopamine was observed in capsular
and medullary tissue preparations, and this was inhibited by carbidopa. 5-HTP
significantly stimulated aldosterone secretion, from capsular tissue. This effect was
more apparent in animals on a low salt diet and less apparent in high salt diet animals as
compared to animals maintained on a normal salt diet. The opposite was true for
studies with L-DOPA. The effect of sodium status would suggest that the enzyme is
regulated by salt intake. No significant effect of L-DOPA and of 5-HTP on
corticosterone secretion from tissue preparations was observed. The results from this
study provide evidence for a role for L-AAAD in converting circulating L-DOPA and
5-HTP to dopamine and serotonin, to either inhibit or stimulate aldosterone secretion
from the rat zona glomerulosa.
The role of the serotonin transporter was studied within the rat adrenal gland. The
transporter molecule was visualised throughout the rat adrenal medulla via
immunohistochemistry. The serotonin uptake inhibitors citalopram and
desmethylimipramine (DMI) were incubated with or without serotonin in isolated rat
zona glomerulosa cells and the resulting aldosterone secretion was measured. Results
varied and this was thought to be due to the harsh collagenase digestion process
destroying the transporter, and so whole capsular tissue was studied in a superfusion
system and aldosterone secretion measured. In all cases both reuptake inhibitors
increased the aldosterone output from capsular tissue. The drug of abuse
methylenedioxymethamphetamine (MDMA; 'Ecstasy') was also used in this system,
and this compound also caused an increase in aldosterone secretion. In Vivo studies
with MDMA produced interesting results with an increase in plasma aldosterone and
PRA. From this study evidence has been found for the existence of the serotonin
transporter molecule within the rat adrenal gland. MDMA may induce a rise in
aldosterone concentration within the plasma by a direct action on the serotonin
transporter within the adrenal gland.
This thesis has provided strong evidence for a role of serotonin in the control of
aldosterone secretion in the rat. Serotonin can be produced locally within the adrenal
cortex and induce aldosterone secretion, and this action may be switched on in cases of
low sodium status. Further studies are required to fully characterise the serotonin
receptor, to elucidate a role for the transporter within the gland and to understand more
fully the importance of serotonin and indeed dopamine, in the physiology and
pathophysiology of the adrenal cortex.
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This chapter will focus on the adrenal gland, the zonation and interactions between
the various zones of the gland, and in particular the steroid hormone aldosterone
will be discussed, focussing on the biosynthesis and factors controlling the secretion
of this hormone. Though various factors have been reported to affect aldosterone
secretion, only those factors whose physiological roles are established or are
relevant to the studies carried out will be discussed.
1.2. Embryology. Development and Blood Supply of the Adrenal Gland.
The adrenal glands lie in the abdominal cavity, close to the upper pole of the
kidneys, surrounded by adipose tissue and by renal fasciae to which they firmly
adhere. The glands themselves are divided into two functionally distinct areas, the
outer steroid-synthesising cortex and the inner catecholamine-producing medulla,
which are of different embryological origin. In the developing adrenal gland the
adrenocortical cells arise from the mesoderm, in particular from the columnar
epithelial cells lining the coelom, chromaffin cells arise from the paraganglion cells
of the neural crest complex which invade the presumptive cortical cell mass and
eventually become surrounded by the mesodermal cells to form the adrenal medulla.
The ectodermal cells of the adrenal medulla then differentiate to form either mature
ganglionic cells or the chromaffin cells that secrete catecholamines.
The blood supply to the adrenal glands originates from small arteries branching
from the aorta (at the level of the superior mesenteric artery) and from the inferior
phrenic and renal arteries (Dobbie et al., 1968). These three main vessels break up
as they approach the gland into arteriae comitantes and penetrate the capsule of the
gland to form an extensive subcapsular arterial plexus. In the rat, the subcapsular
arterioles have muscular walls suggesting that they may be a site for the control of
blood flow through the gland. Effluent blood is collected into a single central vein
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emerging from the anterior surface of the gland. This vein is engulfed by a cuff of
cortical tissue, which exists at the hilus of the suprarenal vein. Only in the head
region of the gland do small muscular venous radicals lie free in the medullary
tissue, unencompassed by this cortical sleeve. In the human glands, this vein
discharges either directly into the superior vena cava, as in the right gland, or joins
the inferior phrenic vein, before entering the renal vein, as in the left gland. In the
rat, the central vein is very thin as it traverses the gland, and becomes thicker as it is
exteriorised.
Inside the gland arterial blood flows through capillary loops which surround the
cortical cells of the zona glomerulosa (ZG). These capillaries widen and descend
through the ZG to the zona fasciculata (ZF), and once they reach the zona
reticularis (ZR) they form the plexus reticularis. The blood now either drains from
this plexus into the sinusoides of the alar raphe, or, in regions containing medullary
tissue, the blood flows in to the medulla itself. This cortico-medullary portal
system is thought to be the sole source of medullary blood in the rat and bovine
adrenal (Vinson et a/., 1985), although the human medulla is also supplied directly
by the arteriea medullae. The deeper cortical layers thus have no direct arterial
supply, but receive blood that has already perfused the outer cell layers. This
centripetal arrangement is extremely well preserved between species, and although
the size of the gland may alter from species to species, the thickness of the cortex
remains the same due to this centripetal arrangement. In order to maintain
adequate perfusion of the deeper cortical layers in larger mammals, adrenal bulk is
increased by lateral expansion and convolution, rather than increases in cortical
width, as an increase in cortical width would cause the venous end of the capillary
bed to be too far from the arterial supply. The centripetal blood supply has
important implications in the gradient theory of adrenocortical zonation, and the
vasculature itself plays an important role in cortico-medullary interactions.
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1.3. Adrenocortical Zonation.
In 1858 Harley first described the different zones of the adrenal cortex, describing
the three concentric shells, which were then named in 1866 by Arnold as the ZG
(glomus-ball), the ZF (fascis-bundle) and the ZR (rete-net). Originally these
divisions were made on the basis of morphological differences between the cells
within each shell, but it is now evident that the adrenocortical zones are functionally
distinct. Different enzymes in each zone lead to differences in the steroids secreted
by them. Thus the hormone aldosterone is secreted exclusively by the ZG, whereas
the inner ZFR produces mainly Cortisol (in primates) and corticosterone (in
rodents). Androgens are secreted by the ZR and the inner zones of the foetal
adrenal. Figure 1.1. depicts a diagrammatic representation of the adrenal cortex.
The outermost zone, the ZG, lies just below the connective tissue capsule and
forms the periphery of the cortex. This zone accounts for ~ 15% of the total mass
of the cortex and comprises relatively small cells arranged in rounded ball-like
clusters with a high nuclear/cytoplasmic ratio. The zone is characterised by
transverse foldings of the cristae of the mitochondria. The cytoplasm is relatively
low in lipid. The intermediate ZF comprises the bulk of the cortex, ~ 70%, and
consists of relatively large cells arranged in radially disposed columnar layers
extending from the ZG. These cells are characterised by their low
nuclear/cytoplasm ratio, lipid-rich cytoplasm and small ovoid mitochondria with
tubulovesicular cristae. They are described as "clear cells", and are separated by
venous spaces, reticular fibres and sinusoidal capillaries. The rest of the cortex, ~
20%, comprises the innermost zone, the ZR, lying adjacent to the medulla. The
cells in this zone are of intermediate size, often referred to as "compact cells", and
exhibit a network arrangement. They have an eosinophilic cytoplasm with few
mitochondria and lipid droplets. The cells are easily characterised by their
pigmentation due to the presence of lipofuscin granules. The cortex surrounds the
adrenal medulla which is composed of columnar shaped chromaffin cells,
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Figure 1.1. Diagrammatic representation of adrenal gland histology ( From
Gorbman, A. & Bern, H.A. (1962) A textbook of comparative endocrinology,
Wiley, New York, London).
individually innervated by cholinergic preganglionic neurones and full of membrane
bound electron dense granules that are thought to be the main storage sites of the
catecholamines noradrenaline and adrenaline.
The exact cellular arrangement of the cortex varies from species to species. In the
human adrenal gland the ZG and the ZF merge imperceptibly with ZF cells often
observed directly underneath the capsule. In contrast, the ZG of the bovine adrenal
gland is sharply defined from the inner zones, while the ZF and ZR form a single
uniform layer. The three zones are clearly distinguishable in the rat, guinea-pig and
rabbit cortex, while the amphibian gland displays no significant zonation.
Other adrenocortical zones have been described in various species. In 1957
Chester-Jones, et al., described a zone, lying between the ZR and the medulla, in
the adrenals of young mice and named it the X-zone. This zone disappears
following sexual maturity in the male and after the first pregnancy in the female,
leaving behind a band of connective tissue. However in the male rat the X-zone
forms the ZR in adult life (Shire & Stewart, 1972). This zone seems to play a role
in foetal or post-natal life. In rat, rabbit, cat, dog, cattle and sheep a fourth zone is
present termed the zona intermediate (ZI), lying between the ZG and the ZF
(Deane, 1962). The human and primate foetal adrenal cortex exhibits two zones,
the outer definitive and the inner foetal zone. Also, a special zone, found only in
the inner cortex of adult female marsupials.
The cells from these different zones within the adrenal cortex, represent different
phenotypes of a single cell type. The adult adrenal cortex undergoes permanent
regeneration. The maintenance of normal adrenocortical size involves cell
proliferation in the ZG, subsequent centripetal displacement and differentiation in
the ZF and cell deletion through apoptosis in the deep fasciculata and ZR zones
(Belloni et al., 1978; Wyllie et al., 1973; Orth et al., 1992).
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1.4. Adrenocortical Steroids
All steroids have the same basic four ringed structure and a various number of
carbon atoms from which a number of substitutions, for example ketones,
aldehydes and hydroxyls, may extend above ((3) or below (a) the plane of the
central ring structure. The biological properties of a steroid are determined by the
number and structure of the functional groups attached to the basic steroid nucleus.
There are four parent hydrocarbon molecules on which all the major steroids are
structurally based (Figure 1.2.). The first, cholestane (C27), which may be
considered chemically to be the parent compound for cholesterol and its related
metabolites which include the bile acids (C24). The second, pregnane (C21), is the
parent hydrocarbon for a group of steroids which are characteristic of the adrenal
cortex. These include the glucocorticoids corticosterone and Cortisol and the
mineralocorticoid aldosterone. The third, androstane (CI9) has no side chain on
ring D and this group includes compounds such as androstenedione and
testosterone. The last parent molecule, estrane (CI8), includes the phenolic
steroids such as estradiol-17/3 and estriol.
The major adrenal steroids secreted are those with mineralocorticoid or
glucocorticoid activity, and the sex steroids. The major mineralocorticoid
produced by the adrenal cortex is aldosterone, a 21 carbon molecule with an 11(3-
hydroxyl group. Aldosterone usually exists in an hemiacetal form with the aldehyde
group at CI 8. The formation of aldosterone is dependent on the presence of the
enzyme P450aldo (aldosterone synthase)(Figure 1.3.). This enzyme is only present
within the ZG. Glucocorticoids are produced primarily by the ZF and ZR. The
major glucocorticoid produced by human, bovine and sheep is Cortisol. The
presence of the enzyme P450cl7 (17a-hydroxylase), is a requirement for Cortisol
production. Most rodent adrenals do not have this enzyme, and so corticosterone






Figure 1.2. Basic structures of the parent hydrocarbon molecules,
pregnane (C21), androstane (C19), estrane (C18) and cholestane (C27).
androstenedione, DHEA and 11 (3-hydroxyandrostenedione, are secreted
predominantly by the ZR in humans and guinea-pigs, but by both the ZF and ZR in
rats.
1.5. Adrenocorticol Steroid Biosynthesis
All of the steroids synthesised in the adrenal cortex are derived from cholesterol,
which can either be synthesised within the adrenal cortex and in other tissues, from
acetate, or derived from animal fat in the diet. Cholesterol is stored, as cholesteryl
ester droplets, within the cell. Stimulation of steroidogenesis, leads to the
conversion of cholesterol esters to free cholesterol, which is then transferred from
the outer to the inner mitochondrial membrane by steroidogenic acute regultory
protein (StAR), where conversion to the 21-hydrocarbon, pregnenolone takes place
(Figure 1.3; Figure 1.4). Pregnenolone is then transported from the inner
mitochondrial membrane to the endoplasmic reticulum by another binding protein.
In the endoplasmic reticulum, pregnenolone is converted to progesterone, from
here depending on the tissue, progesterone can enter a number of biosynthetic
pathways catalysed by enzymatic cascades, producing a range of steroid hormones
with various biological activities. For example within the adrenal cortex
progesterone is hydroxylated to 11-deoxycorticosterone, which is then transferred
from the microsomes back to the mitochondria for conversion to corticosterone.
Corticosterone is converted to aldosterone via 18-hydroxycorticosterone,
alternatively 11-deoxycorticosterone can be hydroxylated to 18-
hydroxydeoxycorticosterone before being hydroxylated to 18-
hydroxycorticosterone (Vinson et al., 1991).
Steroid hormone output is regulated at a number of levels. Substrate availability is
a major regulatory factor, especially the rate of cholesterol transport to the inner
mitochondrial membrane. Enzyme activity and mass of the zone in which the













































Figure 1.3. Diagram depicting the major steroid intercomersions within the









Figure 1.4. Diagram depicting the conversion of cholesterol
pregnenolone.
enzymes, determined by rates of gene transcription, stability of mRNA and
translation rates is also a factor. An increase in all steroidogenic enzymes will lead
to a general increase in steroid production. Each of these parameters can be
regulated together or separately by steroidogenic agonists.
Five cytochrome P450 enzymes (P450scc; P450cl7; P450c21; P450U(3 and
P450aldo) and a steroid dehydrogenase enzyme (3-(3-hydroxysteroid
dehydrogenase (3|3HSD) are involved in corticosteroid synthesis from cholesterol.
The cytochrome P450 enzymes are located in the mitochondria and endoplasmic
reticulum ofmost tissues and contain an active site, which contains an heme group,
and binds the substrate. The enzymes either catalyse a single hydroxylation at a
specific position or a series of consecutive hydroxylations resulting in C-C bond
cleavage or aromatisation of the steroid ring (Hanukoglu et a/., 1992).
Once cholesterol has been transported from the cytosol to the inner mitochondrial
membrane P450scc (cholesterol side-chain cleavage), catalyses the conversion of
the 27-hydrocarbon cholesterol to the 21-hydrocarbon pregnenolone via three
successive monooxygenations, C20 hydroxylation, then C22 hydroxylation and
finally cleavage of the C20-C22 bond. Although cholesterol transfer across the
inner mitochondrial membrane limits steroid flux overall, this enzymatic step is the
rate-limiting step in steroid biosynthesis. This step occurs at the start of all three
steroidogenic pathways. P450scc exists as a complex with adrenodoxin and
adrenodoxin reductase, which act as electron transport proteins, transferring
electrons from NADPH to the terminal oxidase P450scc. The enzyme has been
localised to the inner mitochondrial membrane and is present in all three zones of
the cortex (reviewed by Ishimura & Fujita, 1997).
3j3-hydroxysteroid dehydrogenase (3J3HSD) converts pregnenolone and 17a-
hydroxypregnenolone to progesterone and 17a-hydroxyprogesterone respectively.
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The enzyme catalyses a two step reaction, namely dehydrogenation of 3(3-hydroxy-
5-ene-steroid and isomerisation of 3-oxo-ene-steroid. This enzyme has been
localised in the same cells as P450scc, in all three zones of the adrenal cortex, and
appears to be situated in the membrane of the smooth endoplasmic reticulum
(reviewed by Ishimura & Fujita, 1997).
The enzyme P450cl7, (17a-hydroxylase /17, 20 lyase), catalyses two separate
reactions, 17a-hydroxylation of 21-hydrocarbon steroids and cleavage of the CI 7-
C20 bond of 21-hydrocarbon steroids. The first reaction is involved in
mineralocorticoid and glucocorticoid synthesis, i.e. the formation of 17a-
hydroxypregnenolone and 17a-hydroxyprogesterone. The second reaction is
essential for the biosynthesis of androgens, resulting in formation of DHEA from
17a-hydroxypregnenolone, and androstenedione from 17a-hydroxyprogesterone.
The latter occurs in the rat but not the human (reviewed by Hanukoglu, et al.,
1992). The factors determining which activity, lyase or hydroxylation, P450cl7
performs remian unclear. It has been proposed that lyase activity is dependent on
the availability of electrons to P450cl7. Alternatively, a cAMP-dependent
phosphorylation of serine and threonine residues on P450cl7 has been shown to be
important for lyase activities (reviewed by Miller et al., 1997). The enzyme has
been localised within the smooth endoplasmic reticulum in the ZF and ZR, with no
presence within the ZG. Most rodent adrenals do not have this enzyme and thus
corticosterone is the major glucocorticoid to be produced.
P450c21 (21-hydroxylase) catalyses the formation of the precursors of Cortisol and
corticosterone, i.e. deoxycortisol and deoxycorticosterone, from 17a-
hydroxyprogesterone and progesterone respectively, and is expressed in all three
zones of the adrenal cortex (reviewed by Ishimura & Fujita, 1997).
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P45011p (11 P-hydroxylase), is responsible for the formation of Cortisol from
deoxycortisol and corticosterone from deoxycorticosterone, and exists in a complex
with adrenodoxin and adrenodoxin reductase. It is localised within the inner
mitochondrial membranes of cells in all three cortical zones in the bovine adrenal,
although higher concentrations are found in the ZF and ZR. In fact the bovine
enzyme exists as two isoforms, one present in the ZG and the other in the ZF and
ZR (White et al., 1992). The ZG isoform catalyses the formation of aldosterone
via 11P-hydroxylation of deoxycorticosterone, followed by 18-hydroxylation and
18-oxidation. The 18-hydroxylation and 18-oxidation steps are suppressed in the
ZF and ZR thus stopping aldosterone synthesis in these zones. Within the rat
adrenal this enzyme appears to be localised exclusively within the ZF and ZR. Thus
the rat ZG only synthesises low amounts of corticosterone through the action of
P450aldo. A distinct enzyme, encoded by a separate gene with 11P-hydroxylation,
18-hydroxylationa and 18-oxidation activities exists in the rat and human ZG which
is responsible for aldosterone synthesis. P45011p can also hydroxylate
androstenedione, forming 11P-hydroxylated androgens (reviewed by Ishimura &
Fujita, 1997)
A single enzyme catalyses the last three steps in the synthesis of aldosterone.
P450aldo (aldosterone synthase), catalyses the 11P-hydroxylation and 18-aldehyde
conversion of deoxycorticosterone to aldosterone. The enzyme has similar
properties to P4501 ip but is encoded by a different gene. CYP11B2 encodes for
P450aldo and CYP11B1 encodes for P4501ip. These two genes lie in tandem
50kb apart on chromosome 8 and are highly homologous (>95% nucleotide
sequence) (Boon et al., 1997). In sheep and pigs only CYP11B1 is found,
scattered throughout the whole adrenal cortex, and it may be responsible for
synthesis of both Cortisol and aldosterone. In the cow however five CYP11B1
enzymes have been detected, only two cDNAs have been isolated. These encode
two isozymes that differ by three amino acids (Boon et al., 1997). CYP11B1
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extracted from bovine adrenal cortex can synthesise aldosterone in vitro, however
in situ, only the enzyme located within the ZG can synthesise aldosterone. So
aldosterone producing activity is blocked in those mitochondria that are located
within the ZF and ZR (Muller et al., 1998). CYP11B2 has been localised to the
mitochondria of rat and hamster ZG cells (reviewed by Ishimura & Fujita, 1997).
1.6. Metabolism of Aldosterone.
Steroids are rendered biologically inactive and available for excretion by five main
reactions, reductions, hydroxylations, side-chain cleavage, oxidations and
esterifications. In general metabolism occurs in the liver, but can also occur in the
kidney and adrenal gland.
Aldosterone is metabolised in a number ofways and the key metabolites are shown
in Figure 1.5. Aldosterone content of the adrenal glands is in the range of l-2pg,
while its secretion rate is 70-250 p.g/day, yielding plasma levels of 5-100 pg/ml.
Aldosterone metabolism occurs primarily in the liver where 85% is inactivated. The
initial reaction, a reduction of the A ring and the 3-ketone group, forms
tetrahydroaldosterone, which is then esterified at the 3-hydroxyl position with
glucoronic acid and then secreted. In the kidney, conjugation of the 18 carbon
position with glucoronic acid, without alterations of the A ring and the 3-ketone
group can occur. This forms a labile product in dilute acid and therefore free
aldosterone is released by hydrolysis at pH 1. Urinary measurements of aldosterone
refer to this compound.
1.7. Actions of Aldosterone.
Although the clinical importance of the adrenal cortex in the regulation of
electrolyte balance has long been realised, it was not until the early 1950's that the

























Figure 1.5. Diagram depicting the metabolism of aldosterone.
(1953), using a sensitive mineralocorticoid bioassay based on changes in urinary
sodium and potassium ratios in adrenalectomised rats to characterise aldosterone.
Aldosterone is the most potent mineralocorticoid known, secreted solely by the ZG
of the adrenal cortex. Other steroids with mineralocorticoid activity are 11-
deoxycorticosterone and corticosterone, but although they are produced by the
adrenal in much greater quantitites, they are approximately thirty-fold and three
hundred-fold less potent than aldosterone, respectively. Aldosterone acts
predominantly on the distal convoluting tubules and the collecting ducts of the
kidney, although extra-renal sites of action include the sweat, gut and salivary
glands. The half-life of aldosterone is -twenty to thirty minutes, and its circulating
concentration is low (—200-800pM). This may be explained in part by the fact that
once aldosterone is synthesised it is immediately released from the adrenal gland,
only a small amount is actually stored, and once in circulation it is weakly
associated with plasma proteins such as corticosteroid binding globulin (-20%) and
albumin (-40%), the rest being non-bound or "free".
The action of mineralocorticoids on electrolytes is essentially to conserve sodium
and eliminate potassium. The effect seen is a result of the complex action of these
hormones on different tissues and organs, and these vary widely with different cell
types. The overall action of aldosterone depends markedly on sodium status.
Increased sodium intake results in more tubular sodium available for reabsorption,
thus enhancing potassium excretion. Conversely, sodium restriction diminishes
both sodium reabsorption and kaliuresis. Potassium itself can stimulate aldosterone
secretion, leading to eventual potassium excretion; thus aldosterone serves as an
intrinsic part of the body's defence mechanism against hyperkalaemia. An
additional mechanism protects against persistant mineralocorticoid excess, whereby
the body 'escapes' from further sodium retention and hyperkalaemia. This is
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thought to be mediated via secondary increases in other factors, such as atrial
natriuretic hormone (ANH) and by renal haemodynamics.
Aldosterone binds to the mineralocorticoid receptor to trigger cellular events. The
mineralocorticoid receptor is a member of the steroid/thyroid/retinoid superfamily
of intracellular receptors and was cloned in 1987 (Arriza et al., 1987; Evans et al.,
1988). These are ligand-dependent transcription factors and thus the effects of
aldosterone are mediated through the regulation of the expression of specific
mineralocorticoid receptor responsive genes (Evans et al., 1988). In the absence of
hormone the receptor resides predominantly in the cytoplasm, in a complex with
heat-shock proteins (Evans et al., 1988). When aldosterone binds there is a
conformational change in the receptor's structure, the heat-shock proteins
dissociate and the receptor migrates to the nucleus where it binds to the promoter
region of target genes and regulates transcription from these genes (Fejes-Toth et
al., 1998).
The mineralocorticoid receptor can also be activated by Cortisol and corticosterone.
The glucocorticoids bind with the same high affinity as aldosterone, however iti
vivo the mineralocorticoid receptor specifically binds aldosterone in tissues such as
kidney and colon (Funder et al., 1988). Circulating levels of Cortisol are usually 2
to 3 orders of magnitude greater than those of aldosterone, so mechanisms must
exist to allow the specific activation of this receptor by aldosterone. The most
important of these mechanisms involves the action of the type 2 isoform of the
enzyme 11(3 hydroxy-steroid dehydrogenase (11(3F1SD2) (White et al., 1997). This
enzyme converts Cortisol and corticosterone into inactive 11-reduced metabolites in
mineralocorticoid receptor responsive tissues, such as the kidney and colon, and
protects the receptor from glucocorticoids.
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The electrophysiological or biochemical response to aldosterone involves an initial
latent period of 30 to 60 minutes, followed by an acute phase of 1 to 3 hours, and
then a chronic phase of 3 to 6 hours onwards (Verrey et al., 1998). In the chronic
phase a number of secondary responses occur, which after several days results in
morphological changes in the distal nephron (Wade et al., 1990). The latent phase
reflects the time taken for the transcription and then translation of the specific gene-
product or aldosterone-induced proteins. The identity of these putative
aldosterone-induced proteins has proven elusive, although there are strong
candidates (Verrey et al., 1998). The acute phase reflects the physiologic response
to aldosterone-induced proteins before other factors, which may include gene
expression, make a significant contribution.
Steroid hormones may also act through alternative nongenomic pathways. Several
groups have now reported rapid effects, within minutes, of aldosterone on
intracellular pH, calcium dependant Na+/H+ exchange and cardiovascular function
in vivo (Christ et al., 1995; Gekle et al., 1996; Wehlin et al., 1998).
The importance of aldosterone as a regulator of electrolyte and fluid balance in both
normal and diseased states has led investigators to study its mechanism of action, as
a firm understanding of the biochemical mechanisms of aldosterone action could
facilitate development of new methods and new drugs in the treatment of disorders
of mineralocorticoid secretion. Increased quantities of aldosterone and its
metabolites are present in the urine of patients with a number of diseases, including
primary and secondary hypertension, congestive heart failure, cirrhosis of the liver
and nephrosis. Mineralocorticoid deficiency causes sodium loss, hyperkalaemia and
acidosis. One disease state linked with both mineralocorticoid and glucocorticoid
deficiency is Addison's disease.
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1.8.PhvsioIogical Control ofAldosterone Secretion.
Numerous factors affect aldosterone secretion, acting directly or indirectly. To
discuss them all is outwith the scope of this thesis, and so only the major regulatory
factors, and those relevant to this thesis will be discussed.
1.8.1. The Renin-Angiotensin System.
Since the discovery of renin almost 100 years ago, there have been remarkable
advances in the understanding of the renin-angiotensin system (RAS). The RAS is
thought to be the major physiological regulatory component of aldosterone
secretion, and parallel changes in plasma renin activity (PRA) and aldosterone
secretion under a variety of conditions confirm this (Davis et al., 1975; Fraser et
al., 1979).
1.8,1,1, Formation ofAngiotensin II.
Renin is a proteolytic enzyme stored in intracellular granules as both the inactive
prorenin and active renin in the juxtaglomerular cells of the afferent arteriole of the
kidney. Renin secretion is controlled by neurogenic, haemodynamic and humoral
mechanisms (reviewed in Valotton, 1987). Once stimulated it is released
exocytotically and diffuses into the circulation. After release, renin acts on a
globulin plasma protein, angiotensinogen, cleaving it at the leulO-leull bond to
form a decapeptide, angiotensin I (Al) which has relatively low biological activity.
Angiotensin converting enzyme (ACE), an endopeptidase found in many tissues but
predominantly in the lung, cleaves Al at a leucine and a histidine residue to form an
octapeptide, AIL Angiotensinogen can also be directly converted to All by the
action of serine protease tonin, which is found in the venous affluent of the
submaxillary gland. All has a very short half - life and is rapidly broken down by
aminopeptidases in various tissues to produce inactive peptide fragments.
Aminopeptidase A removes the N-terminal aspartate residue from All to form the
heptapeptide angiotensin III (AIII) (Reviewed by Espiner & Nichols, 1993).
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1.8.1.2. Mechansims of Action ofAngiotensin II
All has a multiplicity of actions, initiating a complex series of events which work
together to restore plasma volume, blood pressure and sodium concentration. It is
a potent pressor agent through direct vasoconstrictor actions, stimulation of the
sympathoadrenal system both centrally and peripherally and via inhibition of vagal
control of heart rate. All also controls fluid and electrolyte balance, stimulates
drinking and salt appetite and directly affects the renal handling of sodium.
However its ability to regulate aldosterone secretion is the key pathway through
which the RAS controls fluid and electrolyte balance.
All exerts its action on target organs by interacting with receptors in the plasma
membrane (Catt et al., 1993). All receptors are coupled to cellular second
messengers such as G-proteins, ion channels and membrane enzymes. The
receptors show a high binding affinity and rapid association and dissociation of
ligands. The receptors can undergo changes in concentration which has a knock on
effect on the actions of circulating All. Sodium intake can alter the concentration
of AH receptors in the ZG and the vascular tissue. Sodium depletion increases AII
receptors, while sodium loading decreases them in the ZG, but has the opposite
effect in the vasculature. Thus the adrenal responsiveness to AII is increased by
sodium depletion, while the vascular response is decreased. The observation that
both sodium depletion and high potassium diets, known stimuli of aldosterone
production, increase levels of the adrenal AT i receptor may be explained by the up-
regulation ofATi gene expression by aldosterone (Inagami et al., 1995).
All binds to one of two major receptor types, ATi and AT2 receptors. They belong
to the class of seven transmembrane receptors coupled to G-proteins (Timmermans
et al., 1993). The ATi receptor has two isoforms ATia and AT]B, exhibiting minor
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differences in amino acid sequences. In contrast the ATi and AT2 receptors exhibit
only 32-34% homology (Csikos et al., 1998).
Most of the biological actions of All are mediated through the ATi receptor,
probably via the ATia receptor, apart from in the adrenal where control of
aldosterone secretion appears to be mediated through the AT1B receptor (Gigante et
al., 1997). The AT2 receptor does not influence aldosterone secretion.
All stimulation of aldosterone secretion requires calcium in the extracellular fluid
and can be blocked by calcium channel blockers. All stimulates calcium influx and
efflux and rapidly elevates the intracellular calcium concentration by mobilising
calcium from intracellular and extracellular sources. This flux of calcium is the
result of All binding to the receptor coupled by G-protein and then activation of
phospholipase C. Phospholipase C breaks down polyphosphoinosotide to
diacylglycerol and inositol 1,4,5-triphosphate. The inositol 1,4,5-triphosphate
mobilises calcium from intracellular endoplasmic reticulum stores and the
diacylglycerol activates protein kinase C. Stimulation of calcium influx by All may
be through voltage-gated or receptor-mediated calcium channels (Franco-Saenz et
al., 1989). The initial rise in intracellular calcium activates calcium calmodulin
dependent protein kinases and is responsible for the early steroidogenic response to
AIL Sustained release of aldosterone requires influx of calcium via T-type voltage
dependent channels as well as increased activity of diacylglycerol sensitive protein
kinase C. In addition All activates phospholipase A2 resulting in the release of
arachidonate and its metabolic products, prostaglandin and leukotriene.
Aldosterone secretion is enhanced within minutes of All stimulation (reviewed by
Lumbers, 1999). In acute doses, All acts on the early stages of the aldosterone
biosynthetic pathway, i.e. prior to formation of pregnenolone. This is true for all
known stimulants of aldosterone secretion. After chronic exposure, All affects
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later stages of the biosynthetic pathway, i.e. on aldosterone synthase, thus All
causes a rise in plasma aldosterone levels in vivo, which can be sustained for hours
(Blair-West et al., 1970). In preparations from K+ deficient, sodium-loaded or
mineralocorticoid treated rats, that is animals who are secreting higher than normal
rates of aldosterone, All does not stimulate aldosterone secretion, instead plasma
deoxycorticosterone levels increase (Muller et al., 1998). Aldosterone synthase
mRNA disappears from the ZG of potassium deplete, sodium loaded or
mineralocorticoid treated rats and markedly increases in sodium restricted rats or
potassium loaded rats (Muller et al., 1978; Shibata et al., 1991; Tremblay et al.,
1992). The increase in aldosterone synthase mRNA can be totally or partially
blocked by treatment with an ACE inhibitor, indicating that induction of
aldosterone synthase depends on either systemic or locally formed All (Shibata et
al., 1991). In the rat potassium loading induces transcription and expression of
aldosterone synthase in the ZG but has no effect on P45011 (3 in the ZF. Thus
potassium status determines the extent to which circulating All modulates
aldosterone secretion, through interactions at the level of expression of aldosterone
synthase (reviewed by Lumbers et al., 1999).
All is converted to AIII and it is believed that AIII has similar actions to All,
although the plasma concentrations of AIII are much lower. The combined
stimulatory effects ofAll and AIII on aldosterone secretion results in inhibition of
renin release from the kidney and as a consequence aldosterone secretion from the
ZG. This is an important negative feedback mechanism involved in the regulation
of aldosterone, sodium homeostasis and blood pressure.
1.8.2. Potassium.
Potassium is another physiological regulator of aldosterone secretion. Low plasma
levels of potassium lead to a decrease in aldosterone secretion, and vice versa, via a
direct action on the ZG (Blair-West et al., 1970; Tait et al., 1972; Braley et al.,
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1986). In acute doses, potassium stimulates the early step in the aldosterone
biosynthetic pathway, i.e. prior to formation of pregnenolone, chronically potassium
stimulates the conversion of deoxycorticosterone to aldosterone, and increases the
width of the ZG. In the rat potassium loading induces transcription and expression
of aldosterone synthase in the ZG, but has no effect on P45011(3 in the ZF, thus a
major site at which potassium controls aldosterone secretion is through the control
of aldosterone synthase (reviewed by Lumbers et al., 1999).
A number of experiments have shown a direct action of potassium on the ZG cell
and aldosterone production, both in vivo and in vitro (Boyd, et al., 1971; 1973).
Aldosterone production is exquisitely sensitive to small changes in potassium
concentration. The state of potassium balance can also alter the response of
aldosterone to AIL Linde et al., (1981) reported that aldosterone secretion in
humans on a high potassium diet (300 mequiv./day) was more sensitive to All
infusions than in subjects on an 80 or 10 mequiv. potassium diet. In another study
potassium depleted rats failed to respond to sodium depletion, with an increase in
aldosterone production or an increase in the width of the ZG (Boyd et al., 1973).
The plasma renin levels were not lowered, indicating a loss of sensitivity to All as a
result of potassium depletion. Ikubo & Ichikawa (1997) produced several strains of
'knock-out' mice that were deficient in a specific gene within the RAS and found
unequivocal evidence that potassium is an effective regulator of aldosterone
secretion during extracellular fluid volume depletion in the absence of the RAS.
At first it was thought that the translocation of extracellular potassium into adrenal
ZG cells by way of the Na+/K+ pump was a prerequisite for the aldosterone
stimulating effect of potassium (Boyd et al., 1973). However, unlike other
aldosterone secretagogues, potassium causes depolarisation of the plasma
membrane, activating voltage-dependent calcium channels in the plasma membrane
as the initial transduction step (Kojima et al., 1985). This increase in calcium
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influx, due to increasing concentrations of potassium, results in a rise in cytosolic
free calcium that is well correlated with aldosterone production (Capponi et al.,
1984; Braley et al., 1986). Measurements of Ca++ with Quin 2 demonstrated that
the increase in calcium influx was rapid and sustained for the duration of the
stimulation. Nifedipine completely inhibited the aldosterone response to potassium,
indicating a role for extracellular calcium and a voltage-dependent calcium channel.
45Ca++ influx and efflux studies confirmed that the calcium is of extracellular
origin and is not mobilised from an intracellular source (Fakunding et al., 1979;
Williams et al., 1981). However cytosolic calcium responses to potassium can be
inhibited by nitrendipine, dantrolene and 1MB 8, suggesting that release of
cytosolic bound calcium may be involved in the response. However these agents
may have other uncharacterised effects on calcium metabolism besides blockade of
membrane bound calcium release (Bradley et al., 1986).
The cAMP response to potassium is controversial. Kojima et al., (1985), reported
a small increase in cAMP in calf adrenocortical cells and suggested that potassium
mediated aldosterone secretion may involve a dual mechanism requiring both
cytosolic free calcium and cAMP participation. However Ganguly et al., (1985),
found no increase in cAMP levels in calf adrenal ZG cells. The weight of evidence
suggests that potassium affects cAMP generation, an effect prevalent at higher
concentrations of potassium, although it is not clear whether this is due to changes
in cytosolic calcium levels, or a direct effect of potassium itself. No increase in
radiolabeled IP3 or tritiated inositol incorporation into phospholipids is observed in
the presence of increased concentrations of potassium (Whitley et al., 1984).
However, a small transient decrease in radiolabeled PIP2 has been reported and an
increase in the mass of IP3 lasting for only ten seconds was observed when ZG cells




Restriction of sodium intake is one of the most potent stimuli for aldosterone
secretion in man and in animals (Davis, 1967). Sodium depletion not only increases
aldosterone secretion but also the width of the ZG, while sodium loading decreases
both of these factors. The mechanisms by which alterations in sodium balance leads
to changes in aldosterone secretion remain unclear, mainly due to the diverse
physiological effects initiated by altered sodium status. Plasma sodium levels have
little or no direct effect on aldosterone production. The rise in aldosterone
secretion in sodium deficient animals depends on the rise ofAll levels, yet sodium
deficiency alters the sensitivity of the adrenal to AIL This may be due to effects of
sodium deficiency on local or paracrine factors, e.g. the adrenal RAS.
Sodium deficiency activates the RAS causing a rise in plasma All levels, stimulating
aldosterone production. The RAS clearly plays an important role in the aldosterone
response to changes in sodium, it seems clear however that this is not the only
mechanism involved. The effects of All on the adrenal are enhanced by sodium
deficiency. Sodium loading of a previously salt deplete animal results in a more
rapid reduction in plasma aldosterone levels than in plasma All levels (Boon et al.,
1997). In vitro studies have shown that sodium directly inhibits the adrenal
response to All, but this effect is probably due to osmotic effects as aldosterone
does not increase when renin levels are elevated in water deplete animals (Schneider
el al., 1984; 1985). Boon et al., (1997), found that a major 4 kb transcript of
P45011(3 in the sheep ZG and also in the ZF increased with potassium loading and
rose further with acute sodium depletion, but did not increase further with chronic
sodium depletion. They suggested that the rise in aldosterone levels in moderately
sodium deficient sheep was due to an increased supply of deoxycorticosterone and
the increased aldosterone synthase levels were due to stimulation by AIL They
postulated that in severe sodium depletion there was a switch in the aldosterone
biosynthetic pathway allowing dissociation from All stimulation. They also
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suggested that other factors such as the adrenal RAS system could be involved. In
nephrectomised animals, aldosterone output is still enhanced during sodium
restriction, which may be due to the involvement of a pituitary derived substance,
not ACTH, which is secreted during sodium depletion and stimulates aldosterone
secretion (McCaa et al., 1974; Pratt et al., 1981).
With the use of continuous superfusion and perfusion techniques, both in vivo and
in vitro, Baniukiewicz et al., (1968), demonstrated that alterations in sodium
balance can influence aldosterone production at different stages of the biosynthetic
pathway, in sheep and in rats; namely at the conversion of corticosterone to
aldosterone and at a step preceding the formation of corticosterone. Adrenal tissue
of sodium deplete dogs was shown to convert more unlabelled and radioactively
labelled progesterone and corticosterone to aldosterone than adrenal tissue of
sodium replete dogs (Davis et al, 1968). Marusic & Mulrow (1967), found an
increased conversion of corticosterone to aldosterone and 18-
hydroxycorticosterone, but a normal conversion of deoxycorticosterone to
corticosterone by capsular adrenal mitochondria of rats that had been kept on a
sodium deficient diet for four days.
1.8.4. ACTH
ACTH is the major regulator of glucocorticoid production, but also has a transient
stimulatory effect on aldosterone, stimulating aldosterone secretion both in vivo
and in vitro, acting at the early stage of the biosynthetic pathway (Davis et al.,
1975; Fraser et al., 1975). However in the rat chronic treatment with ACTH
markedly reduces aldosterone production both in vivo and in vitro (Muller et al.,
1970; 1978). In fact after continuous infusion of ACTH, aldosterone levels return
to normal within 1 to 3 days, while corticosterone levels remain elevated.
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The release of ACTH during acute animal experiments can mask the effect of other
systems on aldosterone secretion. Following hypophysectomy in rats the ZG does
not atrophy, unlike the inner zones (Deane, 1962). Deane et al., (1948)
demonstrated that a low sodium diet increases the width of the ZG in
hypophysectomised rats. Chronic hypophysectomy in a number of species does not
markedly influence sodium balance, however acute injections of ACTH leads to a
marked increase in aldosterone secretion and chronic ACTH administration does
not (Mulrow et al., 1966). ACTH plasma levels do not increase following sodium
depletion, but ACTH is necessary in a permissive way in maintaining the integrity of
the cell and in the early steps of the biosynthesis of aldosterone, i.e. cholesterol to
pregnenolone. Loss of ACTH in sodium depleted rats results in a significant
decrease in aldosterone production (Boyd et al., 1972). Following sodium
depletion and potassium loading there is increased sensitivity of aldosterone
secretion to ACTH (Yamakodo et al., 1983).
A number of suggestions have been made as to the possible mechanisms of the
effects of ACTH in aldosterone biosynthesis, falling into two distinct categories.
Firstly, those involving the direct effects of ACTH on the adrenal ZG cells, and
secondly, those that are secondary to the effects of ACTH on other ZG modulators.
Direct effects of ACTH on the ZG include functional and morphological
transformations of ZG cells into either intermediate or fasciculata-like cells
(Hornsby et al., 1985; Muller et al., 1978; McDougall et al., 1980), and an intra-
adrenal inhibition of the late steps of aldosterone biosynthesis by inappropriately
increased levels of aldosterone biosynthesis (Muller, 1970; Aguilera et al., 1981).
The indirect effects that have been suggested include increases in the volume of the
extracellular fluid compartment due to increased levels of steroids with weak
mineralocorticoid activity, i.e. deoxycorticosterone, 18-OH-deoxycorticosterone
and corticosterone, leading to a reduction in the activity of the RAS (Aguilera et
al., 1978), a negative feedback inhibition of an as yet unidentified aldosterone
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stimulating factor from the pituitary (Legros & Lehoux, 1983) and a fall in plasma
potassium concentrations (Aguilera et al., 1981). However from studies
investigating the chronic inhibitory actions of ACTH it would appear that a direct
action of ACTH on the ZG is responsible for the reduced aldosterone biosynthesis
(Abayasekara et al., 1989).
Receptors for ACTH are expressed throughout the ZG and the ZF (Mountjoy et
al., 1992). The receptor is coupled to adenylate cyclase by a stimulatory G-protein,
which binds GTP and stimulates adenylate cyclase and cAMP production
respectively (Kojima et al., 1985b). The adrenal steroidogenic response to ACTH
is dependent on the presence of extracellular calcium. Calcium is also closely
associated with the activation of the adenylate cyclase system. In the absence of
extracellular calcium, cAMP and aldosterone secretion are inhibited, and ACTH has
a greater effect on cAMP production when extracellular calcium is elevated
(Fakunding et al., 1979; Shima et al., 1979). The former effect was later attributed
to the requirement ofCa^+ for the binding of ACTH to its receptor (Cheitlin et al.,
1985).
1.9. Other Regulators ofAldosterone Secretion.
1.9.1. Innervation of the Adrenal Cortex.
Direct innervation of endocrine cells, in the mammalian adrenal, was illustrated by
both Unsicker et al., (1971) and Garcia-Alvarez et al., (1970), utilising a
catecholamine fluorescence technique, demonstrating innervation of the basal
lamina of cortical cells by autonomic axons, terminating close to the plasma
membrane. Two sources of innervation have been proposed for the rat adrenal.
Firstly, from the adrenal medulla, the adrenal cortex may have originally been a
target organ for adrenomedullary postganglionic nerves, and so during evolution as
the two tissues became more closely associated, the postganglionic fibres
terminated entirely within the adrenal gland, forming the chromaffin tissue and
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innervating the cortical tissue (Hinson, 1990). Secondly, nerves which appear to
have cell bodies outwith the adrenal gland, entering the gland along blood vessels
(Holzwarth et al., 1987). These adrenal nerves entering the gland contain both pre-
and postgangloinic fibres, and the postganglionic fibres supply the adrenal cortex
(Kesse et al., 1988; Carlsson et al., 1990). Sympathetic preganglionic cholinergic
fibers reach the adrenal gland by the splanchnic nerves which traverse the cortex
and synapse on chromaffin cells, where they regulate catecholamine synthesis and
release (Neville et al., 1969). Stimulation of these nerves may also increase the
levels of certain neuropeptides such as vasoactive intestinal peptide and
neuropeptide Y, within the medulla and in a paracrine manner, possibly within the
cortex (Bloom et al., 1988). Adrenocortical innervation includes extrinsic
sympathetic catecholaminergic nerves and intrinsic nerves, predominantly
vasoactive intestinal peptidergic nerves. Neuropeptide Y fibers also appear
associated with blood vessels (Kong et al., 1989).
Numerous neuropeptides are found within the adrenal gland, and transmitter
systems have been identified in nerves supplying the adrenal cortex.
Immunohistochemistry has demonstrated the presence of several amines and
peptides within the adrenal cortex nerves. Catecholamines, tyrosine hydroxylase
and dopamine-P-hydroxylase, which are localised in nerve fibers within the adrenal
capsule and ZG (Oomori et al., 1991; Vizi et al., 1993). Also neuropeptides such
as vasoactive intestinal peptide, neuropeptide Y, galanin and calcitonin gene related
peptide, also localised within the adrenal capsule and ZG (Toth et al., 1995). In
sheep corticotrophin releasing hormone has also been identified in nerve fibers
within the adrenal cortex (Rundle et al., 1988).
The distribution of the various types of nerve fibers occurs in the outer part of the
cortex, mainly within the capsule and the ZG, and so two distinct possibilities exist,
firstly, blood flow regulates steroidogenesis, that is, the major regulatory role of the
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neurotransmitters on steroidogenesis could be indirectly mediated by an action on
the vasculature system, and/or, the neurotransmitters released could also have a
direct effect on adrenocortical cells and steroidogenesis. Also, the splanchnic nerve
plays an important role in regulation of adrenocortical nerve activity. As has
already been discussed, splanchnic nerve stimulation releases many important
neuropeptides into the adrenal venous effluent. However at present it is unclear
how much of this is due to cortical innervation as opposed to the adrenal medulla.
The neuropeptides secreted are not only present within the nerve fibres innervating
the cortex but also within the chromaffin cells of the adrenal medulla.
1.9.2. Cortical-Medullary Interactions.
1.9.2,1. Co-Existence of Cortical and Medullary Cells.
More than twenty years ago, Palcois & Lafarga (1975), reported the existence of
islets of chromaffin cells in the zona glomerulosa of adult rats, although they put
this observation down to an error in adrenal organogenesis rather than a
functionally significant observation. However, strong evidence is now available
from morphological and immunohistochemical studies on the adrenal gland, in
various species, as to the co-localisation of cortical cells and medullary cells.
In the rat adrenal, rays of medullary tissue have been reported to extend across the
outer zones of the cortex, up to the capsular zone, some of these rays actually
follow the connective fibres of the large adrenal vein, and even after cell isolation
the interaction between cell types was still seen (Gallo-Payet et al., 1987).
Chromaffin cells, containing organelles identical to adrenocortical mitochondria and
smooth endoplasmic reticulum, were detected in adrenals of perfusion fixed rats,
and it is thought that these cortico-chromaffin hybrid cells may have the capacity to
carry out steroid biosynthetic reactions (Bornstein et al., 1991).
Immunohistochemical studies in the pig adrenal gland using chromagranin A
revealed the existence of chromaffin cells projecting from the medulla across all
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three cortical zones (Bornstein et al., 1991). Also evident were small islets and
single neuroendocrine cells in the ZF and ZR. Immunostaining for 17a-hydroxylase
stained immunoreactive cells in the medulla. In the bovine adrenal, cortical cells
could also be detected in the medulla especially around the blood vessels. In the
human adrenal gland Bornstein et al., (1994) identified the occurrence of
chromaffin cells in all three zones of the adrenal cortex. Ultrastructural analysis
demonstrated that the cortical and chromaffin cells were in close apposition, not
separated by fibrous tissue, and so sufficient contact between the cells exists to
allow widespread paracrine interactions, and in some rare instances chromaffin cells
appeared to be releasing their secretory products by exocytosis near adrenocortical
cells. The close colocalisation of the two cell types forms the basis for many
interactions between the two endocrine systems.
1.9,2.2. Paracrine Control ofAdrenocortical Function by the Adrenal Medulla.
The medulla is innervated by preganglionic, cholinergic and sympathetic neurones
carried in the splanchnic nerves. Stimulation of the splanchnic nerve results in the
release of splanchnic nerve products within the medulla which may affect the
adrenal cortex. It has now been shown that numerous adrenomedullary secretory
products, including catecholamines, 5-HT, ANP, somatostatin, substance P,
vasoactive intestinal peptide (VIP), neuropeptide Y (NPY), adrenomedullin and
pituitary adenylate-cyclase activating peptide (PACAP), are involved in the
regulation of adrenocortical steroidogenesis, by either stimulating or inhibiting
adrenocortical function.
1.9.2.2.1. Catecholamines and 5-HT.
Bornstein and co-workers (1990) demonstrated that in isolated perfused pig
adrenals with a preserved nerve supply, splanchnic nerve activation stimulated the
release of corticosteroids, specifically Cortisol, aldosterone and androstenedione.
This stimulatory effect may have been mediated by chromaffin cells in a paracrine
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manner, as perfusion of the adrenals with catecholamines also provoked a
significant release of corticosteroids. In addition to this acute effect,
catecholamines have a long-term effect on corticosteroid release in the rat from
isolated adrenocortical cells, involving transcriptional regulation of steroid enzymes
(Erhart-Bornstein el al., 1998). In the frog adrenal gland, catecholamines had the
reverse effect, inhibiting steroid secretion. It has also been suggested that
catecholamines regulate the synthesis of aldosterone in the ZG (De Lean el al.,
1984). Although adrenaline has apparently no effect on intact adrenal glands in
vitro., it did stimulate steroidogenesis in regenerating medullaectomised rat adrenal
glands. In addition medullary products were also found to affect steroidogenesis in
the inner zone cells of the adrenal cortex, for example, catecholamines and ATP
both stimulate the production of Cortisol (Walker et al., 1988).
5-HT has been localised within the adrenal medulla, specifically the chromaffin
cells, of various species, namely mouse, rat and frog. It is now well known that 5-
HT stimulates corticosteroid secretion from the adrenal cortex in various animal
models, and thus this is another example of a neurotransmitter present within the
adrenal medulla which could influence adrenocortical activity (Reviewed by
Nussdorfer, 1996).
1.9.2.2.2. Medullary Neuropeptides.
Medullary chromaffin cells produce, store and secrete not only catecholamines but
also a whole range of neuropeptides, which either act to inhibit or stimulate
steroidogenesis, depending on the circumstances involved. In the main these
peptides stimulate adrenocortical function in different species, thus influencing
adrenal steroid production. ANP, a regulator of aldosterone secretion,
somatostatin, dynorphin, substance P, NPY and the enkephalins are all thought to
have an inhibitory role on steroidogenesis. However, in certain circumstances,
substance P and the enkephalins, act to stimulate steroidogenesis (reviewed by
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Erhart-Bornstein et al., 1998). ANP and somatostatin, preferentially act on the
release ofmineralocorticoids within the ZG.
1.9.2.2.3. Corticosteroids.
Corticosteroids are known to have effects on adrenaline synthesis and release in the
medulla. Steroid hormones secreted from the adrenal cortex exert selective trophic
actions on the medulla promoting growth, maturation and maintenance of
chromaffin cells, as well as modulating the activity of the constitutive enzyme,
phenylethanolamine N-methyltransferase (PNMT), most characteristic of the
medulla.
The medulla and cortex would appear to interact widely with complex regulatory
circuits. Under basal conditions, stimulatory influences appear to be dominant.
When physiological conditions differ, different secretory products come into play
and it remains to be elucidated as to how the different adrenomedullary secretory
products are involved in the control of adrenocortical functions (reviewed by
Erhart-Bornstein et al., 1998).
1.9,2.3. Gap Junctions.
Gap junctions allow water soluble molecules to pass directly from the cytoplasm of
one cell to the cytoplasm of the other, propagating the intracellular signal from
stimulated to unstimulated cells, thus coupling cells both electrically and
metabolically. They have been found to occur within all zones of the mammalian
adrenal cortex, providing an effective cellular communication system (Murray &
Pharrams, 1997). With the use of an interactive laser cytometer the existence of
gap junctions in bovine adrenocortical cells in culture has also been visualised.
These functionally active gap junctions mediate paracrine signals between
chromaffin and cortical cells. Furthermore, gap junctions are induced after
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stimulation with ACTH, which suggests a possible role in response to the hormone
(Murray & Pharrams, 1997).
1.9.3. The Intra-Adrenal Renin-Angiotensin System.
For years the RAS was viewed as a classical circulating endocrine system. There
now exists local tissue or organ specific RAS that acts in a paracrine or autocrine
fashion. The physiological role of such systems remains unknown, although they
may serve as a mechanism for limiting the actions of All to a specific organ or
tissue.
A renin-like enzyme was first identified in rabbit adrenal by Ryan and co-workers
(1967), which reacted with a renin substrate to form AI. Many studies have now
established renin-like activity in a wide number of tissues, including the heart,
adrenal glands, liver, vasculature, brain and testes (Phillips et al., 1993). In the
adrenal cortex, renin has been found in rabbits, dogs, cattle, rats and humans (Wang
et al., 1992), and mRNA for renin has been detected in rats (Dzau et al., 1987) and
mice (Field et al., 1984). In the rat adrenal gland each participating component in
the formation ofAll has been identified (Mulrow, 1998). However, tissue systems
remain controversial due to the notion that much of the renin present in such tissues
arises from uptake of kidney renin, rather than by in situ synthesis. But in sodium
depleted or potassium loaded rats, biosynthesis and secretion of adrenal renin,
localised mainly in the ZG was increased (Doi et al., 1995). Under these
physiological conditions, the increase in renin activity was demonstrated to be
linked to elevated levels of renin mRNA indicating that adrenal renin is synthesised
locally rather than being taken up from the extensive vascular system supplying the
gland (Wang et al., 1992).
Direct evidence for All formation within the adrenal gland has arisen from various
studies. All was secreted from superfused rat and human adrenal glands, and
30
stimulation of both AI and All, by rat tissue, was stimulated by increased potassium
concentrations (Kifor et al., 1991; Sarzani et al., 1992). Superfusion of rat ZG
cells by potassium produced similar results. Chronic stimulation by low dietary
sodium, increased both the output ofAll per cell and the number of cells involved
in All secretion (Chiou et al., 1995).
Although the physiological role for the intra-adrenal RAS has not been established,
many observations have shown that the concentration of renin in the ZG parallels
that of aldosterone. In cultured rat ZG cells, ACTH, All and potassium stimulated
both aldosterone secretion and renin activity. The increase in renin activity
correlated with increased levels of renin mRNA, indicating an increase in the
transcriptional rate of the renin gene or an increase in the stability of the mRNA
(Wang et al., 1992). The activity of the intra-adrenal RAS may affect the density of
adrenal All receptors. Gigante et al., (1997), found that losartan administration to
bilaterally nephrectomised salt restricted rats caused the expected rise in adrenal
renin mRNA and activity and a fall in aldosterone synthase. Also ATib receptor
mRNA levels fell, while ATiA mRNA levels were unchanged and AT2 mRNA
increased. It has been suggested that the intra-adrenal RAS is involved in the
control of P450scc and P45011(3 gene expression in response to sodium restriction
or potassium loading. P45011P is dependent solely on the presence of All,
whereas P450scc is modulated by several factors including All, emphasising the
key part played by this peptide in the control of steroidogenesis (Reviewed by
Erhart-Bornstein et al., 1998).
1.9.4. Dopamine.
Since the initial observation that the dopamine agonist bromocriptine, partially
blocked ffusemide stimulated aldosterone synthesis (Edwards et al., 1975), there
has been controversy surrounding the physiological importance of dopamine in the
regulation of corticosteroidogenesis.
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A possible role for dopamine in regulating aldosterone secretion came largely from
pharmacological in vivo experiments using the dopamine antagonist
metoclopramide, which enhanced aldosterone secretion but not PRA, ACTH or
plasma potassium, indicating that under normal circumstances aldosterone secretion
is under tonic inhibition by dopamine (Carey et al., 1979). The dopaminergic
mechanism appears to be independent of the nervous system as adrenal
catecholamine content is not depleted by splanchnic nerve section or central
inhibitors of catecholamine biosynthesis (McCarty et al., 1984). It has been
suggested that dopamine exerts a tonic inhibitory influence on aldosterone secretion
(Carey el al., 1984). Other workers have suggested that inhibition of aldosterone
synthesis by dopamine was an extra-adrenal effect caused by increased renal
clearance of All (Connell et al., 1987). Further studies, using a rat adrenal cell
perfusion system, demonstrated that the steroid enhancing effects of
metoclopramide, could be blocked by dopamine but not All (Carey et al., 1979;
Edwards et al., 1980a). Aguilera & Catt (1984), then demonstrated that during
sodium repletion the sensitivity of the aldosterone response to All was enhanced in
the presence of metoclopramide, suggesting that the antagonist reversed the
inhibitory effect of dopamine. A similar effect was seen in humans, although
infusions of dopamine in humans, together with All, prevented the increase in
sensitivity to All normally seen in low sodium states (Edwards et al., 1975;
Aguilera & Catt, 1984). Conversely, other groups have demonstrated no
stimulatory effect of metoclopramide on aldosterone secretion both in vivo and in
vitro, also no inhibitory effect of dopamine on aldosterone secretion (Campbell et
al., 1981; Hampton & Ganguly, 1986). Also the 5-HTergic properties of
metoclopramide itself must be considered, making interpretation of these studies
difficult. Metoclopramide is a substituted benzamide prokinetic drug, and in high
concentrations blocks 5-HT3 receptors, but at least part of its prokinetic action can
be ascribed to its agonist activity at 5-HT4 receptors, which are coupled to
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adenylate cyclase (Dumuis et al., 1988). In vitro studies incubating isolated rat and
bovine ZG cells with dopamine are not conclusive either. In these studies,
dopamine had no effect or a moderate inhibitory effect on basal aldosterone
secretion, and in cells stimulated with All or ACTH, aldosterone secretion was not
affected, a slight inhibition was sometimes seen at high concentrations (>10"^M)(
Edwards et al., 1980a, McKenna et al., 1979; Aguilera & Catt, 1984). In contrast,
infusions of All plus dopamine in sodium deplete humans impeded the increased
sensitivity to All normally observed. This regulatory role of dopamine during
altered sodium status has been supported by other studies which have demonstrated
a decrease in urinary dopamine during sodium depletion and conversely an increase
during sodium loading (Alexander et al., 1974; Carey et al., 1981). Porter et al.,
(1992), demonstrated that dopamine infusions in the isolated in situ perfused rat
adrenal for ten minutes resulted in a transient dose-related decrease in aldosterone
secretion (-50% of the basal at 10~6M dopamine). Simultaneous administration of
haloperidol, a dopamine antagonist, reversed the effect of dopamine, without
affecting basal aldosterone release. If the gland was electrically field stimulated the
aldosterone secretion observed was decreased, and this effect was also abolished by
haloperidol. The investigators suggested that the local release of dopamine may be
involved in the inhibitory effects, thus providing evidence for a physiological
control of the ZG by dopamine.
The effects of dopamine on the adrenal are thought to be mediated by specific
dopamine receptors located on the ZG, classified as DAi and DA2 subtypes. The
mechanism of dopaminergic action is not entirely understood, though some groups
have suggested that the DAi receptor stimulates adenylate cyclase activity and
aldosterone production, whilst the DA2 receptor inhibits adenylate cyclase and
aldosterone (Missale et al., 1986). With the discovery of these two receptor
subtypes, the seemingly contradictory results produced from the various groups, on
dopamine control of aldosterone secretion, may be reconciled. The two receptor
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subtypes are present within the adrenal cortex, and mediate opposing effects, and
the net effect of dopamine on steroidogenesis may depend on which response
predominates in the particular preparation (Gallo-Payet et ah, 1990). Thus
inhibition of aldosterone secretion in the perfused rat adrenal may be attributed to
interaction of dopamine with the DA2 receptor. Also the failure of much higher
concentrations of dopamine to affect ZG cells has been related to its ability to
stimulate both subtypes.
The dopamine involved in the control of aldosterone secretion could potentially be
derived from the circulation or the adrenal itself as several groups have shown the
presence of dopamine containing granules within the adrenal gland, in many
species. Further support for the local effect are studies demonstrating the
stimulatory effects of metoclopramide infusion on aldosterone secretion after
blockade of the autonomic nervous system (Wilson et al., 1983). In situ formation
of dopamine may occur, as the presence of the enzyme L-AAAD has been
demonstrated within the adrenal glatid, and so circulating L-DOPA may be




The Stiimilatofy effects of the indoleamine serotonin (5-hydfoxytfyptiftiifie, 5-tlT)
on Stbfbid secretion by the adrenal cortex were originally dCSfctibed by flosGrtkrantz
(1959). tfbm 1962 onwards, a series of studies demonstfated that pihfeai gland
exttacts Were able to stimulate aldosterone secretion in vitro kartell et at., 1062).
The active substance was identified as 5-HT in 1967 (Jouan, 1967).
Since these early reports many groups have shown the aldosterone stimulatory
properties of 5-HT on the ZG, both in vivo and in vitro, in many species. No effect
has been reported on the ZF (Muller et ah, 1970; Haning et ah, 1970).
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In the rat early studies, proposed that the 5-HT induced aldosterone secretion was
mediated by a 5-HT2 receptor positively coupled to cAMP (Matsuoko et al., 1985;
Williams et al., 1984). It is now well documented that activation of 5-HT2
receptors causes stimulation of phospholipase C, with no effect on cAMP formation
(Conn et al., 1986). Also 5-HT has no effect on inositol phosphate formation
within ZG cells of the rat (Rocco et al., 1990). So it is clear that the effect of 5-HT
on aldosterone secretion cannot be mediated through activation of 5-HT2 receptors.
In frog and human adrenocortical cells the receptor site present within the ZG is the
5-HT4 receptor (Lefebvre et al., 1992; Contesse et al., 1994). Contesse et al.,
(1999) characterised the rat receptor as the 5-HT7 receptor, present within the ZG.
5-HT induces a significant stimulation of cAMP production in frog, rat and human
adrenal preparations (Lefebvre et al., 1992; Matsuoko et al., 1985).
Microfluorimetric studies have shown that in frog and human adrenocortical cells 5-
HT4 agonists cause elevation of the cytosolic calcium concentration, due to calcium
influx through T-type membrane channels, which is secondary to the cAMP
activation (Hamel et al., 1996; Contesse et al., 1996). Similarly it has been shown
that 5-HT stimulates 45Ca++ uptake by rat ZG cells (Davies et al., 1991). No change
in calcium efflux was observed from an intracellular source in isolated ZG cells
loaded with 45Ca+' stimulated with 5-HT, suggesting that 5-HT may act in a similar
fashion to ACTH (Williams, et al., 1981).
In addition to its direct effect 5-HT can also stimulate aldosterone release by
increasing adrenal blood flow (Hinson et al., 1989). 5-HT may also modulate
interleukin-6 and tumour necrosis factor secretion from the adrenal ZG (Ritchie et
al., 1996). As these two cytokines can both modulate corticosteroid production,
they may in part mediate the corticotropic effects of 5-HT (Tominaga et al., 1991).
In amphibians, 5-HT acts directly on adrenocortical cells to stimulate corticosterone
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and aldosterone secretion in a dose-dependent manner (Delarue et al., 1988). In
humans, in vitro studies have shown that 5-HT stimulates corticosterone secretion
by adrenal cells derived from patients with Cushing's disease and aldosterone
secretion by adrenal cells from aldosterone-producing adenomas (Shenker et al.,
1985). Also it has been shown that 5-HT triggers Cortisol secretion from perifiised
human adrenal explants (Lefebvre et al., 1992). The use of a perifusion system
model, which provides detailed information on the kinetics of the response of
adrenocortical cells to corticotropic factors has revealed that sustained
administration of 5-HT causes a biphasic stimulation of Cortisol secretion. Initially
there is a rapid and transient increase followed by a rapid decline of Cortisol release
(Lefebvre et al., 1992), indicating that 5-HT, like other regulatory signals, induces
a desensitisation process.
Intravenous injection of 5-HT and/or oral administration of tryptophan and 5-HTP
to normal volunteers causes a significant increase in plasma corticosteroid levels
and ACTH (Mantero et al., 1982; Modlinger et al., 1979; Shenker et al., 1985).
But do 5-HT and its precursors exert their effects on the adrenal ZG in vivo at the
hypothalamic, pituitary, renal or directly at the ZG level. In vivo, 5-HT stimulates
ACTH secretion and activates the RAS. Studies have demonstrated that 5-HT
causes stimulation of corticotrophin releasing factor from rat hypothalamic tissue
(Fuller & Clemens, 1981; Holmes et al., 1982). However isolated cell
preparations, which have no central involvement, produce aldosterone when
stimulated directly with 5-HT. In dexamethasone treated volunteers, after oral 5-
HT4 agonist treatment, there is a significant rise in aldosterone levels, with no
alterations in plasma renin levels, potassium concentration, ACTH and Cortisol
(Lefebvre et al., 1993; 1995). This would seem to indicate that the aldosterone
stimulatory activity of 5-HT in vivo, cannot be accounted for by activation of the
RAS, elevation of potassium or stimulation of pituitary corticotrophs.
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The occurrence of 5-HT within the adrenal gland has been demonstrated by
immunohistochemical and biochemical approaches. 5-HTergic fibers have been
detected in the mouse adrenal cortex (Fernandez-Vivero et al., 1993), and the
occurrence of 5-HT has been immunocytochemically and biochemically
demonstrated in the adrenal medulla of mice and rats (Verhofstad & Jonsson, 1983;
Fernandez-Viveros et al., 1993). In the rat and frog adrenal gland, 5-HT like
immunoreactivity has been visualised in phenylethanolamine-N-methyl-transferase-
positive cells, indicating that only epinephrine producing cells contain 5-HT
(Brownfield et al., 1985; Delarue et al., 1988). In fact, electron microscope studies
revealed that 5-HT is sequestered in secretory vesicles located at the periphery of
the chromaffin cells. Thus 5-HT is likely to be released during splanchnic nerve
stimulation together with catecholamines. In the rat 5-HT also occurs in mast cells,
located in the wall of arterioles at the point they enter the connective capsule of the
adrenal gland, and throughout the medulla and cortex (Hinson et al., 1989). In
humans chromaffin cells do not contain 5-HT, intra- and perivascular mast-like cells
which are present throughout the adrenal gland are the only store of 5-HT
(Lefebvre et al., 1992). HPLC analysis of mouse, frog, rat and human adrenal
gland extracts, combined with electrochemical detection, has revealed the presence
of 5-HT and 5-HIAA. The occurrence of 5-HIAA within adrenal tissue most likely
reflects local metabolism of 5-HT after release of the indoleamine from
serotoninergic cells. Within the human adrenal cortex mast cells secrete 5-HT
which is then metabolised by a type A monoamine oxidase located in intracortical
chromaffin cells (Lefebvre et al., 1996).
Verhofstad & Jonsson, 1983, reported that 5-HT in the rat adrenal gland was
formed by decarboxylation of 5-HTP. In the frog interrenal gland, substantial
amounts of 5-HT and 5-HIAA are synthesised from [3H]-tryptophan, suggesting
that tryptophan hydroxylase activity is expressed within frog chromaffin cells
(Delarue et al., 1992). Active uptake of exogenous 5-HT by chromaffin cells has
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been demonstrated in frog, cattle and rat adrenal glands (Delarue et al., 1992;
Verhofstad & Jonsson, 1983).
1.10. 5-HT, biosynthesis, metabolism and receptor sites.
This next section will serve as an overall review of 5-HT, briefly describing the
biochemistry, metabolism, transport and action, mainly in the adrenal cortex, of the
indoleamine 5-HT. At the end of this section the main aims of this thesis will be
discussed.
1.11. Biosynthesis and Metabolism of 5-HT.
Apart from 5-HT neurones in the brain, spinal cord and in the gut (enteric plexus),
the major site of 5-HT synthesis in man is in the enterochromaffin cells of the gut
(Erspamer & Testini, 1959). These cells have also been described as amine
precursor uptake and decarboxylation, or APUD, cells (Pearce, 1968). Platelets,
which contain a high concentration of 5-HT, do not synthesise 5-HT, but in fact
accumulate 5-HT from the plasma by a high affinity uptake system. Thus under
normal circumstances plasma contains a relatively low concentration of free 5-HT.
5-HT is synthesised from dietary L-tryptophan in two enzymatic steps, via the
intermediate compound 5-hydroxytryptophan (5-HTP) (Figure 1.6). In almost all
tissues that contain large amounts of 5-HT, apart from platelets, the enzyme
tryptophan hydroxylase has been detected, so the enzyme has been located in the
enterochromaffin cells, the pineal gland, mouse mast cells and the CNS (Lovenberg
et al., 1965; Deguci, 1977; Legay et al., 1983). Inside the cell the enzyme activity
can be located in the cytosol or associated with subcellular organelles (Lovenberg
et al., 1967). Centrally 5-HT is synthesised from L-tryptophan entering the brain
through the blood-brain barrier and is not dependent upon peripheral 5-HT
synthesis. Circulating 5-HT does not enter the brain tissue through the blood-brain
barrier, except perhaps locally in areas deficient in this barrier such as the area





































Figure 1.6. Diagram depicting the biosynthesis and metabolism of 5-HT.
peripherally, is not a major metabolic pathway for tryptophan, as only 1-2% of
dietary tryptophan is converted to 5-HT. Tryptophan circulates in the blood in
both free and albumin bound forms. Since the enzyme converting tryptophan to 5-
HTP, tryptophan hydroxylase, is not saturated with substrate in vivo (Km ~ 3x10"
5m) under normal circumstances, and since 5-HTP is rapidly decarboxylated into 5-
HT, the rate-limiting step in 5-HT biosynthesis is the 5-hydroxylation of tryptophan
by tryptophan hydroxylase (Lovenberg et al., 1967). The hydroxylation of
tryptophan into 5-HTP requires the presence of a co-factor, a tetrahydrobiopterin,
and it has been suggested that the concentration of the oxidised form of this co-
factor (dihydrobiopterin) may also play a regulatory role in 5-HT synthesis.
However, an increase in tetrahydrobiopterin concentration in vitro did not lead to
an increase in 5-HT synthesis. At concentrations of 2x10"^M tryptophan, the
enzyme is inhibited. In addition the pharmacological agent p-chlorophenylalanine
(PCPA), inhibits the enzyme and thus provides a specific tool for inhibiting 5-HT
synthesis which can be used to investigate the effects of 5-HT depletion (Reviewed
by Smith, D.G., 1988).
The second enzymatic step in the formation of 5-HT is the conversion of 5-HTP
into 5-HT catalysed by the enzyme L-aromatic amino acid decarboxylase (L-
AAAD; Figure 1.6). The presence of L-AAAD was first reported in mammalian
kidney extracts (Holtz et al., 1938) and is located in a number of tissues including
liver, kidney, brain and adrenal gland. L-AAAD has a Km of 8xl0~^M, which is
quite low and thus this enzymatic step in the formation of 5-HT is not rate-limiting.
The co-factor involved is pyridoxal phosphate, which if present in excess of 6x10"
inhibits L-AAAD activity (Bouchard & Roberge, 1979). L-AAAD is also
involved in the production of catecholamines, such as dopamine, trace amines such
as tyramine from tyrosine, 2-phenylethylamine from phenylalanine and tryptamine
from tryptophan (Juorio & Boulton, 1982; Dyck et al., 1983). In addition, L-
AAAD may have as yet unknown functions in non-monoamine neurones in which
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L-AAAD has been localised (Jaeger et al., 1986; Kitahama et al., 1988; Eaton et al.,
1993) (See Chapter Five).
5-HT undergoes several metabolic transformations (Figure 1.7). Oxidation of 5-
HT, by monoamine oxidase type A, forms 5-hydroxyindoleacetaldehyde, an
unstable intermediate. This enzyme is located on the outer mitochondrial surface
and requires NAD+ as co-factor (Tipton et al., 1976). Further oxidation by
aldehyde dehydrogenase produces 5-hydroxyindole acetic acid (5-HIAA), large
quantities ofwhich are excreted in urine (up to 50 pmol/day; Udenfriend, 1956). 5-
HT is metabolised in this way in the liver and lungs. The liver also contains a
detoxificating enzyme, glucoronyltransferase, which conjugates glucoronic acid to
5-HT as well as other compounds including lipids. 5-HT-O-glucoronide is a major
metabolite in isolated rat liver perfusate and if monoamine oxidase activity is
inhibited 5-HT is readily converted to this product (Tyce et al., 1968). In addition,
if the oxidative pathway, which forms 5HIAA, is inhibited, say after ingestion of
alcohol, an alternative reductive pathway occurs, catalysed by aldehyde reductase,
forming 5-hydroxytryptophol (Davis et al., 1967). This enzyme requires NADP as
co-factor, has a high affinity for its substrate and is a minor metabolic pathway in
mammals. Another metabolic pathway is conversion into N-acetyl 5-HT, by the
enzyme 5-HT-N-acetyltransferase, which is located in the cell cytosol and requires
acetyl co-enzyme A (Paul et al., 1974). N-acetyl 5-HT is then converted into 5-
methoxy-N-acetyltryptamine (Melatonin), by hydroxyindole-O-methyltransferase
which utilises S-adenosylmethionine as the methyl donor. Formation of melatonin
occurs primarily in the pineal gland, and is of particular interest since there is a
marked rhythm in the levels of melatonin in the blood and also in the activity of the
enzyme N-acetyltransferase, which is responsible for the synthesis of N-acetyl 5-HT
from 5-HT. The peak of N-acetyltransferase activity occurs during the hours of
darkness, and coincides with peak levels of 5-HT in the pineal gland. Melatonin is



































Figure 1.7. Diagram depicting the metabolism of 5-HT.
mammals. The enzyme hydroxy indole-O-methyl transferase can also act on 5-HT
to form 5-methoxy 5-HT, and this has been detected in the hypothalamus of the rat
(Green et al., 1973). 5-HT can be conjugated to a sulphate moiety by 5-HT
sulfotransferase, an enzyme which has been located in liver, lung, kidney and the
CNS. Sulphonated 5-HT, 5-HT-O-sulphonate, has little biological activity, while
removal of the sulphate group by arylsulphatase can regenerate free 5-HT
(Kishimoto et al., 1961). This metabolite accounts for a small proportion of 5-HT
metabolites, and its concentration does not increase markedly after monoamine
oxidase inhibition. Another minor metabolic pathway, occurring in the lung and
CNS, is the N-methylation of 5-HT which requires the enzyme S-
adenosylmethionine.
1.12. The Transport and Storage of 5-HT.
1.12.1 Transport of 5-HT.
The levels of biogenic amines in the synaptic cleft, such as 5-HT, are regulated by
the action of plasma membrane biogenic amine transporters. These carrier proteins
couple the uptake of sodium, chloride and potassium ions to the reuptake of
neurotransmitters released into the synaptic cleft, thus removing extracellular
transmitter, and regulating the levels of transmitter acting on the receptor. This
uptake process is the first of two steps required for neurotransmitter recycling.
Once the neurotransmitter is in the cytoplasm, a second transport process, requiring
a hydrogen ion gradient, sequesters transmitter within synaptic vesicles, before the
transmitter is again released via exocytosis. Transporters are located on the plasma
membrane of serotonergic presynaptic terminals, on plasma membranes of platelets,
pulmonary endothelium and placental brush border epithelia, where they participate
in systemic 5-HT homeostasis (Rudnick, 1977; Balkovetz et al., 1989).
The major storage site for 5-HT in the plasma is the platelet, stored within the
dense granules complexed with di- and tri-nucleotides and heavy metal cations
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(Pletscher, 1968). After stimulation of the gut, 5-HT is released from the
enterochromafftn cells, into the bloodstream where it is available for metabolism or
uptake by platelets, a process which can either be active or passive. Active uptake
is energy dependent, rapid and saturable, requiring external sodium and chloride
ions (Rudnick & Nelson, 1978), and internal potassium ions. Passive uptake, or
diffusion, is not dependent on cellular energy, and is the dominant process at high
external concentrations of 5-HT (Born & Bricknell, 1959). Once internalised, 5-
HT is transported into the dense granules for storage. Once inside the dense
granules 5-HT is sequestered with large aggregates of ADP, ATP and divalent
metal ions.
Of the available data on the 5-HT transporter molecule most has originated from
studies performed on platelet plasma membrane vesicles, as platelets are considered
to accumulate and store 5-HT in a manner similar to that seen in 5-HT-ergic nerve
terminals (Rudnick, 1977). Oubain does not inhibit the transport of 5-HT within
platelet plasma membranes, suggesting that 5-HT transport is not directly coupled
to the Na+/K+ ATPase, however uptake can be inhibited by tricyclic
antidepressants and by ionophores such as gramicidin which catalyse
transmembrane exchange of sodium and potassium dissipating the transmembrane
ionic gradients (Rudnick, 1977).
A model for the transport of 5-HT is depicted in Figure 1.8. In the event of
transport of 5-HT into the neurone, 5-HT, sodium and chloride ions bind to the
plasma membrane transporter on the extracellular side, and this complex is then
translocated to the cytoplasmic surface where it dissociates. At this point
potassium ions bind to the plasma membrane transporter enabling reorientation of
the protein so that the binding site once more faces the extracellular membrane
surface (Graham & Langer, 1990). Inhibitors of this transporter include cocaine,
imipramine, desmethylimipramine, amitriptyline, citalopram, fluoxetine and
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Figure 1.8. Model for the translocation cycle of the 5-HT transporter.
In the first step of uptake, 5-HT, sodium ions and chloride ions bind to
the transporter (To) on the exterior plasma membrane, upon which
they are translocated across the membrane. After dissociation of the
complex at the cytoplasmic side, the binding of potassium to the
transporter (Ti), serves to reorientate the 5-HT binding site to the
extracellular membrane surface (adapted from Graham & Langer,
1990).
paroxetine. Once inside the cell the uptake of 5-HT into storage vesicles, by the
vesicular transporter, occurs via two sequential processes. Initially there is a
vacuolar ATP-driven hydrogen ion pump which acidifies the organelle interior
generating an electrochemical gradient across the vesicular membrane for hydrogen
ions, the subsequent coupling of internal hydrogen ions with the vesicular
transporter provides the energy for transport of 5-HT into the storage vesicle in
exchange for hydrogen ion extrusion. For every protonated amine molecule taken
into the vesicle, two H+ ions are released into the cytoplasm. This uptake is
blocked by reserpine and tetrabenezine. 5-HT accumulation within the storage
vesicle is dependent upon a transmembrane pH difference and a transmembrane
electrical potential difference (Rudnick & Clark, 1993). Synaptic vesicles, adrenal
chromaffin granules, mast cells, basophilic secretory granules and platelet dense
granules all contain this transport system.
1.12,1.1. Cloning of the 5-HT Transporter.
A) Plasma Membrane Transporter.
Up until the early 1990's, the absence of cloned noradrenaline transporters and 5-
HT transporters cDNA's restricted various areas of study on the transporter
molecule, including, gene expression, transporter structure and function,
transporter regulation and biophysical properties of the transporters. In 1991
Pacholczyk el al., utilised an expression cloning approach in which cDNAs were
screened for their ability to confer noradrenaline transporter function in non-
neuronal cells. Intracellular accumulation of the surrogate noradrenaline
transporter substrate 125]_iabeiiecj metaiodobenzylguanedine (MIBG) served as an
autoradiographic marker for COS cells expressing the human noradrenaline
transporter cDNA. The potential noradrenaline transporters identified in this study
were then tested for specificity by incubating the transfected COS cells with MIBG
in the presence and absence of desipramine, a noradrenaline transporter selective
antidepressant. From this, a single cDNA was isolated, and, in 1991, Blakely et al.,
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confirmed the synthesis of a catecholamine-selective transporter which was
inhibited by cocaine, antidepressants and amphetamines.
At about the same time Guastella et al. (1990) reported the cloning of the first
isoform of a Na+ and CI" coupled GABA transporter, which had 46% amino acid
sequence homology with the isolated noradrenaline transporter. Since the GABA
and the noradrenaline transporter share sequence homology, but have markedly
different pharmacological profiles, Blakely et al., reasoned that transporters with
similar drug sensitivities to that of the noradrenaline transporters would also exhibit
-50% sequence homology with the cloned noradrenaline transporter and thus could
be isolated by homology based techniques. They were particularly interested in the
5-HT transporter, and, in 1991, Blakely et al. reported the cloning and expression
of a 5-HT transporter within the rat brain. Northern blots and in situ hybridisation
techniques were then used to determine whether any of these homologues might
represent a 5-HT transporter. One clone hybridised selectively to a 3.7kb midbrain
and brainstem RNA that exhibited localised synthesis in the serotonergic raphe
complex. Isolation of a more complete midbrain cDNA, using the original isolate
as a probe and looking at its function in transfected HeLa cells, confirmed the
expression of a 5-HT selective transporter inhibited by selective 5-HT transporter
antagonists, including paroxetine, citalopram and fluoxetine. 5-HT uptake into
transfected cells was blocked by low concentrations of amphetamines and cocaine
(Blakely et al., 1991).
Hoffman et #7.(1991) then described a 5-HT transporter from basophilic leukaemia
cells, and since these initial studies cDNA's encoding functional 5-HT transporters
have been cloned from mouse brain (Chang et al. 1994) and human placenta
(Ramamoorthy et al., 1993). The cDNA's encode proteins that are predicted to
have twelve hydrophobic spanning regions. This topology is shared with other
transporters, including the Na+/glucose transporter. Among the neurotransmitter
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transporters there is a great deal of sequence homology. In fact the close
relationship between the GABA and noradrenaline transporters suggests that they
may have all evolved from a single precursor transporter. Amino acid sequences
among the neurotransmitter transporters are most similar within the hydrophobic
membrane spanning regions. All of these transporters exhibit glycosylation sites on
the extracellular loop between transmembrane domains three and four.
Additionally, all exhibit potential phosphorylation sites on the intracellular portions
of the molecule, suggesting a potential for post-transational regulation. The
potential for subtypes of 5-HT transporters does exist, but the sequence identity of
brain and basophilic leukaemia cDNA's indicates that peripheral and CNS 5-HT
transporters are encoded by a single gene, a hypothesis supported by the
identification of a single 5-HT transporter loci in human and mouse, which lies on
the long arm of chromosome 17 (Gregor et al., 1993; Ramamoorthy et al., 1993).
Also 5-HT transporters encoded by human platelet and brain RNA's appear to be
identical (Lesch et al., 1993).
Rat and human 5-HT transporters are predicted to be encoded by subunits of 630
amino acids with >90% cross-species identity. 5-HT transporters exhibit a
topology of twelve transmembrane domains with a large extracellular loop between
transmembrane domains three and four, which contains sites for n-glycosylation.
NH2 and COOH termini are predicted to lie in the cytoplasm (Figure 1.9).
B) Vesicular Transporter.
Schuldiner et al. (1990) isolated the transporter from detergent solubilised bovine
chromaffin granule membranes using the inhibitor reserpine. The purified
preparation consisted of an 80kDa glycoprotein. Transfection of CHO fibroblasts,
normally sensitive to the neurotoxin MPP+, with cDNA from PC-12 cells produced
MPP+ resistant transfectants which concentrated dopamine into vesicular
structures. When the PC-12 cDNA responsible for this property was isolated and
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Figure 1.9. Schematic representation of the 5-HT transporter,
containing 12 transmembrane domains, cytoplasmic amino and
carboxy-termini, proposed N-linked glycosylation sites and residues
conserved in dopamine and noradrenaline transporters (•).
sequenced, it was found to predict peptide sequences highly homologous to those
of peptides derived from the purified bovine chromaffin granule amine transporter
(Edwards, 1992). Hoflfnan et al.( 1991), transfected CV-1 cells with cDNA
prepared from RBL cell mRNA. These cells take up 5-HT using the plasma
membrane transporter and store it in secretory granules containing a vesicular
transporter. Some cDNA clones from this study conferred increased 5-HT uptake
in CV-1 cells, and were found to encode a vesicular transporter. The sequence of
this transporter is highly homologous to the transporter cloned from PC-12 cells,
and almost identical to a transporter cloned from rat brain (Edwards, 1992).
1.12.1.2. Transporter Families.
At least five distinct families of transporters exist, the divisions based on differences
in ion dependence, topology and sequence homology. Firstly, the sodium and
chloride ion dependent transporter family which can be divided into two
subfamilies; a monoamine subfamily and an amino acid-like subfamily. The
monoamine subfamily consists of the dopamine, noradrenaline and 5-HT
transporter molecules. These transporter molecules are all encoded by a closely
related family of cloned cDNA's. and are all inhibited by cocaine and share
structural and mechanistic properties. The amino acid-like subfamily consists of the
GABA, glycine, betaine, taurine and proline transporters. This family is rapidly
expanding and also contains a number of 'orphan clones'. The other transporter
families are the glutamate transporters, the Na+-dependent glucose transporter, the
H+-dependent vesicular monoamine transporters and a family of other vesicular
transporters, with unidentified transport functions.
1.12.1.3,Distribution and Regulation of the 5-HT Transporter.
Although this transporter is closely related to the dopamine and noradrenaline
transporters, substantial sequence divergence in regions between putative
transmembrane domains as well as in the predicted cytoplasmic NH2 and COOH
46
termini have been observed. This aspect was utilised by Blakely et al. (1994), to
prepare 5-HT transporter antibodies to enable visualisation of the transporter in
situ. 5-HT transporters were found to be distributed in a manner consistent with
the known localisation of 5-HT uptake, 5-HT transporter antagonist binding and 5-
HT immunoreactivity. Specifically, within rat and human brain, 5-HT transporters
were visualised in the dorsal raphe complex, the substantia nigra and throughout the
forebrain.
The mechanisms involved in the regulation of 5-HT transporters are unclear.
Launay et al., (1992) described the effects of histamine in elevating rates of 5-HT
transport in platelets. This effect may be mediated through increases in cGMP.
Activation of protein kinase C has also been implicated in platelet 5-HT transporter
down regulation. In vitro studies in human and rat, have established that the 5-HT
transporter is influenced by cAMP-dependent pathways, by changes in intracellular
calcium, treatment with calmodulin inhibitors, and by activation of PKC and cGMP
(Quian et al., 1995; 1997). Chronic hormonal regulation of transporter gene
expression has also become evident both in vivo and in model cell lines (Reviewed
by Rudnick & Clark, 1993).
1.12.1.4, Clinical Significance of 5-HT Transporters.
Blockade of 5-HT plasma membrane transport results in an acute elevation of
extracellular 5-HT, resulting in an amelioration of a variety of neuropsychiatry
disorders. In fact, neurotransmitter transporter uptake inhibitors are used clinically
as anti-depressant drugs for example paroxetine and fluoxetine. However certain
drugs of abuse also act to block 5-HT transport for example
methylenedioxymethamphetamine (MDMA; 'Ecstasy') and amphetamines. These
drugs are substrates for the transporter, and cause transmitter release by a process
of transporter mediated exchange. MDMA binds to the transporter at the same site
as the selective reuptake inhibitors, and causes the exchange of one molecule of 5-
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HT to the outside of the membrane, for one molecule of drug to the inside, leading
to large concentrations of synaptic 5-HT. The process of transmitter release is a
non-exocytotic process, as the process does not require calcium ions. MDMA also
causes degeneration of serotonergic nerve endings by an as yet unidentified process
but one that may require dopamine release as well (Rudnick & Wall, 1992). This
aspect and the effects of certain uptake blocking drugs will be discussed in more
detail in Chapter Six.
1.13 Storage of 5-HT.
5-HT is widely distributed throughout the plant and animal kingdom and storage
sites have been located in the pituitary gland, the pineal gland, the pancreas,
parafollicular cells of the thyroid gland, the heart, mast cells and the adrenal gland
(Saavedra et al., 1974; Koevary et al., 1983; Verhofstadt & Jonsson, 1983;
Holzwarth et al., 1984). However the most common sites of storage are in the
CNS, the gastro-intestinal tract (GIT) and in platelets.
Neurones containing 5-HT were first identified in the CNS using fluorescent
histochemical techniques (Dahlstrom & Fuxe 1964). 5-HTergic neurones are
derived from clusters of 5-HT containing cell bodies situated in the brain stem,
which project both upwards to various areas in the CNS including the cortex,
striatum and hippocampus, and downwards terminating in the spinal cord. 5-HT in
the CNS plays many important roles in a range of behavioural patterns including
sleep induction, thermoregulation, psychiatric disorders, mood changes, drug
dependence and appetite disorders.
In the gut, 5-HT is synthesised and stored in the enterochromaffin cells. The
storage granules are located near the base of the enterochromaffin cells.
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Almost all circulating 5-HT is contained within platelets. Platelets are small
anucleate cells whose main function is hemostasis. Platelets do not synthesise 5-
HT, and the majority of 5-HT associated with platelets arises from the
enterochromaffin cells of the intestinal mucosa. 5-HT is stored within dense
granules in close association with cations, magnesium and calcium, nucleotides and
proteins.
Within the adrenal gland 5-HT containing cells have been visualised by
immunohistochemistry in various species, including the rat and mouse (Verhofstaad
& Jonsson, 1983; Delarue et al., 1988). At the electron microscope level 5-HT
appears to be sequestered in chromaffin vesicles within adrenochromaffin cells,
indicating that the indoleamine could be released together with catecholamines
during splanchnic nerve stimulation (Brownfield et al., 1985). The major
metabolite of 5-HT, 5-HIAA, has also been detected in adrenal extracts by high
pressure liquid chromatography (HPLC) (Lefebvre et al., 1992). The uptake of 5-
HT by adrenaline storing cells in the rat and mouse adrenal medulla has also been
observed (Verhofstaad & Jonsson, 1983). In 1992, Lefebvre et al., demonstrated
the presence of 5-HT immunoreactive cells in human adrenocortical cells, and
concluded that the 5-HT was in fact localised within mast cells found throughout
the adrenal cortex. So 5-HT in the adrenal gland could act as a regulator of
adrenocortical secretion in a paracrine manner, for example 5-HT released under
splanchnic nerve stimulation could contribute to the co-ordinated response of
adrenochromaffin and adrenocortical cells during stress conditions.
1.14. Release of 5-HT.
Once stored within the enterochromaffin cells, release of 5-HT can be triggered by
a number of stimuli, including vagal nerve stimulation, an increase in transluminal
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pressure or a decrease in intestinal pH (Kellum & Jeffe, 1976; Forsberg & Miller,
1983). Upon its release 5-HT is thought to stimulate secretion of pepsin and mucus
and inhibit gastric acid production. Also, 5-HT increases the motility of the small
intestine and stimulates water and electrolyte secretion. 5-HTergic neurones also
provide 5-HT to the gut.
5-HT is released from the platelets by four main mechanisms; exocytosis, exchange,
inhibition of transport at the granular membrane and by aminophores and
protonophores. These reactions are triggered by a number of stimuli including
thrombin, which is involved in the blood clotting reaction. Platelets may act as a
circulating store for 5-HT, releasing 5-HT at a site or specific tissue which has no
store for 5-HT but does possess 5-HT receptors, such as the thyroid gland and the
adrenal (Osim & Wylie, 1983).
5-HT located in mast cells is stored with histamine in large seceretory granules.
Compounds that cause exocytosis, including compound 48/80 and some peptides,
can release histamine and 5-HT from mast cells simultaneously, and the 5-HT in
mast cells may contribute to the content of 5-HT in other organs such as the liver,
lung and heart (Jarrott et al., 1975; Gillis, 1985).
1.15. 5-HT Receptors.
5-HT is present in most organisms, ranging from humans to species with primitive
nervous systems, for example worms, and the compound itself illicits a wide and
varied range of effects both peripherally and centrally. These include constriction
and relaxation of smooth muscle, motor activity and psychiatric disorders. This
pleiotropy can be explained both by the wide distribution of 5-HT and by the
multiplicity of receptors for 5-HT.
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Evidence for the existence of serotonergic receptors was first presented by Gaddum
& Picarelli in 1957. They described two mechanisms of action of 5-HT in guinea
pig ileum, a direct action on the smooth muscle and an indirect action mediated by
the release of acetylcholine from parasympathetic nerve endings. As the former
mechanism was blocked by dibenzyline (D) and the latter by morphine (M), the
excitatory 5-HT receptors on smooth muscle were designated D-receptors and on
parasympathetic nerve endings M-receptors. This classification was based purely
on pharmacological data and it was not until the advent of radioligands, specific
receptor agonists, that a clearer classification was made.
Receptor sites were first observed by Marchbanks (1967) using [^H]-5-HT. Then
Farrow & Vunakis (1973) demonstrated that [^HJ-LSD binding could be inhibited
by 5-HT. The earliest evidence of selective high affinity and saturable binding of
[3h]-5-HT to a receptor site was presented almost simultaneously by two groups
(Bennett & Snyder, 1976;Fillion et a/., 1976). However it was the work of
Peroutka & Snyder (1979) that led to the initial classification of 5-HT receptors.
They demonstrated that [^H]-5-HT and [^HJ-spiperone, a potent 5-HT antagonist,
each bound to distinct sites. They named the binding site with high affinity for
[3h]-5-HT the 5-HTi receptor and that with high affinity for [^HJ-spiperone the 5-
HT2 receptor. In 1981 Pedigo et al., proposed the existence of two 5-HTi
receptor sites, 5-HT]A which exhibited a high affinity for inhibition of [^H]-5-HT by
spiperone, and 5-HTm which exhibited a low affinity for inhibition of [^H]-5-HT by
spiperone. A third 5-HTi receptor was proposed based on the high affinity for
inhibition of [^H]-5-HT by mesulergine, termed 5-HTjc (Pazos & Palacios, 1985).
Then, various studies with [^H]-ketanserin and [^H]-8-OH-DPAT, by several
groups, led to further 5-HT receptor sites being proposed, which differed from the
existing sites.
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It thus became necessary to reconcile data from functional studies with those from
radioligand studies, and provide a common system of nomenclature for the 5-HT
receptors identified from the studies performed. In 1986 Bradley et al., proposed a
classification system for the three major serotonergic receptor classes, 5-HTi-like,
5-HT2 and 5-HT3. 5-HTi -like receptors, described the group of receptors having a
high affinity for 5-HT and 5-carboxamidotryptamine and antagonised by
methiothepin and methysergide. 5-HT2 receptors were the initial D-receptor
subtype, described by Gaddum & Piccarelli (1957). These receptors mediate a
variety of peripheral actions of 5-HT and correspond to the cortical binding sites
described by Peroutka & Snyder (1979), having a low affinity for 5-HT and a high
affinity for particular serotonergic antagonists such as ketanserin, methysergide,
mianserin and metergoline. 5-HT3 receptors correspond to the M-receptor subtype,
and are present in peripheral neurones that mediate the depolarising actions of 5-
HT, characterised by their high affinity for cocaine derivatives.
Since this classification scheme was proposed the rapid and extensive advances in
development and application of molecular biology techniques has led to the
discovery ofmany new 5-HT receptors, prompting a number ofnew proposals for a
new classification system (Frazer et ah, 1990; Peroutka, 1990). Now the
classification of 5-HT receptors is based on operational (specific agonists,
antagonists and radioligands), structural (molecular biology techniques) and
transductional (second messenger systems) criteria. So with the use of these
essential data, a "fingerprint" classification can be utilised to identify distinct
receptors.
1.15.1. 5-HTi Receptors.
These receptors are characterised by a high affinity for 8-OH-DPAT, a moderate
affinity for methiothepin, methysergide and quipazine, and a low affinity for
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ketanserin, ICS 205-930 and MDL 72222. At least five 5-HTi receptor sub-types
are now recognised, namely 5-HT]A, 5-HTiB (formerly 5-HTiDp), 5-HTiD (formerly
5-HTioa) 5-HTje and 5-HTiF. All are seven transmembrane, G-protein coupled
receptors (Gj or G0), comprising between 365 and 422 amino acids and displaying
an overall sequence homology of 40%. These receptors are linked preferentially to
the inhibition of adenylate cyclase.
1.15,1.1. 5-HTi a Receptors.
Pedigo et ah, (1981) demonstrated that spiperone could be used to discriminate
between two different subclasses of 5-HTi sites, that is 5-HT1A having a high
affinity for spiperone and 5-HTiB having a low affinity. Gozlan et ah, in 1983,
demonstrated that [^H]8-OH-DPAT bound selectively to the 5-HTiA site. Since
these early studies many more selective ligands have become available including 5-
MeO-DPAT, buspirone and isapirone. The high affinity of 8-OH-DPAT allowed
the affinity purification of 5-HT1A receptors from rat hippocampus (El Mestikawy
et ah, 1989). A selective antagonist at this receptor is WAY 100635 (Fletcher et
ah, 1996).
These receptors are located mainly in the hippocampus, septum and amygdala (the
limbic system) areas of the CNS, areas concerned with mood and anxiety. Also, to
a lesser extent, these receptors are also found in the dorsal and median raphe nuclei
where they govern feeding, hyperphagia, male rat sexual behaviour, locomotion and
thermoregulation (Hillegaart, 1991). Animals given selective agonists suffer from a
stereotypic "5-HT syndrome". In humans this syndrome results in confusion,
nervousness, hyper-reflexia, restlessness, hypomania, excitation, myoclony and
shivering (Sternbach, 1991). Postsynaptic 5-HT]A receptors are thought to mediate
this effect (Tricklebank, 1987). On raphe neurones the receptors are predominantly
somatodendritic autoreceptors. Those on serotonergic fibres in the hippocampus
are post synaptic (Verge et ah, 1986). In both cases they mediate neuronal
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inhibition and 5-HT synthesis and release. Northern blot analysis of mRNA from
foetal human tissues demonstrated the presence of 5-HTiA receptors peripherally in
lymphatic tissues, gut, muscle and kidney, but not in lung, heart, adrenal and
placenta (Kobilka et al., 1987). Clinically, selective 5-HT reuptake inhibitors are
thought to act on these receptors to produce their antidepressant effects (Blier &
De Montigny, 1987).
Human and rat 5-HT1A receptors have been cloned. The receptor consists of a
monomelic chain, containing approximately 420 amino acids, characterised by a
long third intracellular loop and a short carboxy terminal domain.
5-HTiA receptors can activate several different second messenger systems within
the same cell, depending on the G-proteins and effectors present, effecting
numerous target proteins and cellular functions. Preferential coupling is to the
inhibition of adenylate cyclase via the pertussis-toxin sensitive protein Gj In HeLa
cells, stimulation ofPLC and an increase in intracellular calcium was also observed
(Fargin et al., 1989; Middleton et al., 1990). In Chinese hamster ovary cells, PI
hydrolysis was stimulated and also intracellular calcium was increased, in addition
to inhibition of adenylate cyclase (Raymond et al., 1992). In the hippocampus, the
receptors were found to modulate K+ channels, via a pertussis-toxin sensitive G-
protein which does not involve cAMP, DAG or IP3 (Andrade et al., 1986; Colino
& Halliwell, 1987). In atrial myocytes, the activation of K+ channels was also
observed (Karschin et al., 1991), and in 1993, Dascal et al., identified a cDNA
which may correspond to the 5-HTiA activated K+ channel observed previously in
the hippocampus.
1.15.1.2. 5-HTm Receptors.
5-HTib receptors were first defined in rat brain (Pedigo et al., 1981) as a
component of the high affinity [^H]-5-HT binding sites with a lower affinity for
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spiperone than 5-HTiA receptors. Binding sites with similar pharmacological
properties have subsequently been described in other rodent species, including the
mouse and hamster (Hoyer & Middlemiss, 1989). This receptor originally appeared
to be specific to rats and some other rodents. However Hoyer & Baddeke, (1993),
characterised the amino acid sequence of this receptor and it was found to be 93%
identical overall and 96% identical within the transmembrane domains with that of
the 5-HTiop receptor, a close homologue found in higher species, with similar
functions and distribution. The difference between these two receptors is attributed
to a single amino acid mutation within the transmembrane spanning region (Hoyer
& Boddeke, 1993). These receptors are now classified as species homologues of
the same receptor, and called h5-HTiB (formerly 5-HTiDp) and r5-HTiB, with the
prefix h denoting human and the prefix r denoting rat. Cyanopindolol, 5-
carboxamidotryptamine and RU24969 are all potent non-selective agonists at the
receptor, and the indole analogue CP93,129 appears to be the first selective agonist
at the receptor site.
These receptors are found mainly in the substantia nigra and basal ganglia, where
they function either as autoreceptors on serotonergic projections to the cortex,
controlling 5-HT release or as hetero-receptors modulating release of acetylcholine
and glutamate (Maura & Raiteri, 1986). Peripherally they inhibit the release of
noradrenaline (Molderings & Gothart, 1990), and mediate vascular smooth muscle
contraction (Craig & Martin, 1993). They also stimulate the release of prolactin in
the rat (Van De Kar et al., 1989). Centrally 5-HTiB receptors may play an
important role in modulating the release of other neurotransmitters. The receptors
in the rodent may play roles in temperature regulation, stress, feeding and sexual
behaviour (Tricklebank et al., 1986; Bendotti & Samanin, 1987; Martin & Peuch,
1991). However more specific agonists and antagonists are needed to provide
conclusive evidence to indicate a role for 5-HTiB receptors in these behavioural
states.
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The rat receptor is a single protein of 386 amino acids, and is linked preferentially
to the inhibition of adenyate cyclase. The human receptor is a single protein of 390
amino acids, linked to inhibition of adenylate cyclase (Mengod et al., 1994).
1.15,1.3. 5-HTm Receptors.
The existence of the 5-HTiD receptor was first described by Heuring & Peroutka
(1987) in bovine brain, on the basis of binding studies with [^H]-5-HT in the
presence of drugs masking 5-HTiA, 5-HTiB and 5-HTiC subtypes, the remaining
binding was termed 5-HTiD. The receptor has a high affinity for 5-HT, 5-
methoxytryptamine, 5-carboxamidotryptamine, metergoline and ergometrine. None
of these compounds are selective, although a number of potent and relatively
selective 5-HTiB/d receptor agonists have been characterised, including sumatriptan,
CP-122288, MK 464, GR 46611 and SKF 99101H.
In the CNS of various species the receptor is present in highest density in the
substantia nigra, basal ganglia and striatonigral pathway (Waeber et al., 1990).
Receptors are also present in the hippocampus, cortex and raphe. Receptor
mapping using autoradiography and mRNA hybridisation in rat brain indicated that
5-HTiDa receptors are co-localised with 5-HTiB, but at lower densities (Bruinvels et
al., 1991). They function as autoreceptors on cortical nerve terminals and are also
located postsynaptically on non-serotonergic terminals, modulating acetylcholine
and glutamate release (Raiteri et al., 1986). In peripheral tissues 5-HTiD receptors
are involved in neuropeptide release from guinea pig sensory afferent neurones and
mediate endothelium-dependent vasorelaxation in some blood vessels (Buzzi et al.,
1991). With the advent of more specific ligands the roles of these receptors
physiologically will become more apparent.
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Human genes encoding two 5-HT]D receptors have been described, 5-HT1Daand 5-
HT idp and as described previously the 5-HTinp subtype is a non-rodent homologue
of the 5-HTib receptor (Adham et al., 1992). The receptors are single proteins
comprising 377 and 390 amino acids respectively. The 5-HT]D (formerly 5-
HTioa exhibits 63% overall structural homology with the 5-HT1R (formerly 5-
HTiop) and 77% amino acid sequence homology within the seven transmembrane
domains. The receptor is negatively linked to adenylate cyclase.
1.15.1.4. 5-HTvf Receptors.
The 5-HTie receptor was first discovered in human cerebral cortex homogenates as
5-CT-insensitive [^H]-5-HT recognition sites (Leonhardt et al., 1989). Again no
selective ligands are available for studying these receptor sites exclusively, they are
characterised by having high affinity for [^H]-5-HT binding that is displaced by 5-
carboxamidotryptamine and ergotamine with relatively low affinity. The lack of
selective ligands has not allowed specific physiological roles for this receptor site to
be elucidated. Studies on the distribution of these sites in the CNS have shown a
similar distribution to that seen with 5-HT,n receptors, although the two receptor
sites exist in various proportions in different areas (Beer et al., 1992). This
receptor is concentrated within the caudate putamen, amygdala, frontal cortex and
globus pallidus.
The human receptor encodes a single protein of 365 amino acids, with seven
transmembrane domains, and sharing approximately 40% homology with other 5-
HTi receptors (McAllister et al., 1992). When expressed in murine LM (tk-) cells
and HEK293 cells the receptor is coupled to inhibition of adenylate cyclase
(McAllister et al., 1992).
1.15.1.5. 5-HTif Receptors
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Amlaiky et al. (1992), first cloned, in the rat, a new 5-HTj receptor site of 367
amino acids, which they termed 5-HTiEp as the site had 70% sequence homology
with the 5-HTie receptor. Subsequently the receptor was cloned in human tissue
and termed 5-HTiF due to the unique pharmacological profile as compared to other
5-HTi receptors, that is a high affinity for 5-HT, sumatriptan, methysergide and
methylergonovine, with low affinity for 5-carboxamidotryptamine (Adham et al.,
1993). Sumatriptan in fact has almost equal affinity for this receptor as for the 5-
HTib/id receptor, and thus it has been hypothesised that this receptor may be a
target for drugs with antimigraine properties (Adham et al., 1996). LY 334370, is
the first selective agonist for this receptor (Wainscott et al., 1996).
In the CNS of the rat the receptor site is found in the cortex, the dorsal raphe and
the hippocampus, and in the mouse it is also present in the striatum, thalamus and
hypothalamus. The presence of this receptor in the dorsal raphe suggests that it
may act as an autoreceptor. Peripherally it is found in the uterus and mesentery.
The receptor preferentially couples to the inhibition of adenylate cyclase, however,
when expressed in LM (tk-) cells is coupled to IP3 formation and a rise in
intracellular calcium, and in NIH-3T3 cells the receptor is coupled to inhibition of
cAMP formation (Adham et al., 1993).
Recently, a further receptor site belonging to the 5-HTj family has been described.
Castro, et al., (1997), reported the existence of a new 5-HT1G sub-type in
mammalian brain. This site expressed high affinity for 5-carboxamidotryptamine,
and is regulated by G-proteins. Due to its unique pharmacological profile, they
have putatively called this site 5-HT8.
1.15.2. 5-HT? Receptors
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The 5-HT2 receptor was first described as a site that bound [^HJ-spiperone with
high affinity and [^H]-5-HT with low affinity (Leyson et al., 1978). It is now
known that there are at least three distinct receptor subtypes in this receptor class,
that is 5-HT2a, 5-HT2B and 5-HT2C. The 5-HT2C receptor was originally termed the
5-HT ic receptor, but the second messenger characteristics and amino acid sequence
of this receptor share more in common with the 5-HT2 receptor class (Hoyer et al.,
1993). The receptors are characterised by their high affinity for antagonists such as
cyproheptadine, ketanserin, mesulergine, methysergide and metergoline. The
receptors exhibit approximately 60% sequence homology, and each is a seven
transmembrane, G-protein linked receptor. Unlike the 5-HTi receptor site the 5-
HT2 site possesses introns and exons and is coupled preferentially to phospholipase
C. Receptor activation thus leads to stimulation of PI metabolism and an increase
in IP3 production.
1.15,2,1. 5-HT?a Receptors.
This is described as the classical 5-HT2 receptor, widely distributed throughout the
CNS and the periphery. The site has high affinity for ketanserin, ritanserin,
spiperone, mesulergine and mianserin, although no compound has been shown to be
truly selective for this receptor.
In peripheral tissues activation of these receptors leads to blood vessel contraction,
contraction of tracheal smooth muscle, bronchoconstriction, platelet aggregation
and an increase in capillary permeability (Leysen et al., 1984). They are also
involved in modulating the release of other neurotransmitters including vasopressin
and dopamine (Muramatsu et al., 1988; Rittenhouse et al., 1990). In the CNS
autoradiographic studies demonstrated the presence of this receptor in the cortex,
hippocampus, hypothalamus and caudate nuclei (Pazos et al., 1987). Although a
role for these receptors centrally remains unclear, in rodents 5-HT2A agonists evoke
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a stereotypical behaviour comprising head twitch and wet dog shakes, so the
receptors may be involved in motor function. Sharpley et al., (1990), have also
reported a role in sleep regulation. In both peripheral and central neurones, the 5-
HT2a receptors modulate neuroexcitation and have been associated with the
transmission of nociceptive stimuli. The receptors are involved in several disorders
including depression, schizophrenia, Parkinson's disease and Alzheimer's disease.
In 1988, Pritchett et al., by screening a rat brain library, isolated a cDNA clone
carrying cDNA homologous to the 5-HT1C receptor. After transfection in
embryonic human renal cells, this clone produced receptor sites having
characteristics of 5-HT2 receptors, although 5-HT itself had a higher affinity for the
cloned receptor. Julius et al., (1990), cloned this gene from rat brain and corrected
the published sequence of Pritchett et al., (1988) by one nucleotide. The human
receptor was cloned by Kao et al., (1989), and corresponds closely to the rat
receptor site with a high degree of homology -90%. The receptor protein consists
of 471 amino acids. The receptor shares an overall sequence identitiy of 53% with
the 5-HT2C receptor (80% within the transmembrane domains), and 43% identitiy
with the 5-HT2B receptor. The 5-HT2A receptor is coupled in the main to IP3
formation, although the stimulation of phospholipaseA2, inducing the release of
arachidonic acid in hippocampal and cortical neurones has been demonstrated
(Felder et al., 1990).
1.15,2.2. 5-HTtr Receptors.
Foguet et al., (1992), first described this receptor type in rat stomach fundus, where
it mediates contraction of smooth muscle. The compounds methysergide,
metergoline and LY53857, display high affinity, whereas ketanserin and spiperone
display low affinity for this receptor. SB 204741 has been reported to be the first
selective 5-HT2b antagonist with approximately 100 fold selectivity over the 5-HT2C
and 5-HT2a sites (Baxter et al., 1995).
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mRNA for the 5-HT2B receptor has been detected in rat heart, lung, kidney, G.I.T.
and discrete regions of the brain (Foguet et al., 1992). A similar distribution was
observed for the mouse homologue (Loric et al., 1993). A role in development has
been suggested after mRNA for the receptor was found to decline in foetal small
and large intestine. In man, 5-HT2b receptor mRNA was found to be expressed in
low levels within the brain, and at much higher levels within placenta, lung, liver,
kidney, heart, intestine and stomach (Baxter et al., 1995).
Only the rat (479 amino acids), human (479 amino acids) and mouse (504 amino
acids) receptor sites have been cloned, exhibiting approx. 50% sequence homology
with the 5-HT2A and 5-HT2c receptor sites (Foguet et al., 1992; Wainscott et al.,
1993). Expressed in mammalian cells 5-HT2B receptors stimulate the production
of IP3, also in the mouse activation of this receptor causes a rapid influx of chloride
ions, this effect may be secondary to IP? activation (Loric et al., 1993).
1,15,2,3, 5-HT?r Receptors.
Originally this receptor was termed 5-HTiC, but the second messenger
characteristics and amino acid sequence clearly demonstrated that this receptor type
belonged to the 5-HT2 family. The receptor has high affinity binding for
which can be displaced by mianserin, 5-HT and spiperone. The novel
ligands, SB 200646A and SB 206553, have been reported to be selective 5-HT2c/2b
receptor antagonists with 50-100 fold lower affinity for the 5-HT2A receptor and
other sites (Kennett et al., 1996). Two truly selective compounds have also been
described, SB 242084, displaying over 100 fold selectivity over other sites and, RS-
102221, also displaying over 100 fold selectivity (Bonhaus et al., 1997; Kennett et
al., 1997).
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Autoradiography and in situ studies demonstrate high receptor densities in the
choroid plexus and lower receptor densities in the limbic system, basal ganglia,
hypothalamus and hippocampus (Molineaux el al1989). The main function of
this receptor is in the regulation of exchanges between the CNS and cerebrospinal
fluid (Hartig, 1989). Tsutsumi & Sanders-Bush demonstrated that the production
of transferrin by choroid plexus epithelial cells was regulated by 5-HT2c receptors.
These receptors may also play roles in locomotion, eating disorders, anxiety and
migraine (Fozard, 1992). A potential role in protooncogenes has also been
demonstrated (Julius et al., 1989). In the periphery, the receptor mediates
endothelium-dependent vasorelaxation (Glusa, 1992).
The rat and human receptors have been cloned. The receptor is a monomelic
protein belonging to a large multigenic family characterised by seven
transmembrane spanning domains and linked to a G-protein, consisting of 460
amino acids (rat) and 458 amino acids (human). The receptor is coupled to
activation of IP3 with a concomitant increase in intracellular calcium levels
(reviewed by Hoyer & Martin, 1997).
1.15.3. 5-HTi Receptors.
The 5-HT3 receptor subtype is unique among other 5-HT receptors in that it is not
linked by a G-protein to its effector system, but in fact it forms a ligand-gated ion
channel analogous to the GABA, glycine and nicotine receptors.
They are present in neurones in many tissues in the periphery and in the brain.
Peripherally the receptors are present both pre- and postsynaptically, in both
branches of the autonomic system and on afferent and enteric neurones (Fozard,
1984). In the GIT 5-HT3 activation modulates secretion and motility (Costall et al.,
1990). Other consequences of 5-HT3 activation in the periphery are cardio-
activation and inhibition, vasodilatation, pain and initiation of the vomiting reflex.
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This latter effect is thought to underlie the nausea side effect of cancer
chemotherapy, and has led to the use of selective 5-HT3 receptor antagonists as
antiemetic agents. In the CNS the receptors have a wide distribution, located in the
area postrema, hippocampus, dorsal vagal complex and substantia gelatinosa. The
cerebellum is devoid of these receptors. The receptors modulate neurotransmitter
release centrally, facilitating the release of dopamine, GABA and 5-HT and
inhibiting the release of acetylcholine and noradrenaline. Behaviourally, these
receptors play a role in anxiety, depression, memory and the effects of tolerance
(Barnes etal., 1992).
A cDNA encoding a single subunit of this receptor has been isolated from a mouse
neuroblastoma cell line (Maricq et al., 1991). The predicted protein comprises 487
amino acids and contains four hydrophobic transmembrane spanning domains.
Receptor activation triggers rapid opening of a transmembrane channel resulting in
an increase in Na+/K+ conductance and a subsequent rapid influx of extracellular
calcium (Peters et al., 1991). The response, which can rapidly desensitise, is G-
protein independent and insensitive to pertussis toxin. Stimulation of IP3
production in response to receptor activation has also been described (Ashby et al.,
1990), implying coupling to a G-protein, however the very fast kinetics of channel
activation suggest that this is more probably secondary to ionic events, such as
elevation of cytosolic calcium.
1.15.4. 5-HT4 Receptors.
The 5-HT4 receptor was first described by Dumuis et al., (1988), in the CNS as a
receptor positively coupled to adenylate cyclase, displaying an unusual
pharmacological profile. The first agonists reported for this receptor were the
substituted benzamide and benzimidazolone derivatives, for example, zacopride,
cisapride, BIMU 1 and BIMU 8 (Dumuis et al., 1992). However these compounds
also displayed various affinities for the 5-HT3 receptor. Tryptamine derivatives
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including 5-methoxytryptamine, 5-carboxamidotryptamine and tryptamine are
relatively selective agonists at this receptor. There are several selective antagonists
for this receptor, including, GR 113808, RS 23597-190, RS 39604 and DAU 6285.
In various species the 5-HT4 receptor has a wide distribution. Centrally these
receptors are located in the hippocampus, striatum, substantia nigra and olfactory
tubercle. No receptors appear in the cerebellum and frontal cortex. In the
periphery 5-HT4 receptors mediate relaxation and contraction of gastrointestinal
muscle (Craig & Clarke, 1990), an increase in cardiac rate and force of contraction
(Kaumann, 1991) and an increase in steroid release from the human and frog
adrenal glands (Lefebvre et al., 1993).
The 5-HT4 receptor has been cloned from rat, mouse and human brain and heart
RNA by the reverse transcriptase-polymerase chain reaction (Gerald et al., 1995;
Claeysen et al., 1996; 1997). Two different cDNA's were isolated, named 5-HT4a
and 5-HT4b. These splice variants encoded proteins of 387 and 406 amino acids
respectively, containing 96.1% identical peptide sequences and diverging in the
second half of the carboxyl terminus tails at position 360 where there appears to be
an intron. Another splice variant 5-HT4c has been cloned from rat, mouse and
human brain, encoding a protein of 372 residues (Claeysen et al., 1998). This
receptor type contains a short third intracellular loop (45 amino acids) and long
carboxyl termini (70; 89 amino acids). Activation of these receptors centrally leads
to elevation of cAMP, a decrease in potassium conductance and a stimulation of
local release of acetylcholine (Dumuis et al., 1988; Boddeke & Kalkman, 1992).
1.15.5. 5-hts Receptors.
The 5-ht5A/5B receptors display high affinity binding to [^5i]_l§d jn certain cell
types, that is displaced by methysergide, methiothepin and ergotamine (Plassat et
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al., 1992; Matthes et al., 1993). 5-HT, 5-carboxamidotryptamine, 8-OH-DPAT
and sumatriptan all act at this receptor.
The 5-ht5A receptor is expressed exclusively within the CNS. 5-ht5A mRNA has
been detected via northern blot analysis and quantitative PCR in mouse brain, spinal
cord and cerebellum, but not in kidney, liver, spleen or heart (Plassat et al., 1992).
In situ hybridisation experiments show the presence of this receptor in mouse
cerebral cortex, hippocampus, cerebellum, habenula and olfactory bulb. Northern
blot analysis of rat brain revealed the presence of this subtype in many areas
including hippocampus, hypothalamus, cortex, thalamus, pons, striatum and
medulla (Erlander et al., 1993). Studies utilising a specific 5-ht5A antibody have
suggested that this receptor is mainly expressed in glial cells and that this receptor
may act as a terminal autoreceptor within the mouse frontal cortex (Erkander et al.,
1993).
Northern blot analysis ofmouse tissue demonstrated that the 5-ht5B receptor is not
present in brain, kidney, heart, lung and intestine, in situ hybridisation on mouse
brain sections located the receptor exclusively in the hippocampus, habenula and
the dorsal raphe (Matthes et al., 1993). In the rat the receptor is present in the
hippocampus, dorsal raphe, olfactory bulb, habenula and subiculum. No receptor
activity was located in rat liver, muscle, lung, heart, kidney and spleen (Wisden et
al., 1993).
Potential physiological roles for these receptors have not been investigated. As the
transductional and operational characteristics of this receptor are still being
investigated the lower case appellation is presently used to define these gene
products.
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The 5-htsa receptor has been cloned from mouse, rat and human tissues, whilst the
5-htsB receptor has been cloned from mouse and rat (Plassat et al., 1992; Erlander
et al., 1993; Wisden et al., 1993). The receptors contain 357 amino acids (5-
ht5Amouse) and 370 amino acids (5-ht5Bmouse) and exhibit a structural homology
of 88%. The receptors are seven transmembrane G-protein coupled receptors, and
at present the second messenger system has not been fully identified. In cells
expressing the cloned 5-htsa site, the receptor was shown to be negatively linked to
adenylate cyclase via the Gi-protein (Carson et al., 1995). When the 5-ht5B
receptor was expressed in COS-1 cells a fraction of the binding sites were displaced
by GTP analogues suggesting that this receptor couples to G proteins in these cells
(Wisden et al., 1993). So this receptor may interact with an effector system other
than adenylate cyclase or PLC.
1.15.6. 5-HTfi Receptors.
This receptor has pharmacological characteristics similar to the 5-HTi receptor,
with high affinity for methiothepin and 5-methoxytryptamine (Monsma et al.,
1993). The receptor also displays high affinity for a number of anti-depressant
drugs, including amitriptyline, clomipramine and amoxipine and the antipsychotic
drugs clozapine and loxapine.
In situ hybridisation studies located this receptor in the rat striatum, olfactory
tubercle, cortex and hippocampus (Ruat et al., 1993a). Low levels were expressed
in rat hypothalamus and stomach. No signal was detected in medulla, pituitary,
retina, thalamus, cerebellum and various peripheral tissues. Northern blot analysis
using guinea pig tissues, striatum and olfactory tubercle produced the strongest
signal, followed by cerebellum, brain stem, olfactory bulb and substantia nigra. A
faint signal was also detected in the adrenal glands (Ruat et al., 1993a). No mRNA
was detected in guinea pig ileum, lung, atrium or pituitary (Ruat et al., 1993a). In
situ hybridisation revealed the presence of 5-HT6 receptor mRNA in rat olfactory
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tubercles and bulb, striatum, nucleus accumbens, hippocampus and cerebral cortex
(Ruat et al., 1993a). An in vivo role for this receptor has been suggested in
neuropsychiatry disorders due to its presence within limbic pathways and its high
affinity for certain antipsychotic and antidepressant drugs (Roth el al., 1994)
The 5-HT6 receptor was cloned from a rat cDNA library and was found to be
positively coupled to adenylate cyclase (Montsama et al., 1993). The cDNA
encodes a 436 amino acid protein with seven hydrophobic regions, with
approximately 40% homology with other 5-HT receptors. The receptor has a short
third intracellular loop (50 amino acids), long carboxy tail (120 amino acids) and an
intron between the sixth and seventh transmembrane loop, and this indicates a novel
5-HT receptor class. The human gene has also been cloned and exhibits 89%
sequence homology with the rat receptor. The receptor is positively linked to
cAMP formation
1.15.7. 5-HT7 Receptors.
The site has high affinity for 5-carboxamidotryptamine, 5-methoxytryptamine,
methiothepin, mesulergine, 8-OH-DPAT and a lower affinity for ketanserin
(Jakeman et al., 1993). [?H]-SB-269970 is the first selective antagonist radioligand
at this site (Thomas et al., 2000).
Northern blot analysis of rat tissue located highest levels of mRNA in
hypothalamus, thalamus, brainstem and hippocampus, with lower levels in cortex,
striatum, olfactory bulb and tubercle (Shen et al., 1993). Faint signals were located
in the spleen, stomach and ileum (Ruat et al., 1993b; Shen et al., 1993). The
expression of this receptor in various hypothalamic nuclei has led to the suggestion
that this receptor may be important in circadian rhythms (Lovenberg et al., 1993)
and may have potential therapeutic roles in depression and schizophrenia (Sleight et
al., 1995; Roth et al., 1994). In man, mRNA was also found in the coronary
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fable 1.1 : 5-HT Receptor Subtypes.
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artery, descending colon, GIT, stomach and ileum (Bard et al., 1993; Schoeffier et
al., 1996). The receptor site has been found to be present within the rat adrenal
gland (Contesse eta/., 1999).
This receptor has been cloned from rat (448 amino acids, Ruat et al., 1993b; Shen
et al., 1993; Lovenberg et al., 1993), mouse (448 amino acids, Plassat et al., 1993),
human (445 amino acids, Bard et al., 1993) and guinea pig (466 amino acids, Tsou
et al., 1994) cDNA libraries. This receptor contains seven transmembrane domains
and is coupled to the activation of adenylate cyclase. Structural data indicate that
this represents another distinct class of receptors. The receptor possesses two
introns in the gene coding region, and possesses various (40%-60%) sequence
homology with the other 5-HT receptors, but high interspecies homology (95%).
A number of splice variants of both the human (5-HT7a/7b/7d) and rat (5-HT7a/7b/7c)
receptor have been identified, which display similar pharmacological and functional
characteristics when expressed in cell lines (Jasper et al., 1997; Heidman et al.,
1997).
1.16. Aims of this Thesis.
In attempting to clarify a physiological role for 5-HT in aldosterone secretion it is
necessary to address a few questions. Is 5-HT able to stimulate aldosterone
directly? Does the sensitivity of this aldosterone response to 5-HT increase in
states of sodium depletion? If 5-HT does influence aldosterone secretion what is the
physiological source of 5-HT reaching the ZG, and can this source also be
regulated by salt intake? Are there specific receptors for 5-HT within the rat ZG?
Does the 5-HT transporter have a role to play in the ZG?
The main aim of this thesis was to establish a role for 5-HT in the control of
aldosterone secretion. 5-HT is well known for its roles as a neurotransmitter and in
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the blood clotting cascade, but the steroidogenic action of 5-HT in the adrenal
gland is an area of interest that still needs to be defined.
In order to gain more knowledge on the direct effects of 5-HT on aldosterone,
structure activity studies were performed using a range of indoleamines in isolated
rat zona glomerulosa cells. These studies, described in Chapter 3, tested the
potency of several indoleamines, some naturally occurring, relative to 5-HT in
order to determine the functional groups on the indole nucleus which are necessary
for eliciting biological activity. In conducting these experiments, the hypothesis
that 5-HT may not be the only physiological indoleamine that can regulate
aldosterone was tested. Following on from this study, experiments were then
conducted, utilising a variety of 5-HT agonists and antagonists, in order to
characterise pharmacologically the 5-HT receptor type that mediates the
aldosterone response to 5-HT within the rat zona glomerulosa. These experiments
are described in Chapter 4. Some of these agonists and antagonists were also
studied in isolated rat zona glomerulosa cells which had been prepared from rats
maintained on different salt diets, in order to test the salt sensitivity of the
aldosterone response to 5-HT receptor activation and inhibition. A further aim of
the work within this thesis was to identify possible local sources of 5-HT in the rat
adrenal gland using both immunohistochemical and biochemical techniques. The
major focus was to determine whether significant levels of the enzyme L-AAAD,
which can synthesise both 5-HT and dopamine from their respective precursors, 5-
HTP and L-DOPA, are present within the adrenal cortex and more specifically the
zona glomerulosa. These studies are described in Chapter 5. The hypothesis that
adrenocortical L-AAAD could potentially be modulated by salt intake was also
tested in the experiments described. The final aim was to investigate whether
aldosterone secretion can be affected by drugs that are known to affect the 5-HT
transporter and to determine by autoradiography the location of a potential 5-HT






This chapter describes the general methodology, specialised techniques and
laboratory procedures used throughout these studies. At the beginning of each new
chapter a brief review of those techniques relevant to that chapter will be given.
2.1.1. Animal and Controlled Drug Legislation.
A. Animal.
All experimental procedures were carried out humanely via Schedule 1
methodology, described in the Animals and Scientific Procedures Act, 1986. Any
procedures not covered by Schedule 1 methodology, were conducted following the
authority of a personal licence, controlled by an appropriate project licence.
B. Controlled Drug.
All use of the controlled drug MDMA was carried out following the Misuse of
Drugs Regulations Act, 1985, under a project licence held at the University of
Edinburgh, Department of Clinical Neuroscience.
2.2 Indoleamine Study.
2.2.1 Isolation Of Zona Glomerulosa Cells.
Female Wistar rats (200-250g), were killed by dislocation of the cervical vertebrae,
and the adrenal glands coarsely dissected with their surrounding fat and placed into
normal saline. Each adrenal was placed on moistened, hardened filter paper and
trimmed of all fat. The capsules and adhering zona glomerulosa were removed
following the method of Haning et al, 1970. Briefly each adrenal was bisected with
a scalpel, leaving a bridge of capsule connecting the two hemiadrenals. When the
adrenal was turned onto its cut surface, and the capsule bridge held with forceps,
the adrenal was easily decapsulated by applying gentle pressure with the back of a
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scalpel blade. The capsules were then placed in normal saline and agitated gently to
remove debris. For collagenase digestion the capsules were incubated for 1 hour at
37°C in Krebs-Ringer bicarbonate buffer, previously gassed for 15 minutes with
95% 02/5% C02 and containing 20g/L bovine serum albumin (BSA), 2g/L D-
glucose (KRBGA) and 2mg/ml/rat collagenase crude type I. The capsules were
disaggregated gently at 20 minute intervals using a wide mouthed 5ml pipette.
After 1 hour the dispersed cells were filtered through a 100 p. gauze to remove
coarse debris. The filtrate was immediately centrifuged at 1000 rpm and 4°C for 15
minutes, causing the cellular suspension to pellet. The supernatant was removed
and replaced with 5ml of fresh KRBGA into which the cell pellet was resuspended.
This washing procedure was repeated 3 times and after the final wash the
supernatant was replaced with lOmls of Medium 199, containing 5g/L BSA and
2g/L D-glucose. After thorough resuspension, the material was filtered through a
56 p. gauze, and an aliquot removed for cell counting using a haemocytometer. On
average this method produced a cell suspension containing at least 95% zona
glomerulosa cells, with less than 5% zona fasciculata cell contamination.
2.2.2. Cell Counting.
20pl of the cell suspension was added to a 20pl aliquot of a 0.2% (w/v) solution of
trypan blue, and mixed thoroughly. A small aliquot was placed in the counting
chamber of a haemocytometer and allowed to diffuse. The cells were then viewed
with a microscope at a 400 fold magnification and those in the outside 4 and centre
squares which excluded trypan blue and thus considered viable were counted. The
number was then corrected as follows to give the total number of cells.
Total Cells = number counted within the squares x 2 (trypan blue dilution factor) x
20,000 (converts volume of chamber to total volume of cells i.e. lOmls). A typical




Initially 400pl of the cell suspension containing ~ 100,000 zona glomerulosa cells
was used per 1ml incubation. However using such a large number of cells per
incubation resulted in a large number of animals being used per experiment, so it
was decided to try and miniaturise the incubation to 200pi, using only 20,000 zona
glomerulosa cells. To ensure that no loss of response resulted in this
miniaturisation the two different protocols were compared (see Figure 2.1.).
lOOpl of the cell suspension, diluted to contain -20,000 zona glomerulosa cells,
was added to eppendorf tubes containing lOOpl of Medium 199 supplemented with
5g/L BSA;2g/L D-glucose, in which all the test substances (10~10m-1CHM) had
been dissolved to the required final concentration. Control incubations contained
zona glomerulosa cells and Medium 199 only, allowing the basal value for
aldosterone secretion into the medium to be measured. Each incubation was
carried out in triplicate and the dose response to 5-HT carried out at least twice
during each individual experiment to allow comparison of aldosterone secretion in
response to 5-HT with responses to other compounds. The tubes were mixed
thoroughly and incubated for 1 hour at 37°C in a shaking water bath. After 1 hour
the tubes were placed on ice to prevent further steroid production and then
centrifuged at 15,000g for 2 minutes at 4°C to pellet the cell suspension. The
supernatant was decanted and the samples stored at -20°C prior to the
measurement of aldosterone secretion into the medium via direct radioimmunoassay
(RIA).
2.2.4. Aldosterone Radioimmunoassay.
Aldosterone was measured by direct RIA (Campbell et al. 1981). 50pl aliquots
from the cell incubation extracts or 50pl aliquots containing a known concentration
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phosphate buffer (5g/L BSA) containing 125I-aldosterone (3000-4000cpm) and
402L antibody to aldosterone, diluted to give an initial titre of 1:100,000. This
polyclonal antibody was kindly donated by Dr F.A.O. Mendelsohn, Australia. The
tubes were incubated overnight at 4°C. Separation of the bound and free radiolabel
in each tube was carried out at 4°C by the addition of 0.5ml of dextran coated
charcoal followed by centrifiigation at 4000rpm for 20 minutes at 4°C. The
supernatant was aspirated and the charcoal pellet, containing the free fraction,
counted in an LKB multiwell gamma counter.
The aldosterone 402L antibody was raised in a rabbit to aldosterone-3-
carboxymethyloxime conjugated to bovine serum albumin by the method of
Erlanger et a/., (1957). The antibody has the following cross-reactivities; 17-
isoaldosterone (25%), tetrahydroaldosterone (20%), 18-
hydroxydeoxycorticosterone (0.025%), 18-hydroxycorticosterone (0.025%) and
aldosterone-y-lactone (0.02%). The following have less than 0.0001% cross-
reactivity, corticosterone, 11-dehydrocorticosterone, deoxycorticosterone, Cortisol,
cortisone, progesterone, pregnenolone, tetrahydrocorticosterone,
tetrahydrocortisol, tetrahydrocortisone, dexamethasone and spironolactone. Using
50pg [l,2,6,7,-3H]aldosterone/assay tube, the assay had a sensitivity of 5pg
(Campbell et al., 1981).
The lower limit of detection for the assay was 0.06 nM, and the working range for
aldosterone measurement was 0.06 to 32nM. The intra and inter assay co-efficients
of variation were 7% and 15% respectively.
2.2.5. Cyclic AMP Radioimmunoassay.
Cyclic AMP was measured by direct RIA developed in this department by Dr
l.F.Gow (Harper & Brooker 1975). Prior to RIA, 500pl of the cell incubation was
acidified by adding 5 pi of 20% (v/v) acetic acid and acetylated, in parallel with
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cAMP standards, with 15pl of a solution containing 2 parts triethylamine. 1 part
acetic anhydride. 50pl aliquots of the acetylated sample or 50pl of cyclic AMP
standards were incubated in triplicate with 200pl of acetate buffer (0.05M, pH 4.8
containing 0.1% BSA) containing 125T tyrosine-methyl-ester succinyl cyclic AMP
(125I-cyclic AMP) (3000-4000 cpm) and antisera (R1B6) to cyclic AMP to give an
initial dilution of 1:10,000. The tubes were allowed to equilibrate overnight at 4°C.
Separation of bound and free radiolabel was carried out using dextran coated
charcoal as described in 2.2.4.
The lower limit of detection for the assay was 0.06nM, and the working range of
the assay was 0.06nM to 32nM. The intra and inter assay co-efficients of variation
were 8% and 16% respectively.
2.2.6. Preparation Of Iodinated Aldosterone.
2.2.6.1. Activation Of Aldosterone-3-carboxvmethyl-oxime.
Aldosterone-3-carboxymethyl-oxime (0.29mg) was dissolved in 400pl ethanol and
then dried down in a dri-block under nitrogen. This was then redissolved in 50pl of
dimethylformamide (DMF), which had been cooled to 10°C. The oxime was
maintained at 10°C in a stirred water bath and to the redissolved oxime, lOpl of
tributylamine (85pl in 5ml DMF) and 10pl of isobutylchloroformate (45.5pl in 5ml
DMF), were added. This solution was then vortexed and kept at 10°C for 20
minutes.
2.2.6.2. Iodination Of Histamine.
lOpl ofNa125I (equivalent to lmCi/37MBq), lOpl of histamine (2.2mg in 10ml
0.25M phosphate buffer) and 10gl of chloramine T (50mg in 10ml of 0.25M
phosphate buffer) were added to a conical glass tube and vortexed for 15 seconds.
lOpl of sodium metabisulphite (120mg in 10ml of 0.05M phosphate buffer) was
then added and the solution was vortexed and cooled to 0°C in ice. 280pl of
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cooled DMF (10°C) was added to the activated steroid after the 20 minute interval
and the solution was vortexed. 50jul of this diluted steroid mixture was then added
to the ice cold iodination mixture, and then 10pl of 0.2M NaOH was added. The
mixture was then vortexed and kept at 0°C for 1 hour. 1ml of 0.1M HC1 and 1ml
of redistilled ethyl acetate was then added to the iodination mixture and the mixture
then vortexed for three seconds. The upper (organic) layer was then removed,
counted and discarded. 1ml 0.1M NaOH and 1ml potassium iodide (lOOmg in
10ml 0.5M phosphate buffer) were then added and the mixture vortexed before
being extracted with 750pl of ethyl acetate as described.
250pl redistilled ethyl acetate was added to the iodination mixture and the mixture
was vortexed for 60 seconds. The lower aqueous layer was removed to a second
conical glass tube and the organic layer was transferred to a clean glass tube. The
aqueous layer was extracted a further two times, with the organic layers being
combined.
The iodinated 3-CMO aldosterone was then purified by thin layer chromatography.
The organic extract was applied in a thin line along the bottom of a 200x200mm
silica gel TLC plate and run in a solvent of toluene: ethanol:acetic acid (75:24:1) for
approximately 1 hour. The plate was then removed from the tank and allowed to
dry before being placed in a film box and exposed to Kodak X-ray film for one
hour. The position of the 125I - 3CMO-aldosterone band was marked on the TLC
plate and the silica scraped off carefully. The silica was then transferred via a glass
funnel to a glass scintillation vial and the iodinated 3-CMO aldosterone eluted with
3ml ethanol for one hour at room temperature. The ethanol was then filtered
through a glass pasteur pipette plugged with a small piece of cotton wool and
containing 2cm celite to remove the silica. The column was washed with 3x1ml
ethanol. The final 1251 -3CMO-aldosterone product was stored at - 20°C.
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2.3. 5-HT A2onist And Antagonist Study.
2.3.1. Isolation Of Zona Glomerulosa Cells.
As in section 2.2.1.
2.3.2.Cell Counting
As in section 2.2.2.
2.3.3.Static Cell Incubations
Incubations were set up as in section 2.2.3. Full dose responses (lO'l^M-lO^M)
to all 5-HT agonists were set up, in triplicate, in individual experiments. For the 5-
HT antagonists dose responses to each antagonist were set up, in triplicate, in the
presence of lO'^M 5-HT, i.e. a sub-maximal concentration of 5-HT. The
incubations were treated and stored as in section 2.2.3.
2.3.4.Aldosterone Radioimmunoassay
As in section 2.2.4.
2.3.5. Cyclic AMP Radioimmunoassay.
As in section 2.2.5.
2.4. L-Aromatie Amino Acid Decarboxylase 1L-AAAD) Study.
2.4.1. Salt Diets.
12 female Wistar rats (200-250g) were housed in individual metabolic cages for 1
week to equilibrate with the environment. They were then maintained on one of
the following diets for one week:-
1. Control diet Wholemeal flour containing 1% NaCl
2. Low sodium diet Wholemeal flour containing 0% NaCl
3. High sodium diet Wholemeal flour containing 3% NaCl
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Urine was collected from each animal two days prior to and daily for the week of
the salt diets. The pH of the urine was maintained between pH 2-3 by addition of
0.5 ml of 5M HC1 into each urine pot. This is essential to preserve all samples in
the reduced state prior to measurement via HPLC. 5-HT, dopamine, L-DOPA and
5-HIAA were all measured in the urine samples by HPLC performed at the RIE by
Neil Johnston. Basically, 0.5g of activated aluminium oxide was added to a series
of tubes and washed with 5ml EDTA (0.2M). 5ml test urine samples and 0.5ml
internal standards were then added to the tube and mixed thoroughly and then
centrifuged at 4°C/1000RPM for 2-3 minutes. The supernatant was siphoned off
and the deposit washed three times with deionized water. 2ml of 0.2M perchloric
acid was then added, to elute the amines to be measured, and mixed thoroughly
and centrifuged at 4°C/1000RPM for 2-3 minutes. Porex filters were then added to
all sample tubes and pressed down until all the supernatant was vented through the
filter. The supernatant was then decanted and the sample stored at -40°C until
measurement by HPLC using electrochemical detection.
After the appropriate time period the animals were killed by decapitation. Blood
samples were obtained, the adrenal glands and kidneys were removed with their
surrounding fat and placed in pots of saline. The capsules, removed following the
method of Haning et al. (1970), with adhering zona glomerulosa were incubated
with increasing concentrations of 5HTP or L-DOPA (lO'^M-lO'^M), all in the
presence of 100 pi 10~4 M pargyline, to inhibit monoamine oxidase, in a total
volume of 1ml of KRBGA. If the capsules were incubated with L-DOPA, the
tissue was prestimulated with 10"^M 5-HT. In each set of incubations one
incubation contained lO'^M carbidopa, to block the enzyme L-AAAD. The tubes
were then incubated in a shaking water bath at 37°C for 1 hour.
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After the incubation, the supernatant was removed into microtubes and stored at -
20°C for subsequent measurement of aldosterone by radioimmunoassay (RIA) and
L-DOPA, dopamine, 5HTP, 5HT and 5HIAA by high pressure liquid
chromatography (HPLC). The tissue was retained for protein assay.
2.4.2. Isolation of zona glomerulosa cells and zona fasciculata cells.
12 female Wistar rats (200-250g) were maintained on normal, low and high salt
diets for 1 week as described above, in free running cages. After the appropriate
time period the animals were killed by decapitation. Blood samples were obtained
and the adrenal glands were dissected as described above. The capsule and
adhering zona glomerulosa were treated as in section 2.2.1 to prepare a suspension
of zona glomerulosa cells. The inner cores of the adrenal glands, containing the
zona fasciculata cells were also treated as in section 2.2.1., the cell suspension was
only mechanically dispersed at the end of the 1 hour incubation. The collagenase
digestion destroyed the medullary component of the adrenal cores. After the final
spin, the zona glomerulosa cells from each diet and the zona fasciculata cells from
each diet, were resuspended in 3.2ml of medium 199 i.e. to correspond roughly to
the amount of zona glomerulosa/fasciculata cells from each capsule/core.
Incubations were set up with increasing concentrations of 5HTP or L-DOPA (in the
presence of 5-HT) as described above, and contained the following:
500 pi Medium 199 containing lO'^M pargyline and +/- lO'^M
carbidopa.
100 pi Agonist
400 pi of cells which equated to roughly 1 capsule
The tubes were mixed gently by vortex, then transferred to a shaking water bath at
37°C and incubated for 1 hour. At the end of the incubation, the tubes were
centrifuged at 10,000 rpm and 4°C for 15 minutes, causing the cells to pellet. The
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supernatant was decanted and stored at -20°C until measurement by HPLC or RIA,
while the cell pellet was kept for protein assay.
2.4.3. Treatment of blood samples.
225 pi of trunk blood was transferred to a tube containing 25 pi of ice cold
ethylenediaminetetraacetic acid (EDTA) inhibitor (27mmol/l). This was vortexed
and then centrifuged at 10,000g for 15 minutes at 4°C. The supernatant was
removed and stored at -20°C until measurement of aldosterone by RIA.
20 pi of the remaining whole blood was added to 180 pi of a cocktail containing
thrombin (1100 units/1), chlorimipramine (1.1 mmol/1), and pargyline (11.1 mmol/1).
This was left at 4°C for 2 hours to allow complete release of 5-HT by the platelets
and then centrifuged at 10,000g for 15 minutes at 4°C. The supernatant was
removed and stored at -20°C before measurement of 5HTP, 5HT and 5HIAA by
HPLC.
2.4.4. HPLC for measurement of L-DOPA, Dopamine, 5HTP, 5HT and
5HIAA.
All compounds were measured in each sample using a high pressure liquid
chromatography (HPLC) with electrochemical detection (Gow et al., 1987). The
HPLC system consisted of a Waters 510 pump, a U6K injector, a Waters 150x3.9
mm pBondapak Ci8 reversed-phase analytical column, a BAS LC-4A
electrochemical detector with a single glassy carbon electrode and a Waters data
module.
Each sample was thawed and prepared on the day of sampling. 400 pi of the sample
was added to 50 pi of the internal standard N- methyl5-HT or N-methyldopa
(10pm) and 50 pi of 15% perchloric acid/2 mM cysteine in a microtube, vortexed
and stored at 4°C for 15 minutes to allow complete deproteinisation. Tubes were
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then centrifuged at 10,000g at 4°C for 15 minutes. Samples were injected
individually in a volume of 25 pi. Before any samples were analysed, the standard
mix was injected. This contained lpM 5HTP, lpM 5HIAA, lpM 5HT and the
internal standard lpM N-methyl5-HT, or for dopamine analysis lpM L-DOPA,
1 pM Dopamine and the internal standard 1 pM N-methyldopa. This was injected at
regular intervals throughout the day of analysis to check the consistency of
retention time profiles for each compound.
Once all samples were analysed, the peak heights were measured and compared to
the standards of the day. Concentrations of each compound were calculated by
comparison of the ratios of peak heights obtained in the test samples with
corresponding values obtained with the standard mixture.
2.4.5 Preparation of mobile phase.
Mobile phase was made up to 2 litres and contained the following: 83% distilled
water, 17% methanol, 31.2 g of 30 mM NaFBPO^ 0.744g of ImM EDTA and 0.8g
of 2.4 mM octane sulphonic acid (previously dissolved in 8mls of acetic acid 0.5M)
for 5-HT analysis. For dopamine analysis the mobile phase was made up to 2 litres
of double distilled water and contained : 2.1mis acetic acid, 11.5g citric acid
monohydrate, 13.6g sodium acetate trihydrate, 2.4g sodium hydroxide, 0.2g octane
sulphonic acid and 0.2g disodium EDTA
The flow rate was 0.7 ml/min for 5-HT and 0.8ml/min for dopamine and the
electrochemical detection set at +0.6V.
2.4.6. HPLC for plasma samples.
HPLC was used to measure 5HTP, 5HT, and 5HIAA in plasma samples. No
dopamine was measured in plasma as this was undetectable. The method was
essentially as described above. The mobile phase was made up to 2 litres and
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contained the following : 95% distilled water, 5% MeOH, 31.2g of 0.1M NaH2P04,
0.744g 1 mM EDTA and 0.5g of 2.4 mM octane sulphonic acid.
2.4.7. Aldosterone radioimmunoassay.
As in section 2.2.4.
2.4.8. Corticosterone Radioimmunoassay.
Corticosterone was measured in the medium from cell stimulations by RIA (Al-
Dujali & Edwards, 1981). Standards for corticosterone were prepared from solid
corticosterone, (purchased from Sigma), and dissolved in ethanol and diluted in
phosphate buffer (0.5% BSA). Standards were in the range 0.5-200nmol/l
(equivalent to 0.2-64ng/ml).
50pl of a standard, for the standard curve, or 50pl aliqout from the cell incubation
were incubated in triplicate with 200pi of phosphate buffer containing 125I-
iodohistamine-3-mono-oxime-corticosterone (125I-corticosterone) (3000-4000 cpm)
and antisera (R1B4) to corticosterone to give an initial titre of 1:10 000.
The tubes were incubated overnight at 4°C. Separation of the bound and free
radiolabel in each tube was carried out at 4°C by the addition of 0.5ml of dextran
coated charcoal followed by centrifugation at 4000rpm for 20 minutes at 4°C. The
supernatant was aspirated and the charcoal pellet, containing the free fraction,
counted in an LKB multiwell gamma counter.
The lower limit of detection for the assay was 1.25 nM, and the working range for
corticosterone measurement was 1.25 to 160nM. The intra and inter assay co¬
efficients ofvariation were 8 % and 14% respectively.
2.4.9. Plasma aldosterone radioimmunoassay.
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Plasma aldosterone was also measured by RIA as described above. Historically this
RIA uses neat charcoal stripped plasma as a diluent for the standards etc.. The
preparation of this solution is laborious and necessitates a large animal cull. It was
decided to compare it with a solution containing 4% BSA, which would act as a
replacement for the neat charcoal stripped plasma. Standard curves were set up
and compared via analysis of variance (n=6), and no statistical significant difference
between the two standard curves was observed. Thus, 50 pi of 4% BSA or 50 pi
of standard containing a known concentration of aldosterone for the standard curve
were incubated in triplicate with 100 pi of phosphate citrate buffer containing 1251-
aldosterone (approximately 4000 cpm) and 100 pi antisera (402L) to aldosterone
diluted to give a final titre of 1:40 K. The tubes were incubated overnight at 4°C
and treated as described in section 2.2.4.
The lower limit of the assay was 0.195nM and the working range from 0.195nM to
25nM. The intra and inter assay co-efficients of variation were 7 % and 15%
respectively.
2.4.10. Plasma Renin Activity Radioimmunoassay.
Plasma renin activity (PRA) was evaluated by measuring Angiotensin I (Al)
generated from sheep substrate at 4°C and 37°C (Haber et al., 1969). The
preparation of I125-iodinated Al for RIA will be described in section 2.4.11. 1 Opl of
plasma was mixed with 190pl of a 'premix' containing 400 parts sheep substrate,
415 parts phosphate buffer, and 20 parts each ofEDTA, British anti-lewisite (BAL)
and 8-OH-quinoline. The mixture, prepared on an ice bath, was then divided and
one half incubated at 37°C for 4 hours, whilst the remaining halfwas maintained at
4°C, to measure endogenous Al. Al was measured using an RIA. 25 pi of each of
the plasma samples or 25 pi of a known concentration of Al for the standard curve
were incubated in triplicate with 200pl of phosphate buffer containing 125-AI (3000-
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4000 cpm) and antisera to AI (R5B4) diluted to give a final titre of 1:10,000.
Standards were made up in the premix solution. The assay was set up on ice.
The tubes were allowed to equilibrate overnight at 4°C. Free and bound radiolabel
were separated using dextran-coated charcoal as previously described. For this
assay the results are expressed in mass rather than molar terms, this is in accordance
with the expression ofPRA data in many journals. The lower limit of detection for
this assay was 0.5ng/ml and the working range was from 0.5 to 64ng/ml. The PRA
was calculated by subtracting the concentration of AI in the sample maintained at
4°C from that of the sample incubated at 37°C. The results were corrected for the
initial 20 fold dilution and the 4 hour incubation period. PRA was expressed in ng
Al/ml/hour. The intra and inter assay co-efficients of variation were 8% and 16%
respectively.
2.4.11. Iodination ofAngiotensin I.
lOpl of lOmg/ml AI was mixed with 10pi 0.5M phosphate buffer, pH 7.4 in a
polypropylene tube. To this lOpl Na125I was added, and the solution was vortexed.
lOpl of chloramine T (lOmg diluted in 10ml 0.5M phosphate buffer pH 7.4), was
then added and the solution vortexed and then incubated for 60 seconds. To stop
the iodination reaction, lOpl sodium metabisulphite (20mg diluted in 10ml 0.5M
phosphate buffer pH 7.4) was added and vortexed before the addition of 500 pi
0.1M phosphate buffer (pH 7.4), and vortexing the contents a final time.
The 125I-AI was then purified by gel chromatography through a 60cm column of
DEAE Sephadex A25, equilibrated with 0.1M phosphate buffer pH 7.4. The
iodination mixture was applied to the column, allowed to flow through it and rinsed
through with the further addition of 1ml phosphate buffer. Buffer was then pumped
through the column at a flow rate of 0.25ml/minute. Fractions were collected every
4 minutes into numbered polypropylene vials. lOpl aliquots from these fractions
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were counted for 60 seconds in a gamma counter to locate the 125I peaks. The first
to appear was the unreacted iodine and was discarded. Second to appear was the
iodinated AI, the highest fraction plus the two highest on each side were collected
and pooled, all other fractions were discarded. The pooled fractions were made up
to 50ml with 0.1M phosphate buffer pH 7.4, containing 0.1% (w/v) sodium azide
and 0.5ml Trasylol (200 kallikrein inhibitor units/ml). 1ml aliquots were placed in
polypropylene tubes (LP4), capped and stored at -20°C.
2.4.12. Protein assay.
lml of NaOH was added to the tissue retained from the incubation experiment
described under 'salt diets'. The microtube was vortexed and sonicated by applying
3 short bursts that lasted approximately 3 seconds. Sonication was repeated for all
the samples to ensure that all the tissue was dissolved. The tubes were then
centrifuged and protein concentration was measured by a centifugal analyser, using
the technique described by Bradford (1976), Dept. of Clinical Biochemistry, Royal
Infirmary, Edinburgh.
2.4.13. Immunohistochemistry.
Rats on a normal salt diet were killed by decapitation. The adrenal/kidney was
dissected and trimmed of all fat, fixed in 10% neutral formalin for 24 hours then
embedded in paraffin. 4pM transverse sections of the adrenal/kidney were cut on a
cryostat and transferred to a gelatine-coated slide. Immunostaining was by a
streptavidin-biotin complex peroxidase method preceded by antigen retrieval using
microwave according to the method described by Gerdes et al, (1992). Negative
controls consisted of replacement of the primary antibody with an equivalent
concentration of normal rabbit serum.
The sections were rinsed in water via xylene and alcohol, rinsed and wiped dry.
They were then immersed in 500mls of citrate buffer at pH 6 and microwave
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treatment applied for 20 minutes. Endogenous peroxidase was blocked by
immersion in 3% aqueous H2O2 for 5 minutes. The sections were then rinsed in tap
water for 3-5 minutes, then wiped dry. Before primary antibody was added the
sections were incubated with 20% normal sheep serum to reduce background
staining. This was drained off and primary antibody added. Incubations in the
primary L-AAAD antibody were 30 minutes at room temperature and the dilution
established via a titration series resulting in a dilution of 1:2000. Following a 10
minute wash in TBS, sections were incubated in biotin-conjugated anti-rabbit link
antibody (diluted 1:400) for 30 minutes. A further 10 minute wash in TBS
preceded incubation in StreptABC-peroxidase reagent (Dako Ltd.) for 30 minutes.
After another 10 minute TBS wash peroxidase was visualised by a standard
hydrogen peroxide/diaminobenzidine substrate/chromagen solution. Finally,
sections were counterstained in haemotoxylin, dehydrated in ethanol, cleared in
xylene and mounted in DPX.
2.5. The 5-HT transporter Study.
2.5.1. Isolated ZG cell incubations.
Isolated rat ZG cells were prepared as previously described. lOOpl of the cell
suspension, diluted to contain -20,000 zona glomerulosa cells, was added to
eppendorf tubes containing lOOpl of Medium 199 supplemented with 5g/L
BSA;2g/L D-glucose, in which all the test substances (10"10M-10"4M) had been
dissolved to the required final concentration. Dose response curves to 5-HT, DMI,
citalopram and MDMA (lO'l^M-lO'^M) were obtained. These incubations acted
as "controls" to allow comparison of the incubations containing 5-HT plus either
DMI, citalopram or MDMA. Incubations with 10"^M-10"4M 5-HT were then
incubated in the presence of 10'^M or lO'^M DMI or citalopram, or IpM or
lOpM MDMA. Control incubations contained zona glomerulosa cells and Medium
199 only, allowing the basal value for aldosterone secretion into the medium to be
measured. Each incubation was carried out in triplicate and the dose response to 5-
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HT carried out at least twice during each individual experiment to allow
comparison between values for 5-HT and other compounds. The tubes were mixed
thoroughly and incubated for 1 hour at 37°C in a shaking water bath. After 1 hour
the tubes were placed on ice to prevent further steroid production and then
centrifiiged at 15,000g for 2 minutes at 4°C to pellet the cell suspension. The
supernatant was decanted and the samples stored at -20°C until measurement of
aldosterone secretion into the medium via direct radioimmunoassay (RIA).
2.5.2. Superfusion ofWhole Rat Adrenal Capsules or Isolated ZG Cells.
The capsule and adhering zona glomerulosa were removed from rat adrenal glands
according to the method ofHaning et a/., (1970). The capsules or a preparation of
isolated ZG cells (prepared as discussed previously) were then placed in a
suspension of Sephadex in saline (0.2mg in 3mis saline), on top of nylon gauze, and
superfused, at a rate of lml/lmin, with Krebs-Ringer bicarbonate buffer (0.2%
BSA) for 1 hour at 37°C to allow the tissue to equlibrate. Before addition of 5-HT
and/or DMI, citalopram or MDMA, samples were collected to allow measurement
of basal aldosterone levels. 5-HT (10"^M-10"^M) either in the presence or absence
of 10"9M or 10"^M DMI, 10"^M or 10'^M citalopram or lpM or 10 pM MDMA
was added to the perfusing medium for 10 minutes and after addition of each
concentration of 5-HT a wash-out period of 30 minutes followed. Samples of
perfusate were collected every 5 minutes. The samples were measured for
aldosterone by direct RIA.
2.5.3. In Vivo study of the effects ofMDMA in Rats.
Female Wistar rats (200-250g;n=6) were anaesthetized with halothane in a mixture
of oxygen (30%) and nitrous oxide (70%) and cannulae inserted into both femoral
arteries ( for the measurement of arterial blood pressure and the sampling of arterial
blood), and both femoral veins ( for the injection ofMDMA or saline). All surgery
was performed by fully trained and experienced personnel and complied with local
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ethical codes and UK government regulations. A loose fitting plaster cast was
applied around the pelvis and lower abdomen and pelvis with care taken to ensure
that respiratory movement of the thorax was not compromised. The rats, thus
restrained and supported on blocks, were allowed to recover for at least 2 hours
before the study commenced. Arterial blood pressure and rectal temperature were
recorded throughout the study. Blood samples were taken before the
administration ofMDMA (Saline for control animals). MDMA was dissolved in
saline (5mg/ml) and rats were injected i.v. with 5mg/kg made up to a final volume
of 0.6ml with excess saline (n=6) or with the same volume of saline alone (n=6).
Once the MDMA was administered blood samples (approx. 250pl), were taken
every minute for 10 minutes, and again at 20 and 30 minutes. At 30 minutes the
animals were sacrificed and the adrenal glands removed. Blood was treated with
ice cold EDTA (27mmol/l), to enable measurement of aldosterone by direct
radioimmunoassay (RIA) and Plasma Renin Activity (PRA) by RIA.
2.5.4. pHl Paroxetine Binding.
Sections ofwhole rat adrenal gland were cut in a cryostat (-20°C), thaw-mounted
onto gelatin covered glass slides and stored at -70°C for subsequent [3H]paroxetine
autoradiography binding analysis of 5-HTergic uptake sites. The slide mounted
sections were processed for [3H]paroxetine autoradiography according to the
protocol described by Battaglia et al., (1987). Briefly, sections were incubated in
Tris buffer containing a saturating concentration (250pM) of [3H]paroxetine. Non¬
specific binding was defined in adjacent sections by [3H]paroxetine binding in the
presence of 4uM citalopram. Following incubation, the sections were washed in
buffer, dipped in deionized water and rapidly dried under a stream of cold air. The
sections, together with a series of [3H] standards were apposed to X-ray film in a
light tight container and stored at -70°C for 4-6 weeks.
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Analysis of ["'H]paroxetine autoradiographs was performed using a computer based
image analysis system (Cambridge Instruments Quantimet 970). Tissue isotope
concentrations were measured from autoradiographic images of brain sections,
relative to appropriate [3H] containing standards (Amersham International).
Specific [Tljparoxetine binding was determined by subtraction of image densities of
non-specific binding images from total binding images.
2.5.5. Western Blotting.
Cell pellets of adrenal capsular tissue and adrenal medulla/fasciculata tissue were
prepared by adding the tissue to 5 parts of PBS, and homogenising in a glass/glass
hand held homogeniser. The homogenate was then centrifuged at 15,000g for 10
minutes at 4°C, and the supernatant decanted. The cell pellet was then washed
with PBS, and centrifuged as above. The supernatant was then removed and the
cell pellet stored at -70°C prior to Western blotting.
The cell pellet was defrosted and PBS was added (enough to dilute the protein in
each sample to ~50-100pg per lane). Once diluted the cell pellet was vortexed and
an equivalent amount of Laemmli added and vortexed. For each capsule 400pl
PBS and 400pl Laemmli was added and for medulla/fasciculata tissue 800pl PBS
and 800 pi Laemmli. Once vortexed the cell pellets are incubated at 37°C for 30
minutes. 50pl of Laemmli was then added to 50pl of 'rainbow markers', and this
was incubated at 100°C for 10 minutes.
The samples were then added to a gel (50pl of each sample per lane), and
electophoresis was carried out at 25-30mA, for 4 hours. The gel was then
transferred overnight at 4°C onto a membrane. To prepare a gel, 2 glass plates
were rinsed in water and ethanol and swabbed with acetic anhydride, and allowed
to dry. The plates were then clamped onto the appropriate stand. Resolving gel
was added, slowly down one side of the plate, leaving -3 cm at the top of the plate
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for addition of stacking gel. A thin layer of water saturated butan-l-ol was then
added to avoid the formation of a meniscus. Stacking gel was added and a comb
inserted immediately. This was allowed to set. The comb was then removed, the
gel rinsed and filled with reservoir buffer. To transfer a gel, a sponge and blot
paper was added to a cassette , soaked in transfer buffer, and the membrane placed
on top of the blot paper. The gel was added onto the membrane, then another blot
paper and then finally a sponge. The cassette was then shut over ready for transfer
overnight.
The membrane was then blocked with 5% Marvel and 0.05% Tween 20 in TBS for
1 hour. The membrane was then incubated with transporter antibody at a 1:200
dilution for 1 hour, washed with 2% Marvel, 0.05% Tween 20 in TBS, then
incubated with horseradish peroxidase conjugated secondary antibody (1:1000) for
1 hour. Bands were detected by ECL with DAB and photographic film.
2.5.6. Immunohistochemistrv.
Rats on normal salt diet were killed by decapitation. The adrenal was dissected and
trimmed of all fat, fixed in 10% neutral formalin for 24 hours then embedded in
paraffin. 4pm transverse sections of the adrenal/kidney were cut on a cryostat and
transferred to a gelatin coated slide. Immunostaining was by an indirect method of
antigen retrieval using microwave according to the method described by Gerdes et
al, (1992). Negative controls consisted of replacement of the primary antibody
with an equivalent concentration of normal rabbit serum.
Two antibodies to the 5-HT transporter were studied. The first, S (5-HT)-240-
KLH (keyhole lympet haemocyanon), was raised in rabbits against a 14 amino acid
sequence present in the second extracellular loop of the 5-HT transporter, a
sequence chosen as it is similar to that used for the dopamine transporter antibody,
which had proven very successful (Quian et al., 1995). The second antibody used,
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S-387-KLH, was again raised in rabbits, but this time against a 14 amino acid
sequence contained in the fourth extracellular loop, a peptide sequence that
corresponds to that used by Blakely et al., (1992), for generation of his 5-HT
transporter antibody
The sections were rinsed in water via xylene and alcohol, rinsed and wiped dry.
They were then immersed in 500mls of citrate buffer at pH 6 and microwave
treatment applied for 20 minutes. Endogenous peroxidase was blocked by
immersion in 3% aqueous H202 for 5 minutes. The sections were then rinsed in tap
water for 3-5 minutes, then wiped dry. Before the primary antibody was added the
sections were incubated with 20% normal sheep serum to reduce background
staining. This was drained off and primary antibody added. Incubations in the
primary antibody were 60 minutes at room temperature and the dilution established
via a titration series resulting in a dilution of 1:200 for both antibodies. Following a
10 minute wash in TBS, sections were incubated in peroxidase conjugated anti-
rabbit link antibody (diluted 1:50) for 60 minutes. A further 10 minute wash in
TBS preceded incubation in StreptABC-peroxidase reagent (Dako Ltd.) for 30
minutes. After another 10 minute TBS wash peroxidase was visualised by a
standard hydrogen peroxide/Diaminobenzidine substrate/chromagen solution.
Finally, sections were counterstained in haemotoxylin, dehydrated in ethanol,
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Medium 199:-1 sachet of medium 199 was dissolved in 100ml of distilled water
and a 15ml aliquot was added to 210ml of salt solution containing NaHC03,
MgS04, KH2P04, CaCl2 and NaCl. The final concentration of ions in the medium
in mM were, sodium 145, potassium 3.9, calcium 2.5, magnesium 1.2, bicarbonate
25, chloride 128, phosphate 1.2 and sulphate 1.2.
Phosphate Buffer:-This solution contained 80 mM Na2HP04, 20mM KH2P04and
15mM NaN3 made up in distilled water (pH 7.4). For use in assays 0.1% BSA was
added.
Dextran Coated Charcoal:-6.25g of charcoal, 0.4g of gelatin pre-dissolved in
20ml ofwarm phosphate buffer and 0.62g of dextran in 1 litre of phosphate buffer
(pH 7.4).
Sodium Acetate Buffer:-120ml acetic acid (0.1M) and 80ml of sodium acetate
(0.1M) (pH 4.75).
EDTA Inhibitor for Blood Collection:- 27mM EDTA in 0.9% saline.
Cocktail for Blood Collection:-1.1 pM clomipramine, 11.1pm pargyline and 1.1
units thrombin/ml, in distilled water.
Phosphate/Citrate Buffer:-20mM citric acid and 12mM NaH2P04in distilled
water (pH4).
EDTA for AI RIA:-270mM EDTA in distilled water.
BAL:-15ml arachis oil, 242pl 2,3-dimercapto-propan-l-ol and 535ml benzyl
benzoate.
8-OH-Quinoline:-454mM 8-hydroxyquinoline in distilled water.
Krebs Ringer Buffer:-120mM NaCl, 2.6mM KC1, 1.2mM CaCl2, 1.18mM
KH2P04, 1.18mM MgS04and 25.8mM NaHC03, made up in distilled water (pH
7.4).
Tris Buffer:-30mM Tris and 15mM NaN3 made up in 30mM E1C1 (pH 7.4).
Citrate Bufifer:-100mM citric acid, 300mM NaOH, ImM EDTA and lg/litre of
gelatin, made up in distilled water (pH 6.2).
4% BSA:-4g ofBSA in lOOmls phosphate buffer.
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Stacking Gel Buffer:-0.5M Tris HC1 (pH 6.8). 6.0g Tris in 40ml distilled water,
add ~48ml of 1M HC1 to bring the pH to 8, and make up to 100ml with distilled
water. Filter through Whatman No. 1 paper, and store at 4°C.
Resolving Gel Buffer:-3.0M Tris HC1 (pH 8.8). 36.3g Tris in 48ml 1M HC1, and
made up to 100ml with distilled water. Filtered and stored at 4°C.
Reservoir Buffer:-0.25M Tris HC1 (pH 8.3). 30.3g Tris in 48ml 1M HC1, 1.92M
glycine (144.Og) and 1% SDS (lOg). Made up to 1000ml with distilled water and
stored at 4°C.
Stacking Gel:-40% acrylamide solution (1.8ml), 2% bisacrylamide solution
(0.9ml), stacking gel buffer (5ml), 10% SDS (0.2ml), 1.5% Ammonium Persulfate
(lml), distilled water (11.1ml) and Temed (added at the last minute)(0.015ml).
Resolving Gel:-For a 7.5% solution; 40% acrylamide (5.63ml), 2% bisacrylamide
(3ml), resolving gel buffer (3.75ml), 10% SDS (0.3ml), 1.5% ammonium (1.5),
distilled water (15.82) and Temed (0.015ml)
Sample Buffer (Laemmli):-For a 7.5% solution; Tris FIC1 0.0625M (pH 6.8).
Tris HC1 (0.76g), 2% SDS (20mls), 5% 2 mercaptoethanol (5ml), 1mm DTT (lml),
10% glycerol (20ml), 0.002% bromophenol blue and water to lOOmls.
Transfer/Running Buffer:-Tris HC1 (25mM) and glycine (192mM), made to
volume with distilled water. Running buffer also contained SDS (0.1%), and
Transfer Buffer contained 20% methanol.
2.8. Data analysis.
Results are shown as mean ± standard error of the mean, n refers to the number of
times the experiment was performed. The significance between different data sets
were assessed by analysis of variance. The significance between basal and different
concentrations of agonist/antagonist in an experiment was assessed by Student's t -








Despite the fact that 5-HT is known to stimulate aldosterone secretion from the
ZG, the physiological relevance of this remains poorly understood, and the role of
other indoleamines, which occur naturally, has not been fully evaluated. Variations
in the structure of tryptamine and 5-HT have mainly been made in a search for
antagonists to 5-HT; much less work has been published, however on the relative
potency of tryptamine derivatives as mimics of 5-HT. At the time that 5-HT was
shown to have stimulatory activity on the ZG there was some disagreement on the
assumption that 5-HT was the most important physiological indoleamine agonist.
A carboline metabolite of the indoleamine melatonin was believed by some to have
100 times the potency of 5-HT in stimulating aldosterone release (Farrell, 1961).
However this carboline was shown to be inactive in vitro (Jouan, 1963).
Mendelsohn et al., (1981) reported that an unidentified component of rat plasma
was able to stimulate aldosterone secretion beyond the maximal stimulation by 5-
HT. The fact that this stimulation was depressed by 5-HT antagonists indicated the
possibility that there could exist an endogenous 5-HT receptor agonist with activity
superior to that of 5-HT.
A few studies in the adrenal gland comparing a number of indoleamines have been
published. Muller (1968), tested nine compounds related to 5-HT in adrenal
quarters in an attempt to discover an alternative physiological agonist, the study did
not, however, look at the effects of these compounds in isolated ZG cells, making
interpretation of these results difficult. Al-Dujali et al., (1982) using rat ZG cells in
a column perfusion system demonstrated that 5-HT, 5-MeOT and to a lesser extent
5-methoxytryptophol and melatonin were able to stimulate aldosterone secretion.
5-MeOT appeared to be more potent than 5-HT in this system. In 1970, Muller
was able to show a stimulatory effect of 5-HT, 5-MeOT and L-5-
hydroxytryptophan in static incubates of adrenal slices. Thus despite considerable
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understanding of the metabolic pathway of 5-HT, little is known of the ability of
other indoleamines to cause aldosterone secretion.
In this chapter, these previous studies have been extended using a more
pharmacological approach. 5-HT and a range of related indoleamines, including
metabolites and precursors and synthetic congeners, were all incubated with
isolated rat ZG cells. In addition to the measurement of aldosterone secretion, the
second messenger for 5-HT, cAMP, was also quantitated. The rationale behind this
study was two fold, firstly to determine how specific 5-HT stimulated
steroidogenesis is in relation to other structure-related indoleamines and to define
more clearly the structure-activity requirements for this stimulation in the ZG cells,
and secondly to determine if the metabolites, precursors or intermediates of the 5-
HT biosynthetic and metabolic pathways could give rise to a steroidogenic
response.
3.2. Statistical Analysis.
Statistical significance was calculated in the individual experiments by ANOVA and
then Student's t-test for unpaired samples. A p value of <0.05 was considered
significant. NS indicates non-significance. *, ** and *** indicates that p<0.05,
p<0.01 and p<0.001 respectively. P values relating to the mean values from the 4
separate experiments were calculated.
3.3. Results.
The graphs illustrated show mean±SEM of four individual experiments, and within
a single experiment each incubation was performed in triplicate. Within each
individual experiment two identical dose response curves to 5-HT were carried out,
i.e. the first assay to be set up and the last. This provided the standard against
which the stimulations by other indoleamines could be quantified. Although the cell
number remained constant within each experiment, from experiment to experiment
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small variations occurred in the basal values for aldosterone secretion into the
medium. For this reason aldosterone secretion is expressed as the stimulation
ratio±SEM in relation to the basal secretion of the control samples which have been
given a value of 1. This normalization procedure is commonly used in studies
involving dispersed cells and cells in primary culture. Variations in the
responsiveness of the cells to a particular stimulus were also observed between
experiments, and may relate to differing degrees of cellular damage caused by the
collagenase digestion (Vinson et al 1985).
The cAMP response was only studied in one experiment (in order to establish that
the compounds which stimulated aldosterone secretion, also stimulated cAMP).
For this reason it was not considered valid to conduct statistical analysis of the
cAMP data.
The mean basal aldosterone secretion in all experiments was 1.0±0.18 (mean
±SEM) nM per 20,000 cells per hour.
The dose responses to 5-HT observed corresponded to those already reported
(Haning 1970, Albano 1974). Characteristically the aldosterone response had a
-9
threshold around 10 M 5-HT (Figure 3.1), below which there was no apparent
-8
response. Significant stimulation of aldosterone was observed at 10 M 5-HT
(p<0.05) and 106M 5-HT produced maximal stimulation. Though there appeared
to be a reduction of the maximal effect at KTM 5-HT this was not significant. The
maximal stimulation of aldosterone release produced by 5-HT was generally in the
order of four times the basal secretion rate (Figure 3.1.).
Of the compounds tested in the study four gave maximal stimulation of cAMP
induced aldosterone secretion comparable to that seen with 5-HT, namely 5-
methoxytryptamine, 5-methyltryptamine, N-methyltryptamine and tryptamine.
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Figures 3.1.-3.6. represent the dose-response curves expressed as stimulation ratios
for the compounds tested in the study. Figure 3.2. shows the aldosterone response
to 5-methoxytryptamine, a minor metabolite of 5-HT, producing comparable
-9
stimulation of aldosterone to that seen with 5-HT, and threshold stimulation at 10
-6
M with maximal stimulation at 10 M, 6-methoxytryptamine producing maximal
stimulation at 10 M, higher concentrations produced no further increase in
aldosterone stimulation and 5-HIAA the major metabolite of 5-HT having no
aldosterone stimulating activity. Figure 3.3. shows the stimulation ratios for 5-
methyltryptamine, producing a maximal stimulation at 10 ?M, and a threshold
-9
stimulation at 10 M and N-methyltryptamine producing comparable stimulation to
-6
that seen with 5-HT, with maximal stimulation again at 10 M and threshold
-9
stimulation at 10 M. Tryptamine produced comparable stimulation of aldosterone
to that seen with 5-HT at 10 5M, concentrations and above this produced no further
increases in aldosterone secretion. Figure 3.4. represents the stimulation ratios for
5-hydroxytryptophan, the precursor to 5-HT, producing a weak maximal
stimulation at 10 M, higher concentrations producing no further increases in
aldosterone secretion, L-tryptophan, a precursor to 5-HT producing no aldosterone
stimulating activity, melatonin, producing a small non-significant rise in aldosterone
-5
secretion at 10 M, and 5-hydroxytryptophol producing no aldosterone stimulating
activity. Figure 3.5. and Figure 3.6. represent the stimulation ratios for 5-
fluorotryptamine, 6-fluorotryptamine, 5,6-dihydroxytryptamine, 5,7-
dihydroxytryptamine and 5-hydroxytryptophol, of which only 5-fluorotryptamine
produced weak aldosterone stimulating activity at 10 M, higher concentrations
producing no further increases in aldosterone secretion. The overall results for the
compounds tested which stimulated aldosterone are shown in Figure 3.7. From the
raw data, EC5o and maximal values were calculated by a curve fitting procedure
(software provided by Dr. R. Barlow).
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From the data gained in this study we were primarily interested in the EC50 values
for the compounds which displayed aldosterone stimulating activity, that is the
concentration required for each agonist to produce half maximal response, and the
% maximal stimulation for each compound compared to the maximal stimulation
produced by 5-HT. This would then enable comparison of each compound with 5-
HT and thus calculation of the important structural requirements for aldosterone
stimulating activity. This data is summarised in Table 3.1.
The EC50 and the % maximal stimulation values are the mean±SEM from 4
individual experiments. The indole nucleus at the top of Table 3.1. shows the
groupings Rq and R2 of which we were interested in looking at the differing
groups.
5-HT, 5-methyltryptamine and 5-methoxytryptamine all contain an amine grouping
at Ri and an hydroxy, methyl and methoxy group respectively at R2, and all have
similar low EC50 values and produce comparable maximal stimulations of
aldosterone. N-methyltryptamine containing an N-methyl group at Ri and no R2
group also has a low EC50 value similar to that of 5-HT and produces comparable
maximal stimulation of aldosterone. However tryptamine containing an amine
group at Ri and again no R2 group shows high maximal stimulation of aldosterone
but with a high EC50 value. 6-methoxytryptamine with an amine group at Ri and
now with a methoxy group at C6 has a high EC50 value and produces weak
maximal stimulation of aldosterone. 5-HTP the precursor to 5-HT containing an
amine carboxylic acid group at Ri and a hydroxyl group at R2 produces weak
stimulation of aldosterone and has a high EC50 value. In contrast however , L-
tryptophan also a 5-HT precursor containing an amine carboxylic acid group at Ri
but no R2 group produces no aldosterone stimulating activity. The major
metabolite of 5-HT, 5-HIAA, containing a carboxylic acid group at Ri and a
hydroxy group at R2 also has no aldosterone stimulating activity. Melatonin,
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Figure 3.1. Dose-dependent increase in aldosterone secretion from isolated rat ZG
cells in response to increasing concentrations of 5-HT. Isolated rat ZG cells were
incubated for 1 hour at 37°C with increasing concentrations of 5-HT. Aldosterone
secretion into the medium was measured by RIA. Data, represented as stimulation ratios,
from 4 separate experiments, with triplicate incubations performed in each, were
combined and expressed as mean±SEM. *p<0.05; **p<0.01 and ***p<0.001 compared
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Figure 3.2. Dose-dependent increase in aldosterone secretion from isolated rat ZG
cells in response to increasing concentrations of5-MeOT, 6-MeOTand 5-HIAA. Isolated
rat ZG cells were incubated for 1 hour at 37°C with increasing concentrations of 5-
MeOT, 6-MeOT and 5-HIAA. Aldosterone secretion into the medium was measured by
RIA. Data, represented as stimulation ratios, from 4 separate experiments, with triplicate
incubations performed in each, were combined and expressed as mean+SEM. *p<0.05;






































Figure 3.3. Dose-dependent increase in aldosterone secretion from isolated rat ZG
cells in response to increasing concentrations of 5-methyltryptamine, N-methyltryptamine
and tryptamine. Isolated rat ZG cells were incubated for 1 hour at 37°C with increasing
concentrations of 5-methyltryptamine, N-methyltryptamine and tryptamine. Aldosterone
secretion into the medium was measured by RJA. Data, represented as stimulation ratios,
from 4 separate experiments, with triplicate incubations performed in each, were
combined and expressed as mean±SEM. *p<0.05; **p<0.01 and ***p<0.001 compared












Figure 3.4. Dose-dependent increase in aldosterone secretion from isolated rat ZG
cells in response to increasing concentrations of 5-hydroxytryptophol, 5-HTP, L-
tryptophan and melatonin. Isolated rat ZG cells were incubated for 1 hour at 37°C with
increasing concentrations of 5-hydroxytryptophol, 5-HTP, L-tryptophan and melatonin.
Aldosterone secretion into the medium was measured by RIA. Data, represented as
stimulation ratios, from 4 separate experiments, with triplicate incubations performed in
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Figure 3.5. Dose-dependent increase in aldosterone secretion from isolated rat ZG
cells in response to increasing concentrations of 5-fluorotryptamine and 6-
fluorotryptamine. Isolated rat ZG cells were incubated for 1 hour at 37°C with increasing
concentrations of 5-fluorotryptamine and 6-fluorotryptamine. Aldosterone secretion into
the medium was measured by RIA. Data, represented as stimulation ratios, from 4
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Figure 3.6. Dose-dependent increase in aldosterone secretion from isolated rat ZG
cells in response to increasing concentrations of 5,6-dihydroxytryptamine and 5,7-
dihydroxytryptamine. Isolated rat ZG cells were incubated for 1 hour at 37°C with
increasing concentrations of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine.
Aldosterone secretion into the medium was measured by RIA. Data, represented as
stimulation ratios, from 4 separate experiments, with triplicate incubations performed in
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Figure 3.7. Summary graph of the indoleamines studied which produced an increase
in aldosterone secretion from isolated ZG cells.
Figure 3.8. cAMP secretion into the medium after incubation of isolated ZG cells with
increasing concentrations of 5-HT. cAMP measurements into the medium after
incubating isolated ZG cells with increasing concentrations of 5-HT. The graph is



























































Table 3.1 Summary of the Indoleamines functional groupings, ec50 values and maximal
stimulation values (n=4).
containing a methoxy group at R2 and an acetyl grouping at Ri, demonstrated a
small rise in aldsoertone secretion which was not significant. 5-hydroxytryptophol,
with an hydroxy grouping at R2 and at Ri, demonstrated no aldosterone
stimulating activity. The compound 5-fluorotryptamine, with a fluorine grouping at
R2 and an amine grouping at Ri, caused a slight non-significant rise in aldosterone
secretion. In contrast the compound 6-fluorotryptamine, with no R2 grouping, and
now a fluorine grouping at C6, had no effect on aldosterone secretion. The
compounds 5,6-dihydroxyltryptamine and 5.7-dihydroxyltryptamine, with no
Rlgrouping and now two hydroxy groupings at R2, demonstrated no aldosterone
stimulating activity.
cAMP secretion into the medium was also measured for the compounds that caused
an equivalent aldosterone secretion to that of 5-HT, although due to the amount of
cells required per experiment and problems with the cAMP assay itself, the
experiments were only carried out once. cAMP as the second messenger for 5-HT
stimulated aldosterone secretion has been proven by many groups, although cAMP
secretion induced by the indoleamines studied here has not been fully evaluated to
date. Our results largely agree with the previous data already published, and also
with a previous study carried out in our laboratory by M. Hughes. The cAMP
-7
response to 5-HT was maximal at 10 M, following the same pattern as aldosterone
secretion stimulated by 5-HT (Figure 3.8.). A cAMP response to 5-MeOT, N-
methyltryptamine and 5-methyltryptamine was also observed (data not shown).
3.4. Discussion.
The molecule 5-HT, or 5-hydroxy-3-(2-aminoethyl) indole, consists of a diffuse 10
electron cloud above and below the heteroaromatic plane which is pulled towards
the aminoethyl group at position 3 making this the most basic region of the
molecule. At pH 7.5 the molecule is completely protonated (cationic form) whilst
at pH 10.5 approximately 30% each of the neutral form and the zwitterionic form
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exists. At alkaline pH, 5-HT in solution is rapidly destroyed when heated and
because of this instability, 5-HT is sold commercially as the creatinine sulphate salt.
At low pH, 5-HT is stable even at elevated temperatures, and can exist also as one
of three stable salts, the picrate, hydrochloride or salicylate salt. Three different
dissociation constants have been determined related to the creatinine moiety (pKa
4.9), the terminal amino group (pKa 10) and the hydroxy group within the benzyl
ring (pKa 11.1).
The results obtained in this study are broadly consistent with the published
investigations of indoleamine activity in stimulating aldosterone secretion. 5-HT
and related compounds are subject to a variety ofmetabolic transformations, and so
there exists a large and diverse group of naturally occurring indoleamines. In this
study the following naturally occurring indoleamines were compared with 5-HT, L-
tryptophan, tryptamine, melatonin, 5-HIAA, 5-HTP, N-methyltryptamine, 5-
Methyltryptamine, 5-hydroxytryptophol and 5-methoxytryptamine.
Two of the naturally occurring compounds displayed similar strong agonist activity
as compared to 5-HT, that is 5-MeOT and N-methyltryptamine. The response to
5-MeOT was equivalent to that of 5-HT. This response within perifused adrenal
slices has also been reported by Contesse et al., (1999). N-methyltryptamine also
produced a strong stimulation of aldosterone secretion, although the response was
different to that produced with 5-HT (Figure 3.3.), with a sharp rise from basal to
maximal aldosterone secretion. This form of response would appear anomolous if
the mechanism of this activation is a simple interaction of a single drug molecule
with a receptor. It must be asked therefore whether this compound produces the
stimulation seen in the same way as 5-HT. It is a unique compound amongst the
various ones tested as it contains a small substituent, which improves the basicity of
the terminal amine group, and this may result in an alteration in receptor binding
providing the steep dose response relationship seen.
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Tryptamine caused a high maximal stimulation of aldosterone, although the relative
potency of this compound was low as seen with the high EC50 value recorded,
consistent with a low-affinity, high-efficacy interaction with the receptor.
Interestingly, Vane (1959) reported that the activity of tryptamine in rat stomach
preparations was enhanced over 12 fold by the addition of an amine oxidase
inhibitor, providing a greater activity in this preparation as compared to 5-HT. It
was suggested that tryptamine had access to the intracellular oxidases, but that this
access was denied to 5-HT, due to polar substituent groups preventing diffusion
across the membrane. Should this oxidation be a factor in the ZG response to
indoleamines, it may be that 10 M tryptamine is needed to saturate an oxidase, and
that only above this concentration are agonist effects evident. It remains to be
shown whether amine oxidase inhibition has an effect on tryptamine potency in this
system. Interestingly, Contesse et al., (1999), studied the ability of tryptamine
(InM to 10pM) to stimulate aldosterone secretion from perifiised rat adrenocortical
slices, and found that it was >1500 times less potent than 5-HT at eliciting a
response.
5-methyltryptamine, 5-HTP and melatonin produced stimulation of aldosterone
secretion, although the responses to these agonists were quite different. Melatonin
caused very slight, non-significant stimulation of aldosterone secretion. 5-
methyltryptamine on the other hand produced a significant stimulation of
aldosterone, and the maximal stimulation seen was comparable to that seen with 5-
HT (Figure 3.3). This occurred at a higher agonist concentration thus leading to a
high EC50 value and a low relative potency. Although in isolation this effect may
be attributed to a low receptor affinity, the potential affects of monoamine oxidase
activity must also be considered. 5-HTP displayed a slight non-significant
stimulation of aldosterone secretion at high concentrations of agonist. This effect
may in fact be due to the slow in vitro formation of 5-HT from 5-HTP, and not in
104
fact due to 5-HTP itself. This effect will be discussed in greater detail in Chapter
Five.
5-HIAA, 5-hydroxytryptophol and L-tryptophan demonstrated no stimulation of
aldosterone at all. Thus along the principal path of 5-HT metabolism, 5-HT itself is
the only compound of significant activity at the zona glomerulosa cell receptor.
These results for the naturally occurring indoleamines suggest that in addition to 5-
HT, other indoleamines, synthesised constituitively by mammals, are equally
capable of activating aldosterone synthesis. 5-MeOT, a compound that produced
equivalent stimulation of aldosterone secretion as that due to 5-HT is found in
plasma and may play an important role in aldosterone secretion. More
investigations in to the physiological availability of these compounds are needed
before any of the above agonists can be identified as potential physiological
stimulants of aldosterone secretion.
To supplement the data from the naturally occurring compounds five synthetic
compounds were looked at namely, 6-MeOT, 6-FT, 5-FT, 5,7DHT and 5,6DHT.
The response to 6-MeOT indicated partial agonist activity (Figure 3.2.). The other
synthetic compounds produced no significant stimulation.
From the observations in this study the substituent at the 5-position has little effect
on the potency of the resulting molecule. This supports the observation of a "bulk
tolerance" at the C5 in binding studies at the pharmacologically similar brain 5-HT2
receptor (Lyon, 1988; Bishop, 1990). The effect of exchanging a C5 group for the
same group at C6 was studied by comparing 5-MeOT and 6-MeOT, and 5-FT with
6-FT. It was found in both cases that the activity of the 6-substituted compound
was lower. This observation is supported by results from several other receptor
types (Vane, 1959; Engel, 1983; Nichols, 1988, Lyon, 1988). The fact that this
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trend appears to be irrespective of the electrostatic changes suggests that there is a
high steric stringency imposed on C6 substitutions. The complete inactivity of both
the dihydroxytryptamines could equally be due to steric or electrosteric effects, so
these results yield no significant information about the pharmacophore. Variations
on the alkylamine side chain were also investigated. 5-HT has a pKa of 10, and so
the terminal amine group is predominantly protonated at physiological pH (Vane,
1959). The existence of a positive charge on the terminal amine indicates that this
group is particularly likely to be involved in binding receptors (Greenberg, 1960).
It is therefore not surprising that the congeners in which this amine is missing, 5-
HIAA and 5-hydroxytryptophol demonstrate no agonist activity. The compound 5-
HTP, a chain substituted compound with a reduced basicity of this amine group
demonstrated weak stimulating activity.
From table 3.1. it can be clearly seen that the indoleamines with a free group at
position C9 or with a methyl group attached to the nitrogen (N) atom are the most
potent stimuli of aldosterone secretion. Thus, increasing the basic character at this
position and thus the electron cloud negativity appears to be of primary importance
in steroidogenic activity. Substitution, as seen in 5-MeOT, where the molecule still
retains the amino portion, but now contains an additional oxygen grouping
producing a more basic molecule, the potency of indoleamine stimulated
aldosterone secretion is not affected, and in fact is equivalent to that seen with 5-
HT. Substitution with a non-basic group as in 5-methyltryptamine, or indeed
complete removal of the group at position C5, for example tryptamine, slightly
reduces the potency of stimulation, but not significantly. Thus the indole moeity
appears to be of primary importance in stimulation of aldosterone synthesis.
Modification of this region as in 5-hydroxytryptophol, gives rise to a compound
that produces no significant rise in aldosterone secretion, and with melatonin,
containing a 5-methoxy grouping and an N-acetyl grouping, conferring reduced
basicity to the molecule, produced a slight non-significant rise in aldosterone.
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Structure activity relationships for 5-HT and related compounds have been used in
most studies investigating receptor types in certain tissues. Initially many groups
believed that the receptor type present within the ZG was a "5-HTlc/5-HT2 like"
receptor, the problem being that the second messenger system is cAMP within the
ZG and not the PI system which is classically linked to these receptors (Mantero et
al., 1982; Matsuoko et al., 1985; Maestri et al., 1988). Now, in the frog and
human gland, the receptor type has been shown to be a 5-HT4 receptor (Lefebvre et
al., 1992; 1996), although in our studies with the rat adrenal gland this receptor
type does not fit, and preliminary studies so far would give rise to the possibility
that in the rat ZG the receptor type is either a 5-HT6 or 5-HT7 receptor, both of
these are positively linked to cAMP, and these studies will be discussed in Chapter
Five. From these structure activity studies, the requirement of an intact ethylamine
structure would tend to suggest that if a 5-HT type receptor exists within the ZG, it
requires this group for steroidogenesis as opposed to binding per se. Previously, it
had been reported in studies by Niles et al., (1983), that the hydroxyl group
possessed by 5-HT and N-acetyl5-HT were essential for high affinity binding in the
rat brain and since N-acetyl5-HT interacted with the 5-HT receptor, it was
suggested that there was a close interaction on the same 5-HT receptor, however
Cohen et al., (1985) demonstrated that tryptamine could interact with 5-HT
receptors in the rat fundic region, so the conformational requirement for stimulating
through 5-HT receptors does not appear to be to rigid. Bennett & Snyder (1976),
demonstrated in a series of binding studies in brain tissue, that the key requirement
for 5-HT, high affinity binding was the 5-hydroxy substituted indole moiety. This
idea is supported by studies carried out by Allgren et al., (1985), in solubilised
bovine cortical brain membranes. This study also observed that membranes
specifically required potent interactions between the 5-hydroxy group and a free
amino terminal group for high affinity binding. This effect was lost on solubilising
the membranes. From this Allgren postulated that the 5-HT, site may exist as a
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complex subunit containing separate amine and indole attachment sites. From the
data in this study it could be suggested that the receptor present within the rat ZG
is of the type 1 class, as previously thought. Perhaps throughout the 5-HT receptor
classes different structural features and characteristics are necessary for binding to
the individual receptor types. More studies with specific antagonists and agonists
are needed before definitive characterisation of this receptor can be carried out.
Definitive proof of the existence of receptors within the ZG requires not only
pharmacological studies, molecular biology studies and ligand binding studies, but
also the existence of a second messenger system which acts as a coupling
mechanism between initial hormone/receptor interaction and end steroid response,
thus enabling the transformation of an initially small signal to a large end response
by a complex cascade mechanism. The second messenger systems to all the major
regulators of aldosterone, including 5-HT, have already been studied in great detail
and are discussed fully in Chapter 1. The results shown clearly illustrate that 5-HT,
as previously published, stimulates cAMP production, indicating that the receptor
type present in the ZG of the rat adrenal gland is positively coupled to cAMP. Of
the other compounds that stimulated aldosterone secretion, cAMP production was
also stimulated. The increase seen may in fact be due to contaminating ZF cells,
although this is highly unlikely as the steroidogenic capacity of 5-HT is confined to
the ZG. However, in the case of the other stimulatory compounds, this fact has not
been proven and further studies into the action of these compounds on the ZF must
be carried out before a complete picture of these compounds within the adrenal
gland can be formed. Of interest is the fact that the concentration of the
compounds, including 5-HT, required to stimulate cAMP was much higher than
that needed to induce steroidogenesis, indicating a clear dissociation between
second messenger and end response. A similar effect was observed for ACTH in
adrenocortical cells obtained from decapsulated adrenal glands by other groups
who demonstrated a discrepancy between adenylate cyclase activity and
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steroidogenesis. They also reported that specific binding of ACTH to cells
correlates well with cAMP production but not steroidogenesis (Beall & Sayers,
1972; Mackie et a/., 1972). These results strongly support the receptor reserve
model by Hornsby & Gill (1978), which suggested that only a small fraction of
cAMP formed in response to hormonal stimulation is required for steroidogenesis.
Further studies are required to fully evaluate the importance of compounds such as
5-methoxytryptamine and tryptamine in aldosterone secretion. A better system for
this evaluation would be the perfused adrenal capsule, allowing investigation of the
whole tissue without the harsh collagenase digestion process involved in the
formation of isolated ZG cells. However, capsular preparations provide little or no
response at low doses of compound due to the inaccessibility of cell surface
receptors. Additivity studies, in which the compounds that did not stimulate
aldosterone secretion are incubated with 5-HT, would be useful in establishing
whether or not those compounds were in fact having an antagonistic effect at the
receptor. The effects of salt diets on aldosterone secretion could also be looked at,
also the effects of amine oxidase must also be looked at in more detail.
These structure-activity studies give preliminary indications of the functional
groupings important for indoleamine interaction with the zona glomerulosa cell
receptor. It would appear that the 5-hydroxyl group is not a requirement for full
agonist activity, although substitution, but that ring substitutions at other positions
may compromise that activity. The basicity of the terminal amine group appears
also to be important in receptor binding. Compounds lacking both a basic terminal




Pharmacological Characterisation of 5-HT Receptors
in the Rat Adrenal Zona Glomerulosa.
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4.1. Introduction.
Functionally, 5-HT is a signalling molecule, acting throughout the body in various
ways. Numerous receptors exist for 5-HT throughout the body, often found in areas
where there is no apparent nearby neuronal or autocrine/endocrine source of 5-HT
supply. Over the past few years a number of "new" 5-HT receptors have been
discovered, so that at the moment seven different classes of 5-HT receptor exist, which
have been discussed in detail in Chapter One.
Although, as yet there is no clearly defined physiological role for 5-HT in aldosterone
secretion, in vitro it remains one of the most potent stimulators of aldosterone secretion
from the ZG, although the functional and physiological relevance of this still remains to
be elucidated. Since the first discovery of the stimulatory capacity of 5-HT on the ZG
of a variety of species, many studies have been carried out to determine the 5-HT
receptor site within the adrenal cortex. Historically, from studies utilising ketanserin
and cyproheptadine, in the rat, it was proposed that 5-HT-induced aldosterone
production was mediated through activation of a 5-HT2 receptor. Classically these
receptors are linked to the stimulation of phospholipase C. In a study by Rocco et a/.,
(1990), no influence of 5-HT on inositol phosphate formation was observed from
isolated rat ZG cells stimulated with 5-HT, indicating that the steroidogenic effect of 5-
HT within the rat ZG is not mediated through 5-HT2 receptors. Moreover, the second
messenger for 5-HT stimulated aldosterone secretion within the ZG is cAMP
(Matsuoka et al., 1985; Maestri et al., 1988). With the discovery of more 5-HT
receptor families, and more agonists, antagonists and radioligands, it has been possible
to identify the receptor site within the adrenal cortex of various species. In one study,
it was reported that the 5-HT4 receptor, positively coupled to cAMP, is present both in
the human and frog adrenal gland (Lefebvre et al., 1993). Also, in one study in the
hamster using a probe for the 5-HT6 receptor, a faint signal was found to be present
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within the adrenal cortex (Ruat et al., 1993). In the rat, certain antagonists for the 5-
HT6 and 5-HT7 receptors have previously been shown to be the most effective
antagonists for inhibition of 5-HT stimulated aldosterone secretion from isolated rat
zona glomerulosa cells (Lisa Bishop, Honours Project, 1989). From these various
studies the corticotropic effect of 5-HT was conserved, however the 5-HT receptor site
differs from species to species. In fact Contesse et al., (1999), finally characterised the
rat receptor site within the ZG as the 5-HT7 receptor, positively coupled to cAMP.
A link between sodium status and aldosterone secretion was first reported over 40
years ago. It is now apparent that sodium status is one of the most potent regulators of
aldosterone secretion. In a sodium deplete state the ZG undergoes morphological
changes, with an increase in the width of the ZG observed, also the responsiveness to
certain factors is increased. The opposite effect happens in a sodium loaded tissue. The
exact mechanism of this has remained largely unclear, due to the large number of
physiological effects initiated by altered sodium status. For example, the RAS is
affected. Lowering sodium increases renin secretion from the juxtaglomerular cells of
the kidney, leading to an increase in All receptors and subsequent increase in ZG
responsiveness to AIL Also a decreased extracellular fluid volume, circulating plasma
volume and arterial blood pressure, all activating the RAS, will be follow on effects of a
sodium deplete state. Another factor would be retention of potassium ions which can
stimulate aldosterone secretion directly. The RAS therefore plays an important role in
the action of sodium levels on aldosterone secretion, although this is not the only factor
involved. For example, it has been shown in nephrectomised animals, that during
sodium restriction, there is an increase in aldosterone production. Some groups have
suggested the involvement of a pituitary derived factor, not ACTH, which is secreted
during sodium depletion and stimulates aldosterone production (McCaa et al., 1974).
Davis et al., (1968), suggested a direct adrenal action of low sodium acting at both the
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early and late stages of the biosynthetic pathway. Another factor is the adrenal RAS
system, which may account for the effects seen, especially in nephrectomised animals
(Doi et a/., 1984). If 5-HT acts physiologically to alter aldosterone secretion from the
ZG, sodium status should also affect the actions of the indoleamine.
At the time of this work no definitive study had been carried out to characterise the 5-
HT receptor type within the rat ZG. The aim of this study, therefore, was to define the
5-HT receptor type present within the zona glomerulosa of the rat adrenal gland, using
a wide range of 5-HT agonists and antagonists, and studying their effect on aldosterone
secretion from freshly prepared isolated rat zona glomerulosa cells. The effects of a
change in sodium status in the rat was also investigated with the 5-HT agonists
showing comparable stimulation of aldosterone as to that seen with 5-HT. This would
add further evidence for a physiological role of 5-HT in aldosterone secretion, if salt
intake modulated its effect.
4.2. Statistical Analysis.
Statistical significance was calculated in the individual experiments by Student's t-test
for unpaired samples. A p value of <0.05 was considered significant. NS indicates non
significance. *, ** and *** indicates that p<0.05, p<0.01 and p<0.001 respectively.
4.3. Results.
The graphs illustrated are the mean ± SEM of four individual experiments, within each
experiment each incubation was repeated in triplicate. Figure 4.1 shows a typical
-10 -5
aldosterone dose reponse to 5-HT (10 M-10 M) in the rat zona glomerulosa cell
-8
preparation. 10 M 5-HT caused a significant rise in aldosterone secretion, maximal
-6
stimulation occurred at 10 M, causing approximately a four to six fold increase in
aldosterone output.
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Figure 4.2 shows the aldosterone stimulation produced by the 5-HT4 agonists BIMU 1
and BIMU 8. No significant stimulation of aldosterone from freshly prepared isolated
rat zona glomerulosa cells was observed, at any concentration of both BIMU 8 and
BIMU 1, as compared to 5-HT (n=4).
Figure 4.3 depicts dose response curves to the second class of 5-HT4 agonists, the
benzamide derivatives zacopride and cisapride. In our study however no significant
stimulation of aldosterone from the rat zona glomerulosa was observed with these
compounds at any concentration, as compared to 5-HT (n=4).
Figure 4.4. depicts the dose response to DAU 6285, a benzimidazolone derivative that
-7
acts as an antagonist at the 5-HT4 receptor, in the presence of 10 M 5-HT (n=4). No
significant inhibition of the stimulation of aldosterone induced by 5-HT within the rat
zona glomerulosa was observed at any concentration.
From the results depicted in Figures 4.2, 4.3 and 4.4 the presence of a 5-HT4 receptor
within the rat zona glomerulosa seem unlikely.
Figure 4.5 represents the dose response to CV 205 502, a 5-HT3 receptor antagonist,
-7
in the presence of 10 M 5-HT (n=4). No significant inhibition of 5-HT induced
aldosterone secretion was observed at any concentration. This result would suggest
that there are no 5-HT3 receptors present within the rat zona glomerulosa.
Figure 4.6 represents the dose response to ketanserin, a 5-HT2 receptor antagonist, in
-7
the presence of 10 M 5-HT (n=4). Significant inhibition of 5-HT induced aldosterone
secretion was observed at 10"^M and 10 M ketanserin. This result has previously been
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observed by other workers, suggesting the presence of a 5-HT2 receptor within the rat
zona glomerulosa (Williams et al., 1984; Matsuoka et al., 1985). However the second
messenger system classically linked to this receptor type is the PI system and it is now
well established that the second messenger system for 5-HT induced secretion within
the zona glomerulosa is cAMP (Fujita, 1979; Kojima et al., 1982).
Figure 4.7 represents the dose response to mesulergine, a 5-HT2 and 5-HT7 receptor
antagonist, with weak antagonistic properties at the 5-HT6 receptor, in the presence of
-7
10 M 5-HT (n=4). Significant inhibition of the aldosterone stimulation induced by 5-
-7 -6 -5
HT was observed at 10 M, 10 M and 10 M mesulergine. This effect again has been
observed in previous studies (Maestri et al., 1982; Lisa Bishop, Hons. Project, 1989).
The second messenger system classically linked to the 5-HTic receptor is the PI system;
however, in the case of both the 5-HT6 and 5-HT7 receptors the second messenger
system is cAMP, a fact that supports the presence of either of these receptors within
the rat zona glomerulosa.
Figure 4.8 represents the dose response to cyanopindolol, a 5-HTia and 5-HTib
receptor antagonist, in the presence of 10 M 5-HT (n=4). Significant inhibition was
observed at the higher concentration of this antagonist. However the 5-HTi receptor
family is linked to the PI system, and the receptor site present within the rat ZG is
positively linked to adenylyl cyclase, so it seems unlikely that a receptor belonging to
the 5-HT] family is present within the rat ZG.
Figure 4.9 depicts ICS 205/930, an indoleamine derivative, a 5-HT? and 5-HT4 receptor
antagonist, in the presence of 10?M 5-HT. No significant inhibition was observed at
any concentration of this antagonist, suggesting that these receptor types are not
present within the rat zona glomerulosa (n=4). This compound within the frog and
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human adrenal gland produced inhibition of 5-HT, zacopride, cisapride, BIMU 1 and
BIMU 8 (Lefebvre et al., 1992; Idres el al., 1991). The results for the antagonists are
summarised in Figure 4.10. The % inhibition for the antagonists are summarised in
Table 4.2.
Figure 4.11, represents dose responses to the agonists 5-methoxytryptamine and 5-
carboxamidotryptamine, as compared to 5-HT (n=3). These agonists are indole
derivatives fairly selective for the 5-HT4; 5-HT6 and 5-HT7 receptor sites, however 5-
CT only produces comparable aldosterone stimulation to that of 5-HT at very high
concentrations at the 5-HT4 receptor site. As can be seen the agonists produce similar
cells. These data strongly support the presence of either a 5-HT6 or 5-HT7 receptor
site within the rat zona glomerulosa, although the presence of a "5-HTic/5-HT2" like
receptor with cAMP as its second messenger as opposed to inositol phosphate can not
be ruled out.
The effects of sodium status, on the aldosterone stimulating abilities of these indole
agonists, are shown, in Figure 4.12 (n=3). Sodium status is probably the main
regulator of aldosterone secretion, and is discussed in Chapter One. Animals kept on a
low sodium diet (0%), a high sodium diet (3%), or a normal sodium diet (1%), for one
week, were sacrificed by cervical dislocation and their adrenals removed and isolated
zona glomerulosa cells prepared. The aldosterone dose response curves to all three
agonists show no significant difference within any particular salt diet; however a
significant difference between salt diets clearly exists (p<0.05). Responses from low
salt diets are highest, conversely, high salt diets have the lowest aldosterone output.
Figures 4.13, 4.14 and 4.15 depict the dose response to mesulergine, in the presence of
10"^M 5-HT, 5-methoxytryptamine and 5-carboxamidotryptamine respectively, from
animals from all three salt diet groups (n=3). Mesulergine resulted in a dose dependent
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Figure 4.1. Dose-dependent increase in aldosterone secretion from isolated ZG cells
in response to increasing concentrations of 5-HT. Isolated rat ZG cells were incubated
with increasing concentrations of 5-HT for 1 hour at 37°C. Aldosterone secretion into the
medium was measured by RIA. Data from 4 separate experiments, with triplicate
incubations performed in each, were combined and expressed as mean±SEM. *P<0.05





Figure 4.2. Dose-dependent increase in aldosterone secretion from isolated ZG cells
in response to increasing concentrations of 5-HT, BIMU1 and BIMU8. Isolated rat ZG
cells were incubated with increasing concentrations of 5-HT, BIMU1 or BIMU8 for 1
hour at 37°C. Aldosterone secretion into the medium was measured by RIA. Data from
4 separate experiments, with triplicate incubations performed in each, were combined and







Figure 4.3. Dose-dependent increase in aldosterone secretion from isolated ZG cells
in response to increasing concentrations of 5-HT, zacopride and cisapride. Isolated rat
ZG cells were incubated with increasing concentrations of 5-HT, zacopride or cisapride
for 1 hour at 37°C. Aldosterone secretion into the medium was measured by RIA. Data
from 4 separate experiments, with triplicate incubations performed in each, were
combined and expressed as mean±SEM. *P<0.05 and **p<0.01 compared to basal
levels.
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Figure 4.4. Aldosterone secretion from isolated ZG cells in response to 5-HT 10' M in
the presence of increasing concentrations of DAU 6285. Isolated rat ZG cells were
incubated with 5-HT at 10"7M in the presence of increasing concentrations of DAU 6285
for 1 hour at 37°C. Dose 0 reflects basal aldosterone secretion into the medium, in the
presence and absence of DAU 6285 (10"7M). Aldosterone secretion into the medium was
measured by RIA. Data from 4 separate experiments, with triplicate incubations
performed in each, were combined and expressed as mean±SEM.
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Figure 4.5. Aldosterone secretion from isolated ZG cells in response to 5-HT 10' M in
the presence of increasing concentrations of CV 205 502. Isolated rat ZG cells were
incubated with 5-HT at 10"7M in the presence of increasing concentrations of CV 205 502
for 1 hour at 37°C. Dose 0 reflects basal aldosterone secretion into the medium, in the
presence and absence of CV 205 502 (10" M). Aldosterone secretion into the medium
was measured by RIA. Data from 4 separate experiments, with triplicate incubations
performed in each, were combined and expressed as mean±SEM.
■ 5-HT 10"7M
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Figure 4.6. Aldosterone secretion from isolated ZG cells in response to 5-HT 10' M in
the presence of increasing concentrations of ketanserin. Isolated rat ZG cells were
incubated with 5-HT at 10"7M in the presence of increasing concentrations of ketanserin
for 1 hour at 37°C. Dose 0 reflects basal aldosterone secretion into the medium, in the
presence and absence of ketanserin (10"7M). Aldosterone secretion into the medium was
measured by RJA. Data from 4 separate experiments, with triplicate incubations
performed in each, were combined and expressed as mean±SEM. Statistically significant
differences between 5-HT stimulated aldosterone secretion and 5-HT stimulated
aldosterone secretion in the presence of an antagonist are indicated by **p<0.01.
■ 5-HT10"7M
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Figure 4.7. Aldosterone secretion from isolated ZG cells in response to 5-HT JO'M in
the presence of increasing concentrations of mesulergine. Isolated rat ZG cells were
incubated with 5-HT at 10"7M in the presence of increasing concentrations of mesulergine
for 1 hour at 37°C. Dose 0 reflects basal aldosterone secretion into the medium, in the
presence and absence of mesulergine (10"7M). Aldosterone secretion into the medium
was measured by RIA. Data from 4 separate experiments, with triplicate incubations
performed in each, were combined and expressed as mean+SEM. Statistically significant
differences between 5-HT stimulated aldosterone secretion and 5-HT stimulated
aldosterone secretion in the presence of an antagonist are indicated by **p<0.01.
■ 5-HT10"7M









































Log Cyanopindolol concentration (M) in the presence and absence of 10"7M 5-HT.
Figure 4.8. Aldosterone secretion from isolated ZG cells in response to 5-HT 10' M in
the presence of increasing concentrations of cyanopindolol. Isolated rat ZG cells were
incubated with 5-HT at 10"7M in the presence of increasing concentrations of
cyanopindolol for 1 hour at 37°C. Dose 0 reflects basal aldosterone secretion into the
medium, in the presence and absence of cyanopindolol (10"7M). Aldosterone secretion
into the medium was measured by RIA. Data from 4 separate experiments, with triplicate
incubations performed in each, were combined and expressed as mean±SEM.
Statistically significant differences between 5-HT stimulated aldosterone secretion and 5-
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Figure 4.9. Aldosterone secretion from isolated ZG cells in response to 5-HT J0"M in
the presence of increasing concentrations of ICS 205/930. Isolated rat ZG cells were
incubated with 5-HT at 10"7M in the presence of increasing concentrations of ICS
205/930 for 1 hour at 37°C. Dose 0 reflects basal aldosterone secretion into the medium,
in the presence and absence of ICS 205/930 (10"7M). Aldosterone secretion into the
medium was measured by RIA. Data from 4 separate experiments, with triplicate
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Figure 4.10. Dose-dependent increase in aldosterone secretion from isolated ZG cells
in response to increasing concentrations of 5-HT, 5-CT and 5-MeOT. Isolated rat ZG
cells were incubated with 5-HT, 5CT or 5-MeOT for 1 hour at 37°C. Aldosterone
secretion into the medium was measured by RIA. Data from 4 separate experiments,
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Figure 4.11. Dose-dependent increase in aldosterone secretion from isolated ZG cells,
prepared from rats fed on a normal, low and high salt diet, in response to increasing
concentrations of 5-HT, 5-CT and 5-MeOT. Female Wistar rats were fed on either a
normal (1%), low (0%) or high (3%) salt diet for one week prior to removal of their
adrenal glands. Isolated rat ZG cells were then prepared and incubated with 5-HT, 5CT
or 5-MeOT for 1 hour at 37°C. Aldosterone secretion into the medium was measured by
RIA. Data from 4 separate experiments, with triplicate incubations performed in each,
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Figure 4.12. Dose-dependent increase in aldosterone secretion from isolated ZG cells,
prepared from rats fed on a normal, low and high salt diet, in response to increasing
concentrations ofmesulergine in the presence of 5-HT HT M. Female Wistar rats were
fed on either a normal (1%), low (0%) or high (3%) salt diet for one week prior to
removal of their adrenal glands. Isolated rat ZG cells were then prepared and incubated
with increasing concentrations of mesulergine in the presence of 5-HT 10"7M for 1 hour
at 37°C. Dose 0 reflects aldosterone secretion into the medium stimulated with 5-HT 10"
7M. Aldosterone secretion into the medium was measured by RIA. Data from 4 separate
experiments, with triplicate incubations performed in each, were combined and expressed
as mean±SEM.
I Normal Salt Diet
^ Low Salt Diet
ID High Salt Diet
Concentration of Mesulergine (M) (in the presence of 10"7M 5-MeOT.)
Figure 4.13. Dose-dependent increase in aldosterone secretion from isolated ZG cells,
prepared from rats fed on a normal, low and high salt diet, in response to increasing
concentrations of mesulergine in the presence of 5-MeOT 10' M. Female Wistar rats
were fed on either a normal (1%), low (0%) or high (3%) salt diet for one week prior to
removal of their adrenal glands. Isolated rat ZG cells were then prepared and incubated
with increasing concentrations of mesulergine in the presence of 5-MeOT 10~7M for 1
hour at 37°C. Dose 0 reflects aldosterone secretion into the medium stimulated with 5-
MeOT 10"7M. Aldosterone secretion into the medium was measured by RIA. Data from
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Figure 4.14. Dose-dependent increase in aldosterone secretion from isolated ZG cells,
prepared from rats fed on a normal, low and high salt diet, in response to increasing
concentrations ofmesidergine in the presence of 5-CT I0"M. Female Wistar rats were
fed on either a normal (1%), low (0%) or high (3%) salt diet for one week prior to
removal of their adrenal glands. Isolated rat ZG cells were then prepared and incubated
with increasing concentrations of mesulergine in the presence of 5-CT 10"7M for 1 hour
at 37°C. Dose 0 reflects aldosterone secretion into the medium stimulated with 5-CT 10"
7M. Aldosterone secretion into the medium was measured by RIA. Data from 4 separate
experiments, with triplicate incubations performed in each, were combined and expressed
as mean±SEM.
inhibition of all three agonists in each experiment. Mesulergine itself did not produce
any effect on aldosterone secretion (data not shown).
4.4. Discussion.
The effects of a number of 5-HT agonists and antagonists, on the secretion of
aldosterone from the rat ZG were studied, in an attempt to characterise the 5-HT
receptor present within the rat ZG. The lack of availability of a suitable radioactive
derivative of 5-HT makes radioligand binding studies in adrenal cells difficult, ^H-5-HT
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has a very low specific activity whilst 1-5-HT is unstable and causes structural
distortion of the 5-HT molecule. These technical limitations necessitate the use of
largely indirect pharmacological studies on the end steroid response to 5-HTergic
stimulation. An ideal study would utilise a wide range of agonists and agonists to 5-HT
to characterise the functional response of the cell type, allowing identification of the 5-
HT receptor present. This would then be confirmed with the use of a selective 5-HT
radioligand in binding studies.
5-HT agonists and antagonists have various degrees of specificity for specific 5-HT
receptors, making a definitive characterisation of a 5-HT receptor with
pharmacological studies alone difficult. For example, mesulergine is an antagonist at
the 5-HT2 and 5-HT7 receptor sites, with very weak antagonistic effects at the 5-HTi
and 5-HT6 and 5-HT5 sites. Ketanserin is a highly selective antagonist for the 5-HT2
site, also showing weak antagonistic properties at the 5-HTi, 5-HT4 and 5-HT7 sites.
The compounds BIMU 1, BIMU 8, zacopride and cisapride, are all selective agonists at
the 5-HT4 site, however they also act as antagonists at the 5-HT3 site. ICS 205/930,
although selective for the 5-HT? receptor does also act as a weak antagonist at the 5-
HT4 site, and DAU 6285 also acts as an antagonist at the 5-HT4 and the 5-HT3 site.
The indole compounds 5-methoxytryptamine and 5-carboxamidotryptamine are fairly
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non-selective agonists, acting preferentially at the 5-HTi, 5-HT4, 5-HT6 and 5-HT7
receptor sites (Reviewed in Boess & Martin, 1993). A table summarising pKd values
for the compounds tested in this study is shown (Table 4.4 & Table 4.5)(Reviewed in
Boess & Martin, 1993).
The results obtained in this study confirm those of other groups that 5-HT acts directly
on the ZG to increase aldosterone secretion in vitro, (Muller & Zeigler, 1968; Haning
et a/., 1970; Tait et al., 1972; Bing & Schulster, 1977). 5-HT caused a 4 to 6 fold
-6
increase in aldosterone output, reaching maximal stimulation at approximately 10 M.
This compares favourably with a number of groups, but is slightly lower than the 8 fold
increase observed by Tait et al., (1972). Also a rise in cAMP was seen following
stimulation of aldosterone secretion by 5-HT, which is in agreement with various
studies that cAMP is the second messenger system for 5-HT induced aldosterone
secretion from the ZG.
Six antagonists were used and their ability to inhibit the stimulatory capacity of 5-HT
on aldosterone output was studied. Based purely on the % inhibition from the four
combined experiments, the order of effectiveness of the antagonists was
mesulergine>ketanserin>ICS 205/930>cyanopindolol>CV 205 502>DAU 6285, the
latter two showing very slight but non significant inhibition (Table 4.2). Of the agonists
used, 5-methoxytryptamine and 5-carboxamidotryptamine displayed aldosterone
stimulating properties almost identical to that of 5-HT. BIMU 1, BIMU8, zacopride
and cisapride displayed no aldosterone stimulating activity in the rat zona glomerulosa.
The antagonists ketanserin and mesulergine, not only inhibited the stimulation of
aldosterone by 5-HT, but also an inhibition of basal aldosterone levels was also
observed. This effect has been observed by other groups working with 5-HT
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antagonists (Muller & Zeigler , 1968; Matsuoka et al., 1985). This basal inhibition is
most probably due to the presence of endogenous 5-HT within the rat adrenal gland,
namely within the medulla and mast cells present throughout the adrenal cortex
(Verhofstadt & Jonsson, 1983; Holzwarth et al., 1984; Lefebvre et al., 1992). This
endogenous 5-HT may occupy 5-HT receptors present within the rat ZG, exerting a
tonic stimulatory influence on aldosterone secretion, and this would be suppressed with
the introduction of 5-HT antagonists to the cells. However, although radiolabelling
studies have shown the rapid uptake of 5-HT and its metabolism to 5-HIAA, there is
very little conclusive evidence of storage of 5-HT in capsular tissue (Trost & Muller,
1976). In the study detailed in Chapter 5, immunohistochemical staining of sections of
the rat adrenal cortex exhibited no staining for 5-HT. One possibility is the presence of
chromaffin cells within the adrenal cortex as described by Bornstein et al., (1992),
which contain 5-HT. It is also feasible that the concentration of 5-HT may be linked to
stress levels within the rat preceding cervical dislocation. Stress facilitates the release
of ACTH, resulting in increased adrenal perfusion by the blood. 5-HT which is
transported by the platelets, may then be released locally, and bind to the receptor.
Alternatively, the 5-HT antagonists may also exhibit partial dopaminergic agonist
properties, which would enhance the tonic inhibitory influence of dopamine on
aldosterone secretion, resulting in a decreased basal output (Carey et al., 1979). High
affinities for 5-HT antagonists for dopamine receptors has been reported by Leyson et
al., (1981), spiperone and haloperidol were 7 and 40 times more potent at dopamine
than at 5-HT2 receptors. A high affinity for the dopamine receptor was also reported
for methysergide. However only very high doses of dopamine have been shown to
inhibit basal aldosterone secretion (>10"5M), and the effect seen was only moderate.
Therefore it is unlikely that a lower dose of a 5-HT antagonist would act on dopamine
receptors (Aguilera & Catt, 1984).
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From the results in this study, the antagonists, ICS 205/930, DAU 6285 and CV 205
502 all produced slight inhibition of the 5-HT induced aldosterone secretion. This data
taken together with the reported pKd values of these compounds and the second
messenger systems linked to the receptors (Table 4.4), would negate the presence of 5-
FITu, 5-HTib, 5-HT3 and 5-HT4 receptors, within the rat ZG. The data from the 5-HT4
agonists used would also negate the presence of a 5-HT4 receptor in the rat zona
glomerulosa. As no selective antagonists for the 5-HT5a or 5-HT5b receptors were
looked at the possibility of this receptor being present within the adrenal gland of the
rat can not be ruled out. In fact the agonist 5-carboxamidotryptamine is active at this
receptor also. The second messenger system has still to be identified for this receptor
type.
Historically, the receptor present within the zona glomerulosa of the rat for 5-HT was
thought to be of the formerly known '5-HTic/5-HT2' type (i.e the 5-HT2c site),
although the second messenger for these receptors was the PI system, and not cAMP
which is the second messenger for 5-HT induced aldosterone secretion. Certainly, the
results with the antagonists ketanserin and mesulergine, would suggest the presence of
a 5-HT receptor in the rat zona glomerulosa of this type. Mesulergine, however, acts
also as an antagonist at the 5-HTi and 5-HT7 receptor sites.
Studies in the frog interrenal gland and the human adrenal gland by Lefebvre et al.,
(1992, 1993, 1996; Idres et al., 1991), have provided conclusive evidence for the
presence of a 5-HT4 receptor present within the adrenal cortex of these species.
Agonists BIMU 1 and BIMU 8, are members of the azabicycloalkyl benzimidazolones,
they produced a comparable stimulation to 5-HT of aldosterone secretion from frog
and human adrenal gland. BIMU 8 was more potent in this respect than BIMU 1 in
these preparations. Also the agonists zacopride and cisapride in frog interrenal tissue
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and the human adrenal gland, produced comparable stimulation of aldosterone form the
zona glomerulosa to that produced by 5-HT, with the compound zacopride being more
potent than cisapride (Lefebvre et al., 1995).
The 5-HT4 receptor was first named by Dumuis et al., (1988), following their
identification of a novel 5-HT receptor linked positively to adenylate cyclase in
neonatal mouse collicular neurones. This receptor is a member of the G-protein
coupled receptors, with cAMP acting as the principal second messenger. The receptor
site shows significant similarities to the receptor subtype previously described by
Shenker et al., (1985, 1987), as a central 5-HT receptor positively coupled to adenylate
cyclase, not classifiable as a 5-HTi-like, 5-HT2 or 5-HT3 receptor. From various
studies (Baxter et al., 1991; Kaumann et al., 1991), the bulk of evidence does not
support receptor heterogeneity. It has been proposed that these differences may be due
to the existence of different receptor subtypes (Eglen et al., 1996), however the
existence of 5-HT4 receptor splice variants is a more likely explanation of tissular
pharmacological differences. The receptor site was cloned in the rat in 1995 by Gerald
et al., who also characterized two splice variants 5-HT4a and 5-HT4b. Since then the
number of splice variants is on the increase. Ullmer et al., (1995), described the
possible existence of splice variants existing in the second extracellular loop. Two
novel splice variants in mouse have been reported by Claeysen et al., (1998) 5-HT4c
and 5-HT4d, and in human 5-HT4b and 5-HT4e and one in rat, 5-HT4c.
Pharmacologically these receptors are resistant to blockade by antagonists for the 5-
HTi-like, 5-HT2 and 5-HT3 receptors. Agonists at this receptor fall into three
categories, the substituted benzamides, zacopride, cisapride, etc., the substituted
benzimidazolones, BIMU 1, BIMU 8, etc. (Dumuis et al., 1992) and indole derivatives
5-methoxytryptamine and 5-HT. Tryptamine acts as a low affinity partial agonist and
5-carboxamidotryptamine at very high concentrations will produce an effect as effective
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as 5-HT. The compounds tropisetron, SDZ 205-557 and DAU 6285 act as antagonists
at this receptor (Buchheit et al., 1991; Dumuis et al., 1992). These receptors have a
wide distribution both within and across species (discussed in Chapter 1), in particular
they are present within the human adrenal gland and frog interrenal gland (Lefebvre et
al., 1992, 1993).
The results from this study do not concur with that found in the frog and human
adrenal glands. The 5-HT4 antagonist used, DAU 6285, did not produce a significant
inhibition of 5-HT stimulated aldosterone secretion, at doses up to 105M. 5-HT4
agonists from all three classes were used, the substituted benzamides zacopride and
cisapride produced no significant stimulation of aldosterone secretion from isolated rat
zona glomerulosa cells, the substituted benzimidazolones BIMU 1 and BIMU 8 again
produced no significant stimulation of aldosterone secretion, the indole derivatives 5-
HT and 5-methoxytryptamine on the other hand did produce significant stimulation of
aldostefone secretion, however the indole 5-carboxamidotryptamine also produced
strong aldosterone stimulation comparable to that of 5-HT, and this agonist at the 5-
HT4 site only displays aldosterone stimulating activity at much higher concentrations.
Also these three agonists are also agonists at the 5-HT6, 5-HT, and the 5-HT7 receptor
siteS, suggesting the presence of a receptor site belonging to one of these families
withih the tG However the secoild messenger system present within the ZG would
not support the existence of a 5-HTi site.
The 5-HT6 receptor was cloned irbttl a rat cDNA libtaty, displays operational
characteristics resembling a 5-Htj rfeteptor and has nanomolar affinity for 5-
carboxamidotryptamine and methiotHbpin (Monsma et al., 1993; Ruat et al., 1993a).
The receptor is positively coupled td adenylate cyclase, however the pharmacological
profile is very different from the 5-HT4 receptor. It is widely distributed in the brain,
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and in the periphery and has been shown to be present within the stomach of some
species and in the adrenal gland of the hamster (Ruat et al., 1993a). This receptor site
appears to be an interesting target for the treatment of CNS disorders, with little
likelihood of peripheral side effects (Sleight et al., 1998). The selective antagonists Ro
04-6790 and Ro 63-0563, will allow verification of this, and other specific effects of
this receptor site and possible clinical uses (Sleight et al., 1998).
The 5-HT7 receptor has been cloned from rat, mouse and guinea pig cDNA libraries
(Ruat et al., 1993b; Plassat et al., 1993; Tsou et al., 1994). Again this receptor is
positively coupled to adenylate cyclase, and is distributed widely throughout the brain,
the heart, the intestine and in the periphery in some species (Plassat et al., 1993). It
displays a unique pharmacological profile, consistent across species. Based on brain
localization and pharmacological studies, it has been suggested that these receptors
may play a role in the control of circadian rhythms and have potential therapeutic roles
in depression and schizophrenia (Sleight et al., 1995). 5-HT, 5-methoxytryptamine and
5-carboxamidotryptamine act as agonists and mesulergine, methiothepin, ketanserin
and ritanserin act as antagonists (Hirst et al., 1996). Interestingly, the pharmacology of
this receptor resembles that of a previously characterised 5-HT receptor which
mediates smooth muscle relaxation directly and is positively coupled to cAMP (Sumner
et al., 1989; Plassat et al., 1993). Also of interest the 5-HT7 antagonists mesulergine,
methiothepin and ritanserin were shown to be strong antagonists for the 5-HT induced
aldosterone secretion in isolated rat zona glomerulosa cells, with estimated pKd values
of 7.63, 7.18 and 7.06 respectively (Lisa Bishop, Honours Project, 1989. Table 4.3).
Methiothepin is also an antagonist at the 5-HT6 receptor site. These pKd values
correspond strongly with reported pKd values for the 5-HT7 receptor site in the rat
(Table 4.4). Thus from the pharmacological studies reported in this chapter, plus the
data from Lisa Bishop's project, and Joyce Yau's preliminary data, the presence of a 5-
123
HT7 receptor within rat adrenal cortex is likely. This conclusion is also in accordance
with studies very recently reported by Contesse et al., (1999).
The agonists 5-carboxamidotryptamine and 5-methoxytryptamine were also studied in
animals placed on a low salt diet and animals on a high salt diet (Figure 4.12). Sodium
status is the main regulator of aldosterone secretion. Zona glomerulosa cells prepared
from animals on a low sodium diet or a high sodium diet, as expected have altered basal
aldosterone levels, as a result of altered mineralocorticoid output from the adrenal
cortex, in order to maintain physiologically acceptable electrolyte levels. All three
agonists produced greater stimulation of aldosterone in the low sodium status as
compared to the normal and high sodium status, and this was significantly different.
This may be due to upregulation/downregulation of the receptors present within the
zona glomerulosa of the rat, although further studies are needed before this can be
ascertained. Preliminary studies utilising a 5-HT7 probe in sections of rat adrenal gland
by Dr. Joyce Yau (WGH), would suggest the existence of a 5-HT7 receptor, and
sections taken from animals on either a low sodium diet or a high sodium diet if probed
with this would indicate if the receptors present are regulated in any way.
If 5-HT plays a physiological role in the control of aldosterone secretion, the amine
must be secreted locally or be present within the gland to act as a secretagogue. 5-HT
circulates free in plasma in very low concentrations as the majority of the amine is
sequestered and stored within platelets. 5-HT is converted from the precursor 5-HTP
by the enzyme, L-aromatic amino acid decarboxylase (L-AAAD). In vitro studies
indicate that the adrenal cortex has the ability to synthesise 5-HT from its precursor
(Delarue et al., 1992), suggesting L-AAAD is present in the adrenal gland. This has
been further supported by immunohistochemical localisation of L-AAAD within the
cortex (Sephton, 1995). This will be discussed in more detail in Chapter 5.
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The pharmacological profile and putative identification of a second messenger system
suggests the existence of specific 5-HT receptors within the rat zona glomerulosa.
However conclusive evidence requires a more detailed pharmacological profile and
molecular experiments, probing the adrenal cortex for specific amino acid sequences
encoding a specific 5-HT receptor. Preliminary studies in rat adrenal sections with the
5-HT? probe, have picked up the existence of a 5-HT7 receptor site (Joyce Yau,
WGH). This taken together with the pharmacological studies detailed above would
suggest the existence of a 5-HT receptor site in the rat zona glomerulosa of the 5-HT7
class, although the presence of another 5-HT receptor can not be ruled out. In
particular the antagonists ketanserin and cyanopindolol, both produced significant
inhibition of the aldosterone response at higher concentrations. Further experiments
such as concomitant incubations with 5-HT and agonists for the 5-HT2 and 5-HTi
receptor families, plus incubations with 5-CT and 5-MeOT with antagonists for these
receptor sites, will allow further definition of the receptor sites present within the rat
adrenal cortex. The presence of the 5-HT7 receptor in the rat ZG was reported by
Contesse et al., (1999). Interestingly, western blotting in the inner zones of the rat
adrenal cortex by Contesse et al., (1999), found that the 5-HT7 receptor site was
expressed by the ZG/ZF and the ZR. The actions of 5-HT and a variety of agonists and
antagonists should be looked at within this area of the rat adrenal gland. With the
advent of new and more selective antagonist radioligands, such as [JH]-SB-2669970
(Thomas et al., 2000), this receptor site may be more fully characterised, and the
regulation of these receptors within the adrenal cortex may be more fully investigated.
Molecular genetics is providing novel insights into 5-HT receptor function, which may
allow for a clearer understanding of 5-HT receptors in human disease. For example,
usage of inducible knockout strategies to probe the functions of 5-HT receptors has
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provided animal models for studying underlying aggressive behaviour and responses to
drug abuse, as in the case of the 5-HTib knockout mouse (Rocha et al., 1997). Clinical
development of new, more selective antagonists and ligands will allow evaluation of the
importance of 5-HT in the adrenal gland. Pharmacological blockade of the receptor
site within the ZG will allow new perspectives for the treatment of various aldosterone
disorders such as primary hypoaldosteronism.
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Table 4.1.
Properties of the 5-HT Agonists and Antagonists.
Agonist or Antagonist MolecularWeight Solubility Receptor Specificity
Mesulergine 362.5 Saline 5-HT2/7 Antagonist
Ketanserin 545.5 Saline 5-HT2 Antagonist
ICS 205/930 320.8 Saline 5-HT3 / 5-HT4 Non-selective
Antagonist
Cyanopindolol 287.3 EtOH 5-HTla/ib Antagonist
Zacopride 364.28 Saline 5-HT4 Agonist / 5-HT3 Antagonist
Cisapride 483.97 Saline 5-HT4 Agonist / 5-HT3 Antagonist
DAU 6285 367.87 Saline 5-HT3 / 5-HT4 Non-selective
Antagonist
BIMU1 382.89 Saline 5-HT4 Agonist / 5-HT3 Antagonist
BIMU8 378.9 Saline 5-HT4 Agonist / 5-HT3 Antagonist
5-MeOtryptam ine 190.2 Saline 5-HT4/5/7 Agonist
5-Carboxam idotrytam ine 319.32 Saline 5-ht1/5/6/7 Agonist
CV 205 502 432.03 Saline 5-HT3 Antagonist
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Table 4.2
% Inhibition ± SEM of the antagonists tested (at concentration 10"6M).
Compound % Inhibition ± SEM
Ketanserin 81.3% ± 2%
Mesulergine 86.6% ± 2.6%
DAU 6285 13.8% ± 3%
CV 205 502 34.5% ± 4%
ICS 205-930 36.2% ± 3.7%
Cyanopindolol 65.6% ± 5%
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Table 4.3






ICS 205 930 5.4
(Taken from Lisa Bishop's honours project)
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Table 4.4
pKd Values for the antagonists tested (Adapted from Boess & Martin,
1993).
Compound 5-HT1A 5-HTjb 5-HT.D 5-HTiE 5-HTtF 5-HT2A 5-HT2b
Ketanserin 5.86 5.72 6 <6 < 6 8.7 5.45
DAU 6285 - - - - - - -
Mesulergine 6.23 4.88 5.2 <6 <6 6.89 7.44
ICS 205930 4.7 4.35 - - - 5.28 -
Cyanopindolol 8.27 8.28 6.85 <6 <6 4.53 -
CV 205 502
Compound 5-HT2C 5-HT3 5-HT4 5-HTSa 5-HTSb 5-HT6 5-HT-
Ketanserin 7.32 - <5 <6 <6 - App. 6-7
DAU 6285 - - 7.8 - - App. 6.6-6.1 App. 6-7
Mesulergine 8.52 - - <6 <6 App. 6.6-6.1 7.68
ICS 205930 4.59 7.6 - - - - -




PKd values for the agonists tested (Adapted from Boess & Martin,
1993).
Compound 5-HT IA 5-HT1B 5-HTid 5-HTIE 5-HT1F 5-HT2A 5-HT2B
BIMU1 - - - - - - -
BIMU8 - - - - - - -
Zacopride - - - - - - -
Cisapride - - - - - - -
5-CT App. 9 8.14 9.43 <6 <6 - 6.82
5-MeOT _ 7.34 8.62 <6 < 6 - 8.04
Compound 5-HT2C 5-HT3 5-HT4 5-HTSa 5-HTSh 5-HTf) 5-HT7
BIMU 1 - - 7.9 - - <6 6-7
BIMU8 - - 7.8 - - - 6-7
Zacopride - - 6.8 - - <6 6-7
Cisapride - - 7.5 - - - -
5-CT - - 5.2 6.4 6.63 <6 9.8
5-MeOT _ 6.5 _ _ 7.41 9.24
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Chapter Five
Role of L-Aromatic Amino Acid Decarboxylase in the
Regulation of Aldosterone Secretion by 5-HT and
Dopamine in the Rat Adrenal Gland.
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5.1 Introduction.
In 1954, a link between sodium status and aldosterone secretion was first reported
(Leutscher & Axelrad). Since that initial observation many studies have investigated
the effect of sodium loading and/or sodium depletion on aldosterone secretion from the
adrenal cortex. In fact sodium depletion is one of the most potent stimulators of
aldosterone secretion in man and animals, also causing morphological changes within
the ZG (Davis, 1967). The exact mechanism of action remains unclear due to the large
amount of physiological effects initiated by altered sodium status. Also altered sodium
status affects the aldosterone response to other regulators such as ACTH, All and
potassium (Muller, 1968, 1969 (Refer to Chapter 1)).
Both the biogenic amines 5-HT and dopamine have been shown in numerous studies to
modulate the secretion of aldosterone from the ZG, in a range of species. It is not clear
however if 5-HT, and /or dopamine, could have a role in the regulation of
mineralocorticoid secretion physiologically. In particular, the physiological source of
both these amines, reaching the ZG, is still under investigation.
Dopamine and 5-HT are present within the adrenal gland, 5-HT is present within the
medulla and dopamine most probably within the ZG (McCarty et al., 1986). Both
regulators have receptor sites present within the ZG. Dopamine binding sites within
the adrenal cortex have been identified, from autoradiographic experiments, as
receptors of the D2 family within the ZG (Amenta et al., 1994). Sibley & Monsma,
1992, further characterised these receptors as the D4 type, negatively coupled to
adenylyl cyclase. 5-HT receptors within the human adrenal gland have been identified
as the 5-HT7 type (Contesse et al., 1999).
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The concentration of free 5-HT in plasma (l-50nM) is within the range shown to
directly stimulate aldosterone production in vitro, although too low a concentration to
have any physiological effect in vivo also, free dopamine concentrations within the
plasma appear to be too low to reach the high concentrations required to elicit changes
in aldosterone secretion (Zinner et a/., 1983). This suggests a local delivery or
production of these regulators to enable a physiological modulatory role in aldosterone
production, either alone or by interacting with other regulators.
Both 5-HT and dopamine are converted from their precursors, 5-HTP and L-DOPA,
respectively, by the enzyme L-AAAD. Plasma concentrations of 5-HTP and L-DOPA
are sufficiently high to support the hypothesis that local production of these amines, by
L-AAAD, could act as a paracrine mechanism for modulating aldosterone secretion.
Immunohistochemistry investigations with an antibody to L-AAAD have shown the
presence of the enzyme within the adrenal gland of several species (Rahman et a/.,
1981). In vitro studies indicate that the adrenal gland has the ability to synthesise 5-HT
from 5-HTP (Verhofstad & Jonsson, 1983; Delarue, 1992). In addition, Beltramo et
al., (1993), reported that biochemically L-AAAD activity was particularly high within
the adrenal gland as compared to the brain, where its concentration is five fold lower.
The availability of antibodies to L-AAAD has permitted direct visualisation of L-
AAAD. Several groups using immunohistochemical techniques have shown the
occurrence of L-AAAD in the adrenal gland. Beltramo et al., (1993), reported that in
the mouse adrenal gland, strong L-AAAD immunoreactive cells were found to be
concentrated in the medulla, while a faint diffuse immunoreactivity was present in the
ZF. Within the hamster adrenal gland L-AAAD immunoreactivity was found present in
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the ZF alone (Lugo et al., 1988). No study has demonstrated the presence ofL-AAAD
immunoreactivity within the ZG of any species.
The presence of L-3,4-dihydroxyphenylalanine (L-DOPA) decarboxylase, was first
reported in mammalian kidney extracts (Holtz et al., 1938). A role for this enzyme in
the synthesis of catecholamines in mammalian tissues was then postulated by Blaschko
et al., (1939). Subsequently it was reported that 5-HTP was readily decarboxylated by
extracts of mammalian kidney and liver, and a role for a 5-FITP decarboxylase enzyme
in the synthesis of 5-HT was postulated (Udenfriend et al., 1953; Clark et al., 1954).
In 1962 the name aromatic L-amino acid decarboxylase (L-AAAD) was proposed as
the enzyme was found to have affinity for a broad number of substrates, catalyzing the
decarboxylation of a number of aromatic L-amino acids and their cc-methylated
derivatives (Lovenberg et al., 1962).
L-AAAD catalyzes the formation of dopamine from L-DOPA, 5-HT from 5-HTP,
tyramine from tyrosine, 2-phenylethylamine from phenylalanine and tryptamine from
tryptophan. In addition L-AAAD may have as yet unidentified functions in
nonmonoamine neurons in which L-AAAD has been localized (Reviewed by Zhu &
Juorio, 1994).
L-AAAD was first purified from hog kidney (Christenson et al., 1970) and
subsequently from rat liver (Ando-Yamamoto et al., 1987), rat kidney (Shirota &
Fujisawa, 1988), bovine brain (Nishigaki et al., 1988), rat pheochromocytoma (Coge et
al., 1990) and human pheochromocytoma (Maneckjee & Baylin, 1983; Shirota &
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Fujisawa, 1988) cells. The primary structures are remarkably conserved between
species. The molecular weight of brain and adrenal medulla L-AAAD is around
lOOkDa (85-112 kDa) (Christenson et al., 1970; Lancaster & Sourkes, 1972). Initially
the molecule was thought to consist of three subunits, however most studies now
concur that L-AAAD consists of two subunits (Lancaster & Sourkes. 1972; Ichinose et
al., 1985). Pyridoxal phosphate (PLP), acts as a co-factor for L-AAAD (Rahman et
al., 1982). The molecule is tightly bound to the s-amino group of a lysine residue ofL-
AAAD (Bossa et al., 1977). The enzyme is not saturated in vivo (Bowsher & Henry,
1986), and thus is not the rate-limiting step in the synthesis of dopamine and 5-HT.
The enzyme is widely distributed within neural tissues where it plays a neuron-specific
role as a neurotransmitter biosynthetic enzyme, and in extra-neuronal tissues where it
acts as a nonspecific decarboxylating enzyme, and perhaps other so far undetermined
functions. L-AAAD is mainly localized in catecholamine and 5-HT containing neurons
in the CNS (Hokfelt et al., 1973). Namely, cerebral cortex, brainstem, hypothalamus,
caudate nucleus, hippocampus and cerebellum in a variety of species to varying degrees
(Rahman et al., 1981). Peripherally, L-AAAD has been located in the kidney, liver,
pancreas and adrenal gland (Rahman et al., 1981). In the kidney L-AAAD is localised
in the proximal convoluted tubules, and straight tubules, and not associated with
nerves. L-AAAD presence within the kidney and liver is surprising as biosynthesis of
monoamines does not appear to occur in these tissues. The physiological significance
of the presence of L-AAAD in these tissues is not yet clear, but perhaps the enzyme
may have a fundamental role in the metabolism of other aromatic amino acids.
Extraneuronal dopamine is thought to be synthesized by L-AAAD in the proximal
tubular cells (Baines et al., 1985). Baines et al (1985) also demonstrated that L-DOPA
was converted to dopamine by a proximal convoluted tubule-enriched fraction from rat
kidneys. Also, Rahman et al., (1981), demonstrated, using L-DOPA and 5-HTP as
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substrates, that the serum of monkeys, guinea pigs and rats contain L-AAAD activity.
Immunohistochemistry techniques have identified L-AAAD containing cells in the
tracheobronchial epithelium, neuroepithelial bodies in the bronchopulmonary
epithelium, Kultschitzky cells in the small intestine and appendix as well as in the
adrenal chromaffin cells. The aforementioned cells all belong to the amine precursor
uptake decarboxylation (APUD) system (Pearse, 1974). The existence of L-AAAD
gene expression within glial cells was demonstrated in 1992 (Li et al., 1992). In
normal striatum L-AAAD content of glial cells is unlikely to contribute to
catecholamine production. However it is possible that some trace amines such as
tyramines or tryptamine could be formed by L-AAAD in glial cells. These trace amines
in turn could then modulate monoaminergic neurotransmission (Paterson et al., 1990).
L-AAAD activity in glial cells may be an additional area where decarboxylation of L-
DOPA may occur, an area important in Parkinsonian patients where most of the striatel
dopamine terminals have been lost and exogenous L-DOPA may be decarboxylated by
glial L-AAAD. In fact L-AAAD may play an important role in Parkinson's disease
(Dairman et al., 1972). L-DOPA is an effective treatment in this disease state.
For a period of time it was thought that there was a family of L-AAAD enzymes.
Based on a number of observations, it was suggested that different enzymes catalyze
the decarboxylation of L-DOPA and 5-HTP. Pharmacological studies on the
decarboxylation of 5-HTP and L-DOPA in rat brain concluded that different optimal
temperatures, pH and substrate concentration were required (Slow & Dakshinamurti,
1985). Another observation was that if only one L-AAAD enzyme existed, then the
ratio of the enzyme activities with regard to L-DOPA and 5-HTP should be closely
similar in all tissues. However this has not always been shown to be the case.
Furthermore, in brain 5-HTP decarboxylase is equally distributed between soluble and
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particulate fractions in contrast to L-DOPA decarboxylase, which is mainly soluble
(Sims et al., 1973). This dissimilar subcellular distribution has supported the existence
of L-AAAD isozymes in the brain (Rahman & Nagatsu, 1982). Also, within
hypothalamic nuclei, the distribution of DOPA decarboxylase correlates directly with
those of NA and DOPA, but not with that of 5-HTP decarboxylase (Palkovits et al.,
1974).
Bender & Coulson (1972), first suggested the existence of one L-AAAD enzyme, with
a single catalytic site, containing different binding sites for the two substrates, based on
their studies of the kinetics of the decarboxylases. This hypotheses has been supported
by numerous studies, including those of the investigation of the nucleotide sequences
coding for the synthesis ofL-AAAD. In a study by Zuo & Yu, (1991), the L-DOPA/5-
HTP decarboxylation ratios were not too dissimilar in a variety of tissues including cat
brain and rat brain. The isolated enzymes from pig kidney, rat kidney, guinea pig
kidney, human phaeochromocytoma and bovine brain can catalyze the decarboxylation
of both L-DOPA and 5-HTP (Nishigaki et al., 1988). Immunological studies support
the existence of one single enzyme. The enzyme present within the adrenal medulla,
pineal gland, liver, kidney and striatum is identical with respect to immunological
crossreactivity and molecular size (Shirota & Fujisawa, 1988). Antiserum prepared
against purified L-AAAD from bovine adrenal or rat kidney, both inhibit L-DOPA and
5-HTP decarboxylase (Shiroto & Fujisawa, 1988).
Molecular biological investigations have provided the most convincing evidence for the
presence of a single L-AAAD enzyme. The presence of a single mRNA species in
bovine liver, kidney and adrenal as well as rat liver, brain and phaochromocytoma cells
and human phaochromocytoma cells has been shown utilising hybridization analysis
with a cDNA probe complementary to bovine adrenal L-AAAD mRNA (Albert et al.,
1987). Tison et al (1991), described L-AAAD gene expression in dopaminergic and 5-
HTergic neurones of rat brain, utilizing in situ hybridization. Definitive proof of a
single enzyme was provided by Sumi et al, (1990), who demonstrated that the
recombinant human L-AAAD decarboxylates 5-HTP to 5-HT as well as L-DOPA to
dopamine. Further to this study analysis with probes corresponding to the entire
coding region of L-AAAD pheochromocytoma cDNA, the L-AAAD primary sequence
in both neuronal and non-neuronal tissue has been shown to be identical (Coge et al.,
1990). Following microinjection into xenopus laevis oocytes mRNA coding for bovine
adrenal medulla L-AAAD has been expressed. This expressed enzyme activity was
stereoselective for L-5-HTP and L-DOPA and blocked by NSD-1015. Also heating
the expressed enzyme at 55°C produced a parallel loss of activity towards both
substrates (Gudehithlu et al., 1992). The aforementioned studies provide definitive
proof that the enzymatic decarboxylation of both L-DOPA and 5-HTP is processed by
a protein issued from the same gene and the same mRNA.
There are however, species and specific tissue variants of L-AAAD. The study of L-
AAAD from the insect Drosophila demonstrated that different forms of the enzyme
were produced by different mRNAs, depending on the tissue examined (Morgan et al.,
1986). Krieger et al., (1991) found the presence of two species ofL-AAAD mRNA in
rat pheochromocytoma differing in their 5 untranslated region, one specific for
neuronal tissue, the other non-neuronal. This may be due to a unique gene encoding
for DOPA decarboxylase, giving rise to at least two transcripts, in response to differing
signals during development.
Further to the studies mentioned above the aim of this study was to firstly localise the
enzyme L-AAAD within rat adrenal gland utilising specific monoclonal antibodies
against the purified enzyme, also to determine if 5-HT itself is localised within the rat
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adrenal gland, (in association with specific 5-HT containing nerves), utilising a specific
monoclonal antibody to 5-HT. Secondly to determine whether the rat adrenal ZG can
synthesize 5-HT from 5-HTP or L-tryptophan, and dopamine from L-DOPA. Thirdly,
to determine if sodium status, a well established modulator of aldosterone, can
modulate the activity of L-AAAD in the rat ZG. Also to determine if 5-HTP or L-
tryptophan are able to stimulate aldosterone secretion from whole rat adrenal capsules
and isolated ZG cells, and whether L-DOPA can inhibit aldosterone secretion from
whole adrenal capsular tissue and isolated ZG cells.
5.2. Data Analysis
Results are shown as mean + S.E.M. n refers to the number of experiments performed.
Significance between basal and test results, from a particular salt diet, was assessed by
Student's t-test. The significance between salt diets was assessed by analysis of
variance. *P<0.05, **P<0.01 and ***P<0.001 were considered significant.
5.3 Results
An initial set of experiments carried out using rat adrenal capsules with L-tryptophan
(10"6M-10"'M) as substrate demonstrated that this precursor to 5-HT did not stimulate
aldosterone secretion. Neither was L-tryptophan converted to 5-HTP or 5-HT by rat
adrenal capsules (data not shown).
Figure 5.1 shows the dose-response relationship between the concentration of 5-HTP
and the biosynthesis of aldosterone from 4 different experiments using adrenal cortex
capsules (this includes the ZG but not the ZF), obtained from rats on a normal salt diet.
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Basal aldosterone secretion was 20.5nmoles/mg of protein ± 1.2 and significant
stimulation of aldosterone occurred at a concentration of 5x10"5M 5-HTP (p<0.05).
The maximal aldosterone response was observed at 10"4M 5-HTP (p<0.01). In the
presence of carbidopa, a specific inhibitor of L-AAAD, the aldosterone response to 5-
HTP (10"4M) was completely inhibited.
Figure 5.2 shows the aldosterone dose response to 5-HTP, in the absence and presence
of carbidopa, from 4 experiments carried out using whole adrenal capsules obtained
from rats maintained on a normal, low and high salt diet. The basal aldosterone
secretion in capsules obtained from rats on a normal salt diet was 27.7 nmoles/mg of
protein ±2.7, and this increased to 33.2 nmoles/mg of protein ± 3.7 in low salt diet rats
and decreased to 19.7 nmoles/mg of protein ±2.5 in high salt diet rats which was a
significant decrease. In the normal salt diet group, the minimal dose of 5-HTP to cause
a significant aldosterone secretion was 10"4M . In low and high salt diet groups, the
minimal dose of 5-HTP which caused a significant (p<0.05) effect was 5xlO"5M. The
maximal aldosterone secretion was 84.4 nmoles/mg of protein ± 5.10 in low salt diet as
compared to 43.1 nmoles/mg of protein ± 1.7 in normal salt diet rats (p<0.05). In all
salt diet groups, aldosterone secretion in the presence of carbidopa, and 5-HTP, was
not significantly different from basal secretion levels. Analysis of variance for the
complete dose-response curves to 5-HTP showed that all diets were significantly
different from each other (p<0.05). Thus, as expected, compared to the normal salt
diet group, more aldosterone was produced in response to 5-HTP by the low salt diet
group, while less was produced by rats from the high salt diet group.
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Figure 5.3 illustrates the aldosterone dose-response to 5-HTP seen with isolated ZG
cells obtained from rats on all three salt diet regimes (n=4). The basal aldosterone
secretion in the normal salt diet group was 1.1 nmoles/mg of protein ± 0.07 and this
increased to 2.0 nmoles/mg of protein ±0.1 in the low salt diet group, and decreased to
0.5 nmoles/mg of protein ± 0.06 in the high salt diet group (not significant for n=4). In
both the normal and high salt diet groups, a significant difference in aldosterone
secretion as compared to basal levels was observed at 5-HTP incubations of 10"5M to
10~3M 5-HTP (p<0.01). In low salt diet animals, 10"6M to 10"3M 5-HTP produced a
significant change in aldosterone secretion as compared to basal (p<0.01). Carbidopa
(10"4M) did not effect basal secretion of aldosterone, but did significantly inhibit the
response to 10"4M 5-HTP.
Plasma aldosterone concentrations from rats on normal, low and high salt diets are
depicted in Figure 5.4a. Normal plasma levels were 1.1 nM/L±0.14. As expected this
increased to 3.1nM/L±0.3 in the low salt diet group, and in the high salt diet group
plasma levels were lower with a value of 0.341nM/L±0.09. The aldosterone plasma
levels in each of the salt diets were significantly different to one another (Student's t-
test, p<0.001). Figure 5.4b depicts the PRA values from the three different salt diets.
As expected, the low salt diet regime caused a marked increase in PRA levels measured
(p<0.01).
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Figure 5.5a & 5.5b show the concentration of 5-HTP in rat adrenal capsules (n=4) and
in renal cortex portions respectively, in tissues obtained from rats on normal, low and
high salt diets, after incubation with increasing concentrations of 5-HTP, in the
presence and absence of carbidopa, measured by HPLC. Also shown are the levels of
5-HTP at the end of the incubations with 5-HTP, the substrate for the L-AAAD
enzyme. Since L-AAAD is known to be present within the renal cortex these
incubations served as a positive control for the adrenal tissue incubations. The basal
concentrations of 5-HTP were not significantly different from zero for adrenal capsules
obtained from rats on all three salt diet regimes (p<0.05).. Carbidopa did not
significantly affect the basal levels of 5-HTP or the levels of 5-HTP remaining at the
end of the incubations.
The concentration of 5-HT when incubated with various concentrations of 5-HTP in
the absence and presence of carbidopa (10"4M) is shown in Figure 5.6a for the adrenal
capsules and Figure 5.6b for the renal cortex tissue. In the adrenal capsule, for all three
salt diets, the production of 5-HT increased dose-dependently, when incubated with
concentrations of 5-HTP ranging from 10"6M to 5xlO"4M (n=4), with maximal 5-HT
produced at a dose of 5xlO"4M. The concentration of 5-HT observed in the low salt
diet was significantly higher as compared to both normal and high salt diet tissue
(p<0.05,n=4). In the presence of carbidopa, 5-HT production from 5-HTP appeared to
be inhibited. In the kidney cortex, 5-HT also showed a dose-dependent increase when
incubated with 5-HTP, while carbidopa also inhibited the production of 5-HT. No
increase in aldosterone secretion with the low salt diet as compared to the normal salt
diet, was observed with the kidney cortex tissue, as may have been expected. The
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tissue was cut into sections of approximately the same size, not measured accurately,
which may have affected the results.
Figure 5.7 shows the effect of increasing concentrations of 5-HTP and in the presence
of carbidopa, on the production of 5-HIAA in a) adrenal capsule and b) kidney cortex.
In both tissues the concentration of 5-HIAA produced does not appear to be affected
by incubations with 5-HTP. There may have been a problem with the HPLC assay as
the standard errors are very high. An increase in 5-HIAA measurement in urine, is
often taken to indicate an increase in circulating plasma 5-HT, as in the carcinoid
syndrome, however this is not the only metabolic pathway of 5-HT.
The blood levels of 5-HTP, 5-HT and 5-HIAA obtained from rats on all three salt diet
regimes are illustrated in Figure 5.8a, and appear to not be modulated by salt intake.
The results for 5-HT, 5-HTP and 5-HIAA in the urine were not significantly different
between salt diets either (data not shown).
The next set of figures illustrates the dopamine side of this study. Figure 5.9 shows the
mean concentrations of dopamine present in the urine obtained from rats on each of the
salt diets. No significant difference existed between any of the values suggesting that
sodium status has no effect on dopamine excretion. We did expect an increased
dopamine output from animals on a high salt diet. Urinary dopamine values are
difficult to measure due to oxidation, the urines were collected 12 hourly and
maintained at pH3. However, the volume of urine changed from day to day, samples
144
sometimes were knocked over and food etc. ended up in the urine samples as well,
making reproducible results difficult.
Figure 5.10 shows the dose response relationship between the concentration of L-
DOPA and the biosynthesis of aldosterone from four experiments, using intact adrenal
capsular tissue, from rats on a normal salt diet. Capsules were stimulated with 10"6M
5-HT. Significant inhibition (p<0.05) was seen with L-DOPA concentrations above
5x10"5M. With the addition of carbidopa aldosterone secretion returned to near basal
levels. The maximum inhibition was found with 10"4M L-DOPA, which reduced
aldosterone secretion from 19.1nmol/l (basal) to 10.1 nmol/1.
The aldosterone dose responses to 5-HT in the presence of increasing doses of L-
DOPA from four experiments using adrenal capsules taken from rats on normal, low
and high salt diets are depicted in Figure 5.11. The effect of carbidopa was also
recorded. Basal secretion levels for normal, low and high salt diet groups were
18.1+3.086, 24.1±2.551 and 16.4±2.321 nmol/1 respectively (not significantly different,
n=4). L-DOPA administration appeared to reduce aldosterone biosynthesis at all
doses, with inhibition increasing with increasing doses. The minimal dose required to
cause a significant change in all three diet groups was 5xlO"4M (p<0.05 (Normal &
Low), p<0.001(High)). However significant changes were found with lower
concentrations (5xlO"5M & 1CT4M) in the high salt diet group. The presence of
carbidopa prevented any effect ofL-DOPA. Aldosterone levels from these incubations
were approximately the same as basal levels. In all cases, low salt diet groups had a
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higher aldosterone output then normal salt diet groups, which in turn had higher levels
than those in the high salt diet groups.
Figure 5.12 shows these changes in aldosterone secretion as a percentage change from
basal levels. The maximum percentage inhibition for each group was 50.5% (normal),
32.7% (low) and 76.4% (high).
The aldosterone dose response relationship from incubations with isolated ZG cells are
shown in Figure 5.13. In all incubations the presence of L-DOPA reduced aldosterone
secretion from basal levels, 1.2±0.425 (normal), 1.5±0.259 (low) and 0.9±0.568 (high).
Significant changes (p<0.05) were only seen in the low salt group using doses of L-
DOPA above 10~4M. The maximum inhibition found within each group was 58.95%
(normal), 71.76% (low) and 78.74% (high).
The effect of L-DOPA administration on corticosterone biosynthesis by portions of
inner zones of the adrenal cortex (containing ZF cells) and isolated ZF cells respectively
was measured. No significant changes were seen in the whole portions of inner zone
for any salt diet (n=4). In isolated cells, inhibition of secretion was seen at
concentrations of L-DOPA above 5xlO"4M in all salt diet groups, this was not
significant (Figure 5.14).
Figure 5.15 illustrates the conversion of L-DOPA to dopamine by L-AAAD in both
intact capsules and medullary portions taken from rats on normal salt diets, measured
by HPLC. Due to technical problems analysis of samples on low and high salt diets
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could not be undertaken. In both situations the amount of dopamine present within the
sample increased dose-dependently with the increasing L-DOPA concentration, with
concurrent carbidopa incubation reducing the production of dopamine.
Sections of kidney were used to perform control tests for staining with the L-AAAD
monoclonal antibody Figure 5.16 shows a section through the kidney stained with (a)L-
AAAD. Magnification was x 200. The L-AAAD immunoreactivity was observed
throughout the kidney tubule, no L-AAAD immunoreactivity was evident within the
glomeruli. Figure 5.17a) illustrates the general morphology of the rat adrenal gland
through H/E staining at magnification of x80. The zonation of the gland can clearly be
seen. Figure 5.17b) illustrates similar staining of a section of rat adrenal cortex at
magnification x500, where differences in cell morphology can be observed.
Immunohistochemical localisation of L-AAAD, using a specific monoclonal antibody
raised against the purified enzyme, within the whole rat adrenal gland is shown in
Figure 5.18a) (magnification x80), L-AAAD immunoreactive cells can be seen
throughout the ZG, ZF and the adrenal medulla, no staining was evident within the
adrenal capsule or the ZR. Figure 5.18b) illustrates the localisation of L-AAAD across
a section of adrenal cortex (magnification x200). The presence of L-AAAD can be
visualised within the medulla and cortex. Staining is apparent within the ZG and ZF.
Figure 5.19a) illustrates immunoreactivity to 5-HT within the rat gut (control tissue
sample), (b) illustrates the staining evident within the rat adrenal gland (magnification x
500), and it is evident that there is no 5-HT immunoreactive cells present within the
adrenal capsule or ZG.
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Graphical Illustration
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Figure 5.1. Dose-dependent increase in aldosterone secretion from whole adrenal
capsule in response to increasing concentrations of 5-HTP in the presence and absence
of carbidopa (J0'4M). Whole rat adrenal capsules were incubated with increasing
concentrations of 5-HTP in the presence and absence of carbidopa lO^M for 1 hour at
37°C. Aldosterone secretion into the medium was measured by RIA, and corrected for
protein content. Data from 4 separate experiments, with triplicate incubations performed
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Figure 5.2. Dose-dependent increase in aldosterone secretion from whole adrenal
capsule, prepared from rats fed on a normal, low or high salt diet, in response to
increasing concentrations of 5-HTP in the presence and absence of carbidopa (10~4M).
Female Wistar rats were maintained on a normal (1%), low (0%) or high (3%) salt diet
for one week prior to removal of their adrenal glands. Whole rat adrenal capsules were
incubated with increasing concentrations of 5-HTP in the presence and absence of
carbidopa lO^M for 1 hour at 37°C. Aldosterone secretion into the medium was
measured by RIA, and corrected for protein content. Data from 4 separate experiments,
with triplicate incubations performed in each, were combined and expressed as
mean±SEM. *p<0.05 and **p<0.01 compared to basal levels. +p<0.05 compared with































I Normal Salt Diet (Z.G.C.)
S3 Low Salt Diet (Z.G.C.)
IE High Salt Diet (Z.G.C.)
■11
Concentration 5-HTP (M)
Figure 5.3. Dose-dependent increase in aldosterone secretion from isolated ZG cells,
prepared from rats fed on a normal, low or high salt diet, in response to increasing
concentrations of 5-HTP in the presence and absence of carbidopa (10'4M). Female
Wistar rats were maintained on a normal (1%), low (0%) or high (3%) salt diet for one
week prior to removal of their adrenal glands. Isolated ZG cells were incubated with
increasing concentrations of 5-HTP in the presence and absence of carbidopa lO^M for 1
hour at 37°C. Aldosterone secretion into the medium was measured by RIA, and
corrected for protein content. Data from 4 separate experiments, with triplicate
incubations performed in each, were combined and expressed as mean+SEM. *p<0.05
and **p<0.01 compared to basal levels. +p<0.05 compared with low salt diet of the same
concentration.
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Figure 5.4. (a) Plasma aldosterone levels measured in rats maintained on a
normal, low or high salt diet for one week. Values are mean±SEM, n=4.
***p<o ooi as compared with normal salt diet levels.
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Figure 5.4. (b) Plasma renin levels measured in rats maintained on
a normal, low or high salt diet for one week. Values are mean±SEM, n=4.
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Figure 5.5. (a) Concentration of 5-HTP measured by HPLC present in the
medium after incubating whole adrenal capsules, prepared from rats fed on a normal,
low or high salt diet, with increasing concentrations of 5-HTP in the presence and
absence of carbidopa (10'4M). Female Wistar rats were maintained on a normal (1%),
low (0%) or high (3%) salt diet for one week prior to removal of their adrenal glands.
Whole adrenal capsules were incubated with increasing concentrations of 5-HTP in the
presence and absence of carbidopa lO^M for 1 hour at 37°C. The concentration of 5-
HTP in the medium after the incubation period was measured by HPLC, and corrected
for protein content. Data from 4 separate experiments, with triplicate incubations
performed in each, were combined and expressed as mean±SEM. *p<0.05 compared to
basal levels.
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Figure 5.5. (b) Concentration of 5-HTP measured by HPLC present in the
medium after incubating sections of kidney cortex, preparedfrom rats fed on a normal,
low or high salt diet, with increasing concentrations of 5-HTP in the presence and
absence of carbidopa (10~4M). Female Wistar rats were maintained on a normal (1%),
low (0%) or high (3%) salt diet for one week prior to removal of their kidneys. Sections
of kidney cortex were incubated with increasing concentrations of 5-HTP in the presence
and absence of carbidopa lCfVl for 1 hour at 37°C. The concentration of 5-HTP in the
medium after the incubation period was measured by HPLC, and corrected for protein
content. Data from 4 separate experiments, with triplicate incubations performed in each,
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Figure 5.6. (a) Concentration of 5-HT measured by HPLC present in the medium
after incubating whole adrenal capstdes, preparedfrom ratsfed on a normal, low or high
salt diet, with increasing concentrations of 5-HTP in the presence and absence of
carbidopa (10'4M). Female Wistar rats were maintained on a normal (1%), low (0%) or
high (3%) salt diet for one week prior to removal of their adrenal glands. Whole adrenal
capsules were incubated with increasing concentrations of 5-HTP in the presence and
absence of carbidopa lO^M for 1 hour at 37°C. The concentration of 5-HT in the
medium after the incubation period was measured by HPLC, and corrected for protein
content. Data from 4 separate experiments, with triplicate incubations performed in each,


















































Figure 5.6. (b) Concentration of 5-HT measured by HPLC present in the
medium after incubating sections of kidney cortex, preparedfrom rats fed on a normal,
low or high salt diet, with increasing concentrations of 5-HTP in the presence and
absence of carbidopa (10'4M). Female Wistar rats were maintained on a normal (1%),
low (0%) or high (3%) salt diet for one week prior to removal of their kidneys. Sections
of kidney cortex were incubated with increasing concentrations of 5-HTP in the presence
and absence of carbidopa lO^M for 1 hour at 37°C. The concentration of 5-HT in the
medium after the incubation period was measured by HPLC, and corrected for protein
content. Data from 4 separate experiments, with triplicate incubations performed in each,
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Figure 5.7. (a) Concentration of 5-HIAA measured by HPLC present in the
medium after incubating whole adrenal capsules, prepared from rats fed on a normal,
low or high salt diet, with increasing concentrations of 5-HTP in the presence and
absence of carbidopa (10~4M). Female Wistar rats were maintained on a normal (1%),
low (0%) or high (3%) salt diet for one week prior to removal of their adrenal glands.
Whole adrenal capsules were incubated with increasing concentrations of 5-HTP in the
presence and absence of carbidopa lO^M for 1 hour at 37°C. The concentration of 5-
HIAA in the medium after the incubation period was measured by HPLC, and corrected
for protein content. Data from 4 separate experiments, with triplicate incubations
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Figure 5.7. (b) Concentration of5-HIAA measured by HPLCpresent in the
medium after incubating sections of kidney cortex, preparedfrom rats fed on a normal,
low or high salt diet, with increasing concentrations of 5-HTP in the presence and
absence of carbidopa (J0~4M). Female Wistar rats were maintained on a normal (1%),
low (0%) or high (3%) salt diet for one week prior to removal of their kidneys. Sections
of kidney cortex were incubated with increasing concentrations of 5-HTP in the presence
and absence of carbidopa lO^M for 1 hour at 37°C. The concentration of 5-HIAA in the
medium after the incubation period was measured by HPLC, and corrected for protein
content. Data from 4 separate experiments, with triplicate incubations performed in each,
were combined and expressed as mean±SEM.
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Figure 5.8. Plasma 5-HT, 5-HTP and 5-HIAA levels measured in rats
maintained on a normal, low or high salt diet for one week. Values are
mean±SEM, n=4.
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Figure 5.9. Urinary dopamine levels measured in rats maintained on a normal
low or high salt dietfor one week. Values are mean±SEM, n=4.
I Concentration Aldosterone (nm/1)
c
0)
Basal 10-6 10-5 5x10-5 10-4 10-4/C.
Concentration L-DOPA (M) in the presence of 10-6M 5-HT.
Figure 5.10. Effects of increasing concentrations of L-DOPA on prestimulated (5-HT
10' M) whole adrenal capsules on aldosterone secretion, incubated in the presence and
absence of carbidopa (10'4M). Whole adrenal capsules, prestimulated with 5-HT lO^M,
were incubated with increasing concentrations of L-DOPA in the presence and absence of
carbidopa lO^M for 1 hour at 37°C. After the incubation period aldosterone was
measured by RIA, and corrected for protein content. Data from 4 separate experiments,
with triplicate incubations performed in each, were combined and expressed as
mean±SEM. Statistically significant inhibition of 5-HT-induced aldosterone secretion by
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Figure 5.11. Effects of increasing concentrations of L-DOPA on prestimulated (5-HT
10~6M) whole adrenal capsules, preparedfrom animals maintained on a normal, low or
high salt diet, on aldosterone secretion, incubated in the presence and absence of
carbidopa (10T*M). Female Wistar rats were maintained on a normal (1%), low (0%) or
high (3%) salt diet for one week prior to the removal of the adrenal gland. Whole adrenal
capsules, prestimulated with 5-HT lO"6]^, were incubated with increasing concentrations
of L-DOPA in the presence and absence of carbidopa lO^M for 1 hour at 37°C. After the
incubation period aldosterone was measured by RIA, and corrected for protein content.
Data from 4 separate experiments, with triplicate incubations performed in each, were
combined and expressed as mean±SEM. Statistically significant inhibition of 5-HT-
induced aldosterone secretion by L-DOPA is indicated by *p<0.05 and **p<0.01.
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Figure 5.12. Depicts the effects of L-DOPA as seen in Figure 5.11 as a
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Figure 5.13. Effects of increasing concentrations of L-DOPA on prestimnlated (5-HT
10~6M) isolated ZG cells, prepared from animals maintained on a normal, low or high
salt diet, on corticosterone secretion, incubated in the presence and absence ofcarbidopa
(10'4M). Female Wistar rats were maintained on a normal (1%), low (0%) or high (3%)
salt diet for one week prior to the removal of the adrenal gland. Isolated ZG cells,
prestimulated with 5-HT lO^M, were incubated with increasing concentrations of L-
DOPA in the presence and absence of carbidopa lO^M for 1 hour at 37°C. After the
incubation period aldosterone was measured by RIA, and corrected for protein content.
Data from 4 separate experiments, with triplicate incubations performed in each, were
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Figure 5.14. Effects of increasing concentrations of L-DOPA on prestimulated (5-HT
10~6M) isolated ZF cells, prepared from animals maintained on a normal, low or high
salt diet, on corticosterone secretion, incubated in the presence and absence ofcarbidopa
(10~4M). Female Wistar rats were maintained on a normal (1%), low (0%) or high (3%)
salt diet for one week prior to the removal of the adrenal gland. Isolated ZF cells,
prestimulated with 5-HT lO"6^/!, were incubated with increasing concentrations of L-
DOPA in the presence and absence of carbidopa lO^M for 1 hour at 37°C. After the
incubation period aldosterone was measured by RIA, and corrected for protein content.
Data from 4 separate experiments, with triplicate incubations performed in each, were
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Figure 5.15. Concentrations of dopamine measured by HPLC present in the medium
after incubating prestimidated (5-HT10~6M) a)adrenal capsules and b)medidlary
portions, prepared from animals maintained on a normal, low or high salt diet, with
increasing concentrations ofL-DOPA, in the presence and absence of carbidopa (10"*M).
Female Wistar rats were maintained on a normal (1%), low (0%) or high (3%) salt diet
for one week prior to the removal of the adrenal gland. Whole adrenal capsules or
medullary portions, prestimulated with 5-HT lO^M, were incubated with increasing
concentrations of L-DOPA in the presence and absence of carbidopa lO^M for 1 hour at
37°C. After the incubation period dopamine levels were measured by HPLC. Data from
4 separate experiments, with triplicate incubations performed in each, were combined and
expressed as mean±SEM.
Figure 5.16 : A section through the rat kidney cortex stained with a monoclonal antibody to L-





W " w & - &




• t , *
jft * • * •




t « " f* ■ * ffM * • * w *
• , • #
a * 1 * 9 • . • "•
• • * • ^ «*1 v sP *
:






Pf n */• . '# «*#■Bf/ '*1^ «*■» - Jg m nkW . *_ ^ *
* a % ^ * - * •? ■»■■ f;''®
- ,"•• ♦ •" »# T I
• •*.•••* • / %•% /;
V * ». , - —iMwWBrMlWBMr K'f'oi, 'i.A«li »
#<*Ks • ^ A ilk
• **»» •Srtt
t* r$ *g>Q
- ©• i#ft . jf
ZG
• •*► i r»/" • I




Figure 5.17 : A section tiirough the rat adrenal gland showing general morphology stained with H/E. (a) magnification x80,
(b) magnification x200. C-capsule, ZF=zona fasciculata, ZG=zona glomernlosa and M^medulla.
Figure 5.18 : A section through the rat adrenal giand showing L-AAAD immunoreactivity. (a) magnification i80, (b)
magnification x200. C=capsule, ZF=zona fasciculata, ZG=zona glomerulosa and M=medulla.
Figure 5.19 : 5-HT inununoreactivity present within, (a) the rat gut, (b) the rat adrenal cortex. Ocapsule, ZF=zona
fasciculata, ZG=zona glomerulosa and GOenterochromaffin cells. Magnification = *500.















Aldosterone is the main mineralocorticoid found in man, responsible for the regulation
of electrolyte balance by stimulating active sodium transport and promoting secretion
of potassium ions in the kidney and several other epithelial tissues, for example, sweat
glands, intestinal mucosa and salivary glands (Morris, 1981). The production of
aldosterone by the cells of the ZG in the adrenal cortex, is under multifactorial control,
regulatory factors include plasma potassium levels, All, ACTH and ANH (Porter et a/.,
1992). Under normal physiological conditions the most important regulator of
aldosterone is the RAS system, which produces the effector peptide All. In states of
sodium depletion, the sensitivity of the adrenal ZG response to the stimuli All,
potassium ions and ACTH is increased. In the case of All, there is an increase on
receptor density and circulating levels ofAll are also elevated due to the effect of the
low sodium status which activates renin release from the juxtaglomerular cells of the
renal cortex. Studies carried out in isolated ZG cells from the rat demonstrated that the
sensitivity of the aldosterone response to 5-HT was increased if the rats were
maintained on a low sodium diet (Al-Dujali et al., 1982). As expected, altering salt
intake in the rats used in this study significantly altered plasma aldosterone
concentrations (Figure 5.1). The lower the salt content of the diet, the greater the
concentrations of aldosterone measured, as a result of increased mineralocorticoid
output from the adrenal cortex, in order to maintain physiologically acceptable
electrolyte levels.
The biogenic amines, dopamine and 5-HT, have both been shown to modulate
aldosterone secretion. Although unlike the regulators mentioned above their roles are
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poorly understood. The idea of both 5-HTergic and dopaminergic control over
aldosterone secretion is of particular interest because dopamine and 5-HT are known to
have reciprocal effects upon renal sodium handling in the kidney (Itskovitz et al.,
1988). Hence, reciprocal effects upon aldosterone secretion from the adrenal cortex
would therefore be complementary to this.
Dopamine, 5-HT, 5-HTP and 5-HIAA output in the urine of rats from the different salt
diets were measured. There was no significant change in the output of any of these
compounds over the time course of the diets, or a difference between values from each
of the diet groups. Blood levels of 5-HT, 5-HTP and 5-HIAA from animals on the
different salt diets were also measured, and the results were not significantly different
between the salt diet groups. Dopamine levels and L-DOPA levels were not able to be
measured due to the failure of the HPLC system, however, as urine levels are directly
proportional to plasma concentrations, it is likely that once measured these results
would also not be significantly different from each other. This would seem to indicate
that dopamine and 5-HT levels are not altered by changes in sodium status, and suggest
that if dopamine or 5-HT do indeed function as physiological regulators of aldosterone
biosynthesis they do not act via the circulation.
Many studies have confirmed that 5-HT acts to stimulate aldosterone secretion from
the ZG of the adrenal cortex from a variety of species. In contrast the inhibitory effect
of dopamine on aldosterone secretion is still to be fully understood. An inhibitory
effect of dopamine on aldosterone secretion was first proposed by Muller in 1979.
Dopamine was shown to attenuate All stimulated aldosterone secretion by bovine
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adrenal cells (McKenna et al., 1979). Furthermore, investigations with
metoclopramide, a dopamine antagonist, were shown to increase plasma aldosterone
levels in normal adults (Carey et al., 1982), an effect which could be attenuated or
abolished through concurrent administration of dopamine (Brown et al., 1982). This
effect could not be blocked by infusion of dexamethasone, saralasin or converting
enzyme inhibitors, suggesting a specific dopaminergic mechanism is involved (Sowers
et al., 1986; Stern et al., 1981). Experiments using isolated ZG cells have supported
the idea that this effect is through dopamine antagonism at the adrenal level (Stern et
al., 1986).
The negative control of aldosterone secretion is through inhibition of agonist stimulated
cAMP formation (Gallo-Payet et al., 1991). Evidence from autoradiographic studies
has shown the presence of D2-like dopamine receptors within the adrenal cortex
(Amenta et al., 1994). Analysis of 3H-spiroperidol binding to sections of the human
adrenal cortex has shown that the most powerful competitor to binding was clozapine,
indicating the presence of a D4 receptor within the adrenal gland, negatively coupled to
adenylyl cyclase (Caccavelli et al., 1992; Sokoloff & Schwarz, 1995). No binding of
the Di- ligand "H-SCFI23390 was reported in the human, in contrast to earlier reports
in rat adrenal glands (Missale etal., 1986).
The origin of 5-HT and dopamine in relation to their actions on the cortex is still under
investigation. Circulating levels of 5-HT are low, (less than lnmole/L), as 5-HT is
mainly confined to platelets were it is stored, and also any infused 5-HT is rapidly taken
up by platelets where it is stored (Humphrey & Toh, 1954). Free 5-HT is constantly
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being cleared from the circulation through a number of mechanisms, including uptake
by endothelial cells of the lung, inactivation in the liver and uptake by platelets
(Gershon & Tamir, 1985). It has been reported that the dose of 5-HT needed to
overcome the rapid uptake by platelets constitutes a lethal dose in the rat (Liddle,
Island & Meador, 1962). Circulating dopamine is also too low (0.3-12nmol/l) to reach
the high concentrations required in in vitro studies (10-100mmol/l) to inhibit
aldosterone secretion (Vizi et al., 1993). Thus local delivery, or production of 5-HT
and dopamine from precursors, within or around the adrenal cortex is necessary to
allow the high concentrations required to elicit an effect.
In platelets 5-HT was originally thought to be biologically inert unless it was released
when platelets aggregate at the site of tissue damage.. In a study by Osim et al.,
(1983), platelets from three species of animals were obtained. The platelets were
labelled with "'in oxine to tag individual platelets and with 14C-labelled 5-HT. In brief,
this study showed that platelet 5-HT was not inert and that in fact it could be deposited
in three major organs, one of which was the adrenal gland. The mechanism for this
deposition remains unclear. Hinson et al., (1989), demonstrated the presence of mast
cells within the walls of arterioles which penetrate the capsular tissue of the adrenal
gland in the rat. These cells are appropriately positioned for their products to reach the
subcapsular arterioles which are thought to be the site at which blood flow through the
gland is controlled. Since mast cells can store 5-HT, it was proposed that these mast
cells could be a local source of 5-HT. Dopamine infused into the rat for 30 minutes
resulted in significantly raised plasma levels of dopamine, but the levels present within
the adrenal gland remained unchanged (Buu & Lussier, 1990). This study did
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demonstrate that L-DOPA was readily taken up by the rat adrenal cortex, which was
accompanied by a rapid rise in dopamine levels seen in the adrenal cortex. The L-
DOPA increase was specific to the cortex, however dopamine levels increased both in
the cortex and the medulla. Local noradrenergic varicose axon terminals in the ZG of
the rat were found to be capable of taking up dopamine from the circulation, and to
then release it or convert it to noradrenaline, providing the possibility of a fine tuning of
the local circulation and aldosterone biosynthesis (Vizi, etal., 1993).
Evidence has now accumulated from many studies for the close colocalisation of
adrenocortical and medullary cells, within the adrenal gland of many species, which
may form the basis of many interactions between the two endocrine systems. Uptake
of 5-HT by adrenaline-storing cells has been observed in the rat and mouse adrenal
medulla (Kent et ah, 1984; Sudar et ah, 1979). In the rat adrenal, rays of medullary
tissue have been reported to extend across the outer zones of the cortex, up to the
capsular zone, some of these rays follow the connective fibres of the large adrenal vein.
Even after cell isolation the interaction between the two cell types was visualised
(Gallo-Payet, et ah, 1987). Chromaffin cells have also been revealed in pig and human
adrenal gland projecting from the medulla across all three cortical zones (Bornstein, et
ah, 1991, 1994). The fact that 5-HT has been localised within chromaffin cells of the
adrenal medulla in the frog, rat, human and mouse adrenal gland, and can be released
under splanchnic nerve stimulation, gives rise to the hypotheses that this medullary 5-
HT may be the local source of the amine 5-HT in the regulation of aldosterone
secretion from the ZG (Delarue et ah, 1988).
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The possibility of local production of both 5-HT and dopamine within the adrenal
cortex of various species has been hypothesised by various groups. Plasma
concentrations of both 5-HTP and L-DOPA are sufficiently high to support the idea
that 5-HT and dopamine could act by a paracrine mechanism, via changes in L-AAAD
activity, to modulate aldosterone secretion. The idea that 5-HTP could be converted to
5-HT either centrally, peripherally or locally, to act directly on the ZG, increasing
aldosterone secretion was first reported in in vitro studies in isolated cells and in the
whole isolated perfused adrenal gland (Muller & Zeigler, 1968; Haning et al., 1970;
Hinson & Vinson, 1989). Trost & Muller (1976) reported that capsular tissue
metabolised 5-HT to 5-HIAA and another unidentified metabolite. 5-HTP itself has
been shown to have a slight stimulatory effect on aldosterone (Chapter 3).
The presence of 5-HT and 5-HIAA in rat and frog adrenal extracts by HPLC has been
reported (Holzwarth et al., 1984). In a study by Delarue et al., (1992), conversion of
5-HTP to 5-HT and also tryptophan to 5-HT was demonstrated in the frog inter-renal
tissue. Holzwarth & Brownfield (1984), showed that L-tryptophan treatment increased
5-HT immunostaining in adrenal chromaffin cells of reserpine-depleted animals. In
contrast Verhofstad & Jonsson reported that 5-HT could be formed only by
decarboxylation of 5-HTP, and not by L-tryptophan administration or by a tryptophan-
hydroxylase inhibitor, in the adrenal gland of rats. This is in agreement with the results
presented in this study.
Both biogenic amines are converted from their precursors, 5-HTP and L-DOPA,
respectively by L-AAAD. In vitro studies indicate that the adrenal cortex has the
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ability to synthsise 5-HT and dopamine from their precursors (Delarue, 1992; Buu &
Lussier, 1992), suggesting the presence of L-AAAD within the gland. Beltramo et al.,
(1993) investigated the distribution of L-AAAD immunoreactivity in the adrenal gland
by utilizing a polyclonal antibody raised in rabbits against an L-AAAD recombinant
protein made in E. coli. Their results showed strong L-AAAD immunoreactive cells
present within the medulla of the mouse adrenal, a faint diffuse immunoreactivity was
also evident within the ZF. No immunoreactivity was found within the ZG. This study
has shown, via immunohistochemistry with a specific monoclonal antibody, L-AAAD
immunoreactive cells present within the medulla, ZG and ZF of the rat adrenal.
In order to investigate whether 5-HT itself is present within the rat adrenal ZG, staining
for 5-HT was performed using a specific monoclonal antibody. This staining if evident
would provide evidence for potential 5-HTergic innervation. Figure 5.20b) shows a
distinct lack of staining in the rat adrenal cortex, suggesting a lack of 5-HTergic
innervation in this area.
In the rat adrenal capsule, aldosterone secretion was found to be significantly higher in
low salt diet compared to normal salt diet when incubated with 5-HTP, this was the
opposite for the L-DOPA side of things, in which the results were significantly different
in animals fed on the high salt diet, with more inhibition seen. Parallel results were seen
in the isolated cell experiments, however the concentration of aldosterone was
approximatley ten-fold lower in the isolated cell preparations. This may be explained in
terms of the collagenase digestion technique used, which may have destroyed a
proportion of the ZG cells. Another factor that may affect the results is that the cells
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are isolated thus removing cell to cell contact (e.g. gap junctions), between the ZG
cells. The ZG cells of rats on the lower salt diet clearly show a higher capacity to
secrete aldosterone in response to 5-HTP in a dose-dependent manner. This suggests
that the 5-HTP is converted by the enzyme L-AAAD to 5-HT, and that this 5-HT acts
to stimulate aldosterone secretion from the ZG. Inhibition of L-AAAD by carbidopa
also resulted in inhibition of the aldosterone response to 5-HTP and L-DOPA.
Carbidopa did not however affect basal aldosterone production. Measurement of 5-HT
when incubated with 5-HTP in increasing concentrations, in both adrenal capsule and
kidney cortex, show a dose-dependent increase of 5-HT production. In the case of the
adrenal cortex, the increase of 5-HT production appeared more prominent with rats on
a low salt diet. These results suggest that L-AAAD may be regulated by salt intake in
the rat. In both the adrenal capsule and the kidney cortex, carbidopa appeared to
inhibit the production of 5-HT from 5-HTP, but did not inhibit the basal levels of 5-HT
produced. One area of concern would be contamination of the isolated cell preparation
with ZF cells. The staining of the gland located L-AAAD immunostaining within this
region, and so this may add to the effect purported to be due to the ZG. The method
of isolation has been used for many years and systematically produces a cell suspension
with a very low, insignificant ZF contamination (Haning et al., 1970). Also the
capsular preparations could act as a positive control to the isolated cell work, no ZF
contamination will be present within these incubations. However, to finalise these
experiments a full dose response to 5-HTP in incubations containing ZF cells alone
could be carried out and any aldosterone secretion into the medium measured and
subtracted from the isolated ZG results. This would also enable us to answer whether
or not the effect seen is a physiologically important one.
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Conversion of L-DOPA to dopamine was seen in capsular and medullary preparations,
consistent with this idea of local production of 5-HT and dopamine. These results are
supported by the immunohistochemical localisation of the enzyme within the rat adrenal
medulla and cortex. Incubation of intact adrenal capsules, pre-stimulated with 5-HT,
with increasing concentrations of L-DOPA, resulted in a significant dose dependent
inhibition of aldosterone secretion, further indicating a local effect of dopamine, as L-
DOPA itself has no effect on aldosterone biosynthesis. In similar experiments on
capsules taken from rats on different salt diets, such an inhibitory effect was seen in all
cases, and could be prevented by carbidopa, an inhibitor of L-AAAD. In isolated ZG
cells, parallel results emerged. However, in these experiments, aldosterone secretion
was much lower (>10 fold). This is possibly the result of the dispersion process, with
some cells being destroyed by the collagenase digestion or sheer force. Perhaps the
receptor sites are affected by the collagenase process also. In both capsules and cells
L-DOPA appeared to inhibit aldosterone secretion from high salt diet groups more
strongly (>70%), than from the normal salt diet group, which in turn was affected more
than the low salt diet group.
L-AAAD has been reported to have an optimum pH of 7.2 for dopamine production
and 8.3 for 5-HT biosynthesis (Rahman et al., 1980). Changes in salt intake may affect
the Na+/H+ antiport present on cell membranes of all mammalian cells studied, and
offers a possible mechanism whereby changes in sodium intake may regulate enzyme
activity.
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The regulation of the L-AAAD enzyme remains a controversial area. The enzyme itself
and its regulation are important in disease states such as Parkinson's and Alzheimer's.
In fact ageing may affect brain L-AAAD activity, it has been shown that the
ontogenetic evolution of L-AAAD activity is biphasic, increasing from birth to
adulthood and then decreasing with age (Brus, 1975). In a study with a potent
enzyme-activated irreversible inhibitor of L-AAAD, MFMD, given systemically to
mice, L-AAAD activities were markedly inhibited in the brain, heart and kidney,
producing a substantial and long-lasting decrease in the catecholamine and 5-HT
content of these organs (Jung et al., 1979). It has been shown that some physiological
stimuli and compounds that affect dopamine receptors can also affect L-AAAD
activity. In the rat retina L-AAAD activity increases in response to light, this change is
mediated by Di-receptors (Rossetti el al., 1990). Various agonists and antagonists to
the Di- and D2-receptor sites in rat brain have been shown to modulate L-AAAD
activity, and this study hypothesised that L-AAAD activity within the rat brain may be
modulated by these receptors (Zhu et al., 1993). In fact, brain L-AAAD is thought to
be modulated by dopamine receptors, being activated after blockade of the receptor
and inhibited after stimulation of brain dopamine receptors (Li et al., 1993). Coge et
al., (1990) reported that a direct phosphorylation via an AMP-dependent protein kinase
may have a role in the regulation of L-AAAD, also altered gene expression is the
mechansim responsible for the long-term regulation of L-AAAD. The results from the
work presented in this chapter make a tentative hypotheses that sodium intake may be a
modulator of L-AAAD activity. Further studies are needed to validate this idea, such
as immunohistochemistry studies of adrenal glands taken from animals on differing salt
diets.
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Corticosterone levels from inner zone incubations remained essentially unaffected by
the presence of L-DOPA and 5-HTP (Data not shown) except at very high
concentrations. This suggests that dopamine and 5-HT preferentially affect the late
pathway of steroid biosynthesis. Aldosterone synthase converts corticosterone to
aldosterone and has been shown to be regulated by other steroidogenic factors such as
potassium ions and sodium status (Rabattu et al., 1994). With a relatively selective
effect on aldosterone production, it seems likely that dopamine and 5-HT also act here.
Further studies resulting from this study will be to look at the 5-HTP effect on the inner
zones of the rat adrenal cortex in more detail. Initial experiments in this area have
shown the general trend already reported, with a higher rate of secretion from animals
on a low salt diet, although the results seen so far were not significant. Also
measurement of corticosterone levels produced from the ZG and the ZF, after
incubations with 5-HTP and L-DOPA would be interesting
The results of this study support the role ofL-AAAD in a paracrine mechanism through
which circulating L-DOPA and 5-HTP are converted to dopamine and 5-HT
respectively within the ZG of the rat adrenal cortex. The locally produced dopamine
will act to inhibit the biosynthesis of aldosterone, possibly through an action on the
enzyme aldosterone synthase, on the late pathway of steroidogenesis. The 5-HT will
act to stimulate aldosterone secretion from the ZG. Thus a local fine tuning of the
adrenal cortex appears to exist with two opposing regulators of aldosterone, both
present within the adrenal gland, both have receptor sites within the adrenal cortex and
both have been shown to be produced locally within the ZG from their circulating
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precursors. 5-HT produced and released locally within the ZG may have a role in the
co-ordinated response of adrenochromaffin and adrenocortical cells during stress
conditions.
Sodium status appears to affect the conversion ofL-DOPA to dopamine and 5-HTP to
5-HT, suggesting that salt intake regulates the activity of L-AAAD. Eisenhofer et al.,
(1989) demonstrated the release of plasma L-DOPA from noradrenergic neurons,
reflecting neurotransmitter turnover. Previous studies have demonstrated dopamine
inhibiting All induced aldosterone secretion during sodium deficiency in humans
(Drake et al., 1984). The findings from studies like these and the fact that L-DOPA
can be converted to dopamine within the adrenal gland, suggest a possible link between
sympathetic nervous activity and aldosterone regulation. This notion is entirely
compatible with an earlier suggestion that 'primary alterations in endogenous dopamine
production may be responsible for physiological and pathophysiological modification of
aldosterone responses to angiotensin' (Carey et al., 1986). How sodium affects L-
DOPA release from sympathetic neurons and its conversion to dopamine is an area to
be investigated. Decreasing circulating All by converting enzyme inhibition increases
the uptake of 5-HT in the lung (Gershon et al., 1985). Since All is increased during
sodium depletion, it is possible that All may in fact inhibit 5-HT uptake and
consequently increase circulating 5-HT, which then may act on the ZG. Further
studies, preferably in vivo, are needed to fully elucidate the role ofL-AAAD within the
ZG, and the effect of salt intake.
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The results of this study suggest that the enzyme L-AAAD, present within the rat
adrenal cortex, may form part of a paracrine or autocrine mechansim for the
modulation of aldosterone secretion by 5-HT and dopamine. Immunohistochemistry
and biochemical studies suggest that the 5-HT that stimulates aldosterone secretion,
and the dopamine that inhibits aldosterone secretion, from the rat ZG, may originate
from the circulating precursors of these biogenic amines. In particular the
concentrations of 5-HTP measured in rat blood were similar to those levels found to
produce aldosterone secretion both in rat adrenal capsules and rat glomerulosa cells.
The presence of L-AAAD within the ZF of the rat adrenal gland requires further
attention. This may be important in corticosterone modulation. The presence of the 5-
HT transporter within the adrenal cortex has been determined, however as yet no
evidence has been shown for the existence of a transporter for dopamine or L-DOPA.
Competition experiments using an inhibitor of this system, 3-o-M-DOPA, may be able
to determine the presence of such a system (Soares-da-Silva et al., 1994). The
possibility of changing intracellular pH as a mechanism of regulation ofL-AAAD could
also be investigated. The use of pH-sensitive fluorescent probes, such as BCECF, on
cells taken from rats on differing salt diets would indicate if pH was affected by salt
diet. The effect ofmanipulating the intracellular pH of isolated ZG cells on aldosterone
biosynthesis, through the use of such agents such as NH4C1 and Na^ proprionate, could
then be investigated. It may be that intracellular pH determines the relative activity of
L-AAAD in producing 5-HT and dopamine. L-AAAD activity may be affected by
other regulators of aldosterone secretion such as ACTH and All. All causes
alkalinization of ZG cells, thus decreasing the intracellular pH. Could this affect the
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relative synthesis of 5-HT and dopamine? Another factor is sodium status, receptor
sites for both 5-HT and dopamine may be affected by sodium loading and depletion.
The sodium status itselfmay alter intracellular pH, by activation of the RAS. L-AAAD
is also important in the formation of tryptamine, which has been shown to affect
aldosterone secretion from isolated ZG cells (Chapter 3). This may then have an
additive effect on the response seen with 5-HTP. Another area to be investigated is the
effects of noradrenaline within the ZG. Dopamine (3 hydroxylase is present within the
ZG, which converts dopamine into noradrenaline.
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Chapter Six




The 1960's gave the first evidence of nerve terminals taking up and sequestering
monoamines, specifically norepinephrine and 5-HT, and it was soon recognised that
uptake back into the nerve terminals, via transporter molecules present on the neuronal
membrane, was the predominant means of inactivating monoamines that have been
released into the synaptic cleft. High affinity 5-HT transporters are present on the
presynaptic membranes of 5-Htergic neurons where they act to regulate the
concentration of 5-HT on receptor sites. To carry out their role efficiently transporters
should be present at or near sites of 5-HT release. Whether or not the 5-HT
transporter molecule is uniformly distributed along plasma membranes, or if it is
present only in specific areas linked with 5-HT production and release is still to be
elucidated.
Inhibition of the transporter process would increase the concentration of monoamines
in the synaptic cleft, thus increasing their contact with synaptic receptors. Thus
antagonists of neurotransmitter transporters rank among our most important tools in
biological psychiatry, for example antidepressants. On the downside they can also be
potent addictive substances such as cocaine, Methylenedioxymethamphetamine
(MDMA; 'Ecstasy') and amphetamines.
Depression is a wide spread clinical problem. For years the tricyclic antidepressants
were the drugs of choice to treat depression, although their side effects were numerous
including dry mouth, nausea, cardiac toxicity and addiction (Milne & Goa, 1992). As a
deficit in 5-HTergic neurotransmission is implicated in the aetiology of clinical
depression, potent and selective 5-HT reuptake inhibitors have been developed as
potential antidepressant drugs, such as fluoxetine (Prozac), paroxetine (Seroxat) and
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citalopram (Cipramil), marketed as having less side effects than previous remedies and
non addictive. Since the advent of these new wonder drugs, a certain amount of
overprescribing has occurred and as with valium and amitryptyline before these drugs
have now been found to be addictive, causing in some cases more problems than the
depression itself.
The 5-HT transporter itself has been implicated in the mechanism of action of various
drugs of abuse, including amphetamine based drugs and MDMA. In fact prolonged
ingestion ofMDMA leads to the appearance of the "5-HT Syndrome" amongst other
effects, caused by increased 5-HT function, leading to alterations in cognition,
behaviour, autonomic nervous system function and neuromuscular activity.
Trost & Muller in 1976, in a series of experiments with radiolabeled 5-HT, first
described the uptake of 5-HT into zona glomerulosa cells. Osim & Wylie in 1983
demonstrated that stored platelet 5-HT could in fact be released into other tissues. In
1994 Blakeley et al., demonstrated the presence of mRNA for the 5-HT transporter
within the rat adrenal gland, and since then with the use of immunohistochemistry, this
group have visualised the transporter molecule specifically within the rat adrenal
medulla. No traces of the transporter molecule were found within the adrenal cortex of
the rat. In a study by Pahkla & Rago, (1997), utilising whole decapsulated rat adrenal
gland, specific saturable ['H]-citalopram binding sites were detected in the rat adrenals,
with an affinity comparable to that seen in rat brain. In fact the number of binding sites
seen was reported to be even higher than that reported for rat brain. In addition
Schroeter et al., (1997), have reported the 5-HT transporter present within epinephrine
synthesizing chromaffin cells of the rat adrenal medulla. No transporter protein was
detected in the ZG or the capsule.
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5-HT has been shown to affect adrenal gland physiology, specifically as mentioned
before the release of aldosterone from the ZG. To date no evidence has been reported
as to the existence of a 5-HT transporter within the rat adrenal cortex. The source of
5-HT within the gland is still to be elucidated, although the studies detailed in Chapter
5 may in part explain one source of 5-HT within the adrenal gland. Another source
may be chromaffin cell 5-HT, which could be captured from the blood, as occurs in the
transporter mediated uptake of 5-HT by platelets (Gillis & Pitt, 1982).
Further to these studies, immunohistochemical studies with two antibodies to the 5-HT
transporter and {^H} paroxetine autoradiography, were utilised to visualise the
transporter within the rat adrenal gland. Also superfusion and isolated cell work with
5-HT reuptake inhibitors were carried out to define a role for the transporter within the
rat adrenal gland. Finally the drug of abuse MDMA, known to act on the 5-HT
transporter, was studied both in vivo and in vitro, in the rat, to elucidate the effects of
MDMA ingestion on the adrenal gland.
6.2. Statistical Analysis.
Statistical significance was calculated in the individual experiments by Student's t-test
for unpaired samples. A p value of<0.05 was considered significant. NS indicates non
significance. *, ** and *** indicates that p<0.05, p<0.01 and p<0.001 respectively.
6.3. Results.
The graphs represent the mean ± SEM of four individual experiments. Within each
experiment each incubation was repeated three times.
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Figure 6.1 represents a dose response to 5-HT, citalopram and DMI in isolated ZG
cells. As can be seen a significant increase in aldosterone production was seen with 5-
HT. No alteration in aldosterone secretion was observed with citalopram or DMI in
increasing concentrations (10"10-10"5M).
Figure 6.2 represents dose response relationships, in isolated ZG cells, between
aldosterone secretion and increasing concentrations of 5-HT, of 5-HT in the presence
of 10"6M citalopram and of 5-HT in the presence of 10_9M citalopram. A slight
increase in aldosterone secretion was observed in the presence of 10"9M citalopram,
and this increase was more evident in the presence of 10"6M citalopram. The increase
seen was not significant (n=4).
Figure 6.3 represents dose response relationships, in isolated ZG cells, between
aldosterone secretion and increasing concentrations of 5-HT, of 5-HT in the presence
of 10~9M DMI and of 5-HT in the presence of 10"6M DMI. A slight increase was again
seen in the presence of 10_9M DMI, which again was more evident in the presence of
10"6M DMI. This was also not significant (n=4).
The effect of increasing the cell concentration of the isolated ZG cell preparation was
also looked at. Incubations containing 20,000 cells, 50,000 cells and 80,000 cells
approximatly were incubated as detailed above for Figures 1, 2 and 3. There was no
significant difference between the 20,000 and 50,000 cell incubations (n=2). However
the 80,000 cell incubation produced a more marked increase in aldosterone secretion in
the presence of citalopram and DMI. This was not significant for n=2, and more
experiments will have to be carried out with larger amounts of cells to find out if this
trend is significant. Data not shown.
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Figure 6.4 represents the dose response relationship seen in whole capsular tissue
superfused (rate lml/lmin) with increasing concentrations of 5-FIT (10~9-10"5M) or
increasing concentrations of 5-HT in the presence of 10"9M DM1. An increase in the
secretion of aldosterone was seen with capsular tissue superfused with 10"6M DMI,
which was significant (p<0.05). Maximal aldosterone secretion was 7.7 ± 0.3 nmol/1 in
the presence of DMI as compared to 4.9 ± 0.6 nmol/1 for 5-HT alone (10"5M). This
was repeated in isolated ZG cells, and there was a slight increase seen in secretion of
aldosterone, although it was not significant (n=4). Data not shown.
Figure 6.5 represents the dose response relationship seen in whole capsular tissue
superfused with increasing concentrations of 5-HT (10"9-10"5M) or increasing
concentrations of 5-HT in the presence of 10"6M DMI. A more significant increase was
observed in aldosterone secretion from capsular tissue (p<0.01). Maximal aldosterone
secretion was 9.3 ± 0.5 nmol/1 in the presence ofDMI as compared to 4.0 ± 0.4 nmol/1
for 5-HT alone (10"5M). Again this was repeated in isolated ZG cells and although a
rise in aldosterone secretion was observed it was not significant.
Figure 6.6 represents the dose response relationship seen in whole capsular tissue
superfused with increasing concentrations of 5-HT (10"9-10"5M) or increasing
concentrations of 5-HT in the presence of 10"9M citalopram. An increase in the
secretion of aldosterone was seen with capsular tissue superfused with 10"6M
citalopram, which was significant (p<0.05). Maximal aldosterone secretion was 5.4 ±
0.7 nmol/1 in the presence of citalopram as compared to 4.9 ± 0.6 nmol/1 for 5-HT
alone (10"5M). This was repeated in isolated ZG cells, and there was a slight increase
seen in secretion of aldosterone, although it was not significant (n=4). Data not shown.
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Figure 6.7 represents the dose response relationship seen in whole capsular tissue
superfused with increasing concentrations of 5-HT (10"9-10"5M) or increasing
concentrations of 5-HT in the presence of 10~6M citalopram. A more significant
increase was observed in aldosterone secretion from capsular tissue (p<0.01). Maximal
aldosterone secretion was 7.8 ± 0.3 nmol/1 in the presence of citalopram as compared
to 4.4 ± 0.4 nmol/1 for 5-HT alone (10"5M). Again this was repeated in isolated ZG
cells and although a rise in aldosterone secretion was observed it was not significant.
Figure 6.8 represents A) the total binding and B) the non-specific binding observed in
sections of rat adrenal gland via [3H]-paroxetine autoradiography. As can be seen
binding was evident within the rat adrenal medulla (220 ± 20 fmol/mg of tissue), and no
binding was evident within the adrenal cortex (7 + 6 fmol/mg of tissue).
Figure 6.9 represents the immunohistochemical staining seen in whole adrenal gland
sections from rat. The antibodies were used at a 1:200 dilution. S-240-KLH
demonstrated background staining throughout the gland, with a slightly darker staining
evident in the medulla (Figure 6.9A). S-387-KLH, demonstrated dark
immunoreactivity within the adrenal medulla, and slight background staining
throughout the adrenal cortex. Also evident were areas of dark staining within the
cortex associated with the vasculature and may be due to trapped platelets (Figure
6.9B).
Figure 6.10 represents the dose response relationship seen in isolated ZG cells
incubated with increasing concentrations of 5-HT (10"10-10"SM) or increasing
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concentrations of 5-HT in the presence of lpM MDMA. As can be seen there is no
significant difference between the two dose response curves (n=4).
Figure 6.11 represents the dose response relationship seen in isolated ZG cells
incubated with increasing concentrations of 5-HT (10~IO-10~5M) or 5-HT in the
presence of 10pM MDMA. There is now evident a significant increase in aldosterone
secretion as compared to incubations with 5-HT alone (p<0.01).
Figure 6.12 represents the dose response relationship seen in whole capsular tissue
superfused with increasing doses of 5-HT (10"10-10"5M) in the presence and absence of
lp.M MDMA. A significant rise in aldosterone secretion into the medium was
observed (p<0.01). Maximal aldosterone secretion was 9.9 ± 0.7 nmol/1 in the
presence ofMDMA as compared to 6.3 ± 0.4 nmol/1 for 5-HT alone (10~5M).
Figure 6.13 represents the dose response relationship seen in whole capsular tissue
incubated with increasing doses of 5-HT (10"10-10"5M) in the presence and absence of
10pM MDMA. A significant rise in aldosterone secretion into the medium was
observed (p<0.001). Maximal aldosterone secretion was 10.2 ± 0.2 nmol/1 in the
presence of MDMA as compared to 6.3 ± 0.4 nmol/1 for 5-HT alone (10"5M).
Incubations with MDMA alone in both capsular tissue and isolated ZG cells produced
an increased aldosterone secretion. However this response was not consistent (data
not shown). Also superfusion studies with isolated ZG cells again produced slight
increase of aldosterone secretion in response to incubations of 5-HT in the presence of
differing concentrations ofMDMA, but again the increase was not significant (n=4).
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Graphical Illustration







Figure 6.1. Dose-dependent increase in aldosterone secretion from isolated ZG cells
in response to increasing concentrations of 5-HT, citalopram and DMI. Isolated rat ZG
cells were incubated for 1 hour at 37°C with increasing concentrations of 5-HT,
citalopram and DMI. Aldosterone secretion into the medium was measured by RIA.
Data from 4 separate experiments, with triplicate incubations performed in each, were







Figure 6.2. Dose-dependent increase in aldosterone secretion from isolated ZG cells
in response to increasing concentrations of 5-HT, in the presence and absence of
citalopram ]0'6M and citalopram 10~9M. Isolated rat ZG cells were incubated for 1 hour
at 37°C with increasing concentrations of 5-HT alone or 5-HT in the presence of 10"9M
citalopram or lO^M citalopram. Aldosterone secretion into the medium was measured
by RIA. Data from 4 separate experiments, with triplicate incubations performed in each,



















Figure 6.3. Dose-dependent increase in aldosterone secretion from isolated ZG cells
in response to increasing concentrations of 5-HT\ in the presence and absence of DMI
10'6M and DMI I0'9M. Isolated rat ZG cells were incubated for 1 hour at 37°C with
increasing concentrations of 5-HT alone or 5-HT in the presence of 10"9M DMI or lO^M
DMI. Aldosterone secretion into the medium was measured by RIA. Data from 4




i i i i i i r





































































































































































































































































































































































































































































































































































































































































































Figure 6.8. : Representative [3H]paroxetine autoradiographs from adjacent
cryostat sections of whole rat adrenal gland. Total binding was defined using
250pM [3H]paroxetine (A) and non-specific binding was defined using 250pM
[3H]paroxetine in the presence of 4pM citalopram (B). Binding was evident
within the medulla (220120 fmol/mg of tissue), and no binding was evident
within the adrenal cortex (716 fmol/mg of tissue) (n^).
Figure 6.9 (a): Sections through the rat adrenal gland stained with the antibody S-240-KLH at magnification
x80 and x200.
Figure 6.9 (a): Sections through the rat adrenal gland stained with the antibody S-240-KLH at magnification
x80 and x200.
**■ . 1 *
Figure 6.9 (b): Sections through the rat adrenal gland stained with the antibody S-387-KLH at magnification
x80 and x200.
Figure 6.9 (b): Sections through the rat adrenal gland stained with the antibody S-387-KLH at magnification
x80 and x200.
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Figure 6.10. Dose-dependent increase in aldosterone secretion from isolated ZG cells
in response to increasing concentrations of 5-HT, in the presence and absence ofMDMA
1 pM. Isolated ZG cells were incubated for 1 hour at 37°C with increasing concentrations
of 5-HT alone or 5-HT in the presence ofMDMA lpM. Aldosterone secretion into the
medium was measured by RIA. Data from 4 separate experiments, with triplicate
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Figure 6.11. Dose-dependent increase in aldosterone secretion from isolated ZG cells
in response to increasing concentrations of 5-HT, in the presence and absence ofMDMA
JOpM. Isolated ZG cells were incubated for 1 hour at 37°C with increasing
concentrations of 5-HT alone or 5-HT in the presence of MDMA lOuM. Aldosterone
secretion into the medium was measured by RIA. Data from 4 separate experiments,
with triplicate incubations performed in each, were combined and expressed as
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Figure 6.12. Dose-dependent increase in aldosterone secretion from superfused whole
capsular tissue in response to increasing concentrations of 5-HT, in the presence and
absence of MDMA 1phd. Whole adrenal capsules were superfused with increasing
concentrations of 5-HT alone or 5-HT in the presence of MDMA lpM. Perfusate was
collected every 5 minutes for 120 minutes. Perfusate sample numbers :- 1-4 = basal, 5-6
= 5-HT10~9M +/- MDMA, 7-8 = washout, 9-10= 5-HTlO'^M +/- MDMA, 11-12 =
washout, 13-14 = 5-HT10"7M +/- MDMA, 15-16 = washout, 17-18 = S-HTIO^'M +/-
MDMA, 19-20 = washout, 21-22 = 5-HT10"5M +/- MDMA, 23-24 = washout.
Aldosterone secretion into the medium was measured by RIA. Data from 4 separate
experiments, with triplicate incubations performed in each, were combined and expressed



























Figure 6.13. Dose-dependent increase in aldosterone secretion from super/used whole
capsular tissue in response to increasing concentrations of 5-HT, in the presence and
absence of MDMA 10 pM. Whole adrenal capsules were superfused with increasing
concentrations of 5-HT alone or 5-HT in the presence of MDMA 1 OpM. Perfusate was
collected ever}' 5 minutes for 120 minutes. Perfusate sample numbers 1-4 = basal, 5-6
= 5-HT10"9M +/- MDMA, 7-8 = washout, 9-10= 5-HTlO^M +/- MDMA, 11-12 =
washout, 13-14 = 5-HT10"7M +/- MDMA, 15-16 = washout, 17-18 = S-HTIO^M +/-
MDMA, 19-20 = washout, 21-22 = 5-HT10"5M +/- MDMA, 23-24 = washout.
Aldosterone secretion into the medium was measured by RIA. Data from 4 separate
experiments, with triplicate incubations performed in each, were combined and expressed
as mean±SEM. *p<0.05, **p<0.01 and ***p<0.001 compared to basal levels.
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Figure 6.14. (a) Depicts plasma aldosterone levels in rats after in vivo
administration ofMDMA. Values are mean±SEM, n—12. p<0.05 and P 0.01
compared with basal levels.
Time (Minutes)
Figure 6.14. (b) Depicts plasma renin levels in rats after in vivo
administration ofMDMA. Values are mean+SEM, n=12. *p<0.05 and **p<0.01
compared with basal levels.
Figure 6.14 A) represents the in vivo results for plasma aldosterone in rats after
injection with MDMA (n=12). Basal aldosterone levels in the control animals was
3.114 ± 2.1 mmol/1 and did not change significantly during the time course of the
experiment. In MDMA treated animals basal aldosterone levels were 3.490 ± 1.1
mmol/1, increasing with time to 12.0 ± 2 mmol/1 after 30 minutes (p<0.01). Basal PRA
was 6.8 ± 1.65 ng/ml/hr in the MDMA treated animals increasing to 228.5 ± 34.1
ng/ml/hr after 30 minutes (p<0.01) (Figure 6.14B). There were no significant
differences in physiological status between the two groups of rats before treatment, or
in the control group after injection with saline. Following injection with MDMA, a
transient hypertension (MABP in the range 160-190mmHg), rapid in onset and lasting
approximatley 1 minute was evident resolving around 2 minutes after injection (MABP
130 ± 8mmHg). This rise in blood pressure coincided with a period of intense motor
activity similar to the symptoms seen in the "5-HTergic syndrome". A slight rise in
rectal temperature was observed in the MDMA treated animals, although this was not
statistically significant.
Preliminary western blot analysis of rat adrenal tissue located the transporter protein
within medullary/fasciculata cell pellet tissue, but not within capsular tissue cell pellets.
The western blot analysis was only carried out once, due to time limitations (data not
shown).
6.4. Discussion.
Many biochemical, physiological and molecular biology experiments support a role for
5-HT within the adrenal gland. The study discussed in Chapter 5 gives one hypothesis
for the local source for 5-HT within the rat adrenal cortex. Another hypothesis as
mentioned before involves the 5-HT localized within rat chromaffin granules. These
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granules also contain large quantities of noradrenaline and adrenaline and are typically
associated with stress-induced release of these amines into the circulation (Holzwarth
& Brownfield, 1985). It is estimated that as much as 8pM of 5-HT is stored within
these granules, and, once released, can elevate extracellular 5-HT above the nanomolar
concentrations previously used in in vitro studies (Boess & Martin, 1994). So, 5-HT
may be transported across the plasma membrane from plasma sources and further
concentrated in secretory granules prior to release within the adrenal gland, analogous
to mechanisms for platelet 5-HT storage (Gillis & Pitt, 1982).
The results of this study have confirmed the presence of the 5-HT transporter within
the medulla of the rat adrenal gland. However from the immunostaining data there
would appear to be 5-HT transporter protein within the cortex, and this observation is
given credence via the pharmacological studies which show elevated aldosterone
secretion from the adrenal capsule and isolated ZG cells when 5-HT is in the presence
of citalopram, DMI and MDMA. One anomoly between the isolated cell studies and
the whole capsular studies was the very reduced effect seen in the isolated cells. In fact
in some experiments no effect of citalopram, DMI and MDMA was seen not only in the
isolated cells but also in whole capsular tissue. An explanation for the reduced effect
seen in the isolated cell preparation would be the collagenase digestion, which may
have destroyed any transporter protein present, or ruptured membranes, leading to a
reduced effect. Another more plausible explanation is that the results seen within the
cortex are due to the presence of trapped platelets and/or mast cells which contain
transporter protein and could be responsible for the effect seen within the rat cortex.
As no other group has seen any evidence for the 5-HT transporter within the cortex,
this would seem a likely reason for the results reported in this study. Another plausible
hypotheses would be the existence of cortico-medullary interactions. Indeed the dark
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staining evident with antibody S-387-KLH, was within the cortex associated with the
vasculature, and this could be linked to the rays of medullary tissue reported to extend
across the cortex following the connective fibres of the large adrenal vein in the rat
(Gallo-Payet et al., 1987). Schroeter el al., (1997), reported the existence of the 5-HT
transporter within the rat adrenal gland associated with chromaffin granules, more
importantly, they noticed intense 5-HT transporter activity within the chromaffin cells
on the cortico-medullary border. Co-localisation of the two cell types has been
reported, with medullary products exerting effects on the cortex (Bornstein et al.,
1992). So the results seen in this study can be explained by the existence of these
cortico-medullary interactions. The close proximity of the chromaffin cells containing
the transporter as reported by Schroeter et al., (1997), to the steroid synthesizing cells
of the cortex, is consistent with a paracrine interaction between the cell types mediated
by 5-HT. These chromaffin cells are well positioned to release 5-HT onto the receptor
sites within the cortex and modulate corticosteroid release (Lefebvre et al., 1992). In
fact since corticosteroids regulate catecholamine release, medullary 5-HT may be
released as part of a coordinated feedback loop to ensure integrated function of the
adrenal gland (Schubert et al., 1980).
The in vitro cell work and supervision studies described in this chapter provide initial
evidence for a role of the 5-HT transporter within the rat adrenal cortex. Further
studies are required to fully characterise a role for the protein within the cortex. Is the
transporter modulated by salt intake, where is it localised within the ZG? Initial studies
carried out with increasing concentrations ofZG cells in incubations with 5-HT, found
an increase in aldosterone output in the presence of both uptake inhibitors, although
this was not significantly different from 5-HT incubations as controls. The existence of
other transporter proteins may have an effect on aldosterone output within the ZG. In
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fact, the vesicular transporters that package catecholamines for release also transport 5-
HT with high affinity (approx. 8pM), and on granule fusion enough 5-HT could be
present within the cortex to produce an increase in aldosterone secretion (Schroeter, et
a/., 1997).
The results seen from the in vivo study resulted in elevated levels of aldosterone and
PRA in the rats tested within the plasma. These effects could contribute to the side
effects ofMDMA such as the stimulation of thirst, the elevation of blood pressure and
the "5-HT syndrome". They may alternatively be secondary responses related to acute
hypovolaemia and hyponatraemia induced by MDMA. During the study 3 of the rats
dies before the 30 minutes experimentation time, an alarming statistic. One interesting
study would be to administer a 5-HT antagonist along with the MDMA and measure
PRA and aldosterone levels in blood.
MDMA was first synthesised 80 years ago, and is now one of the most commonly used
illegal recreational drugs of abuse. Structurally similar to amphetamine and mescaline
MDMA has both stimulant and psychotomimetic activity. In the late 1970's and early
1980's MDMA was used "underground" (FDA-unapproved) as an adjunct to
psychotherapy, and so now there is a widely held belief amongst users that it is safe to
take, despite a growing number of deaths and severe acute toxicity after ingestion of
MDMA. Also there is growing concern of the toxic effects of MDMA, both in long
term and short term abuse, on 5-HT nerve terminals.
In animals MDMA produces hyperthermia, which amongst other symptoms form part
of the "5-HT Syndrome". This syndrome consists of a series of behavioural changes
due to increased 5-HT function, including alterations in cognition and behaviour,
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changes in mental status, restlessness, myoclonus, hyperreflexia, tremor, shivering,
incoordination, diaphoresis and diarrhoea, other symptoms are changes in function of
the autonomic nervous system and in neuromuscular activity. The hyperthermia
appears to precipitate other severe clinical problems and the outcome is usually fatal.
In humans MDMA abuse has led to increasing accounts of severe toxicity, and in a
report from the USA, in 7 fatalities, the pattern of toxicity included hyperthermia,
convulsions, disseminated intravascular coagulation, rhabdomyolysis and acute renal
failure, toxic symptoms that are similar to those seen in the "5-HT Syndrome". In
some reported cases of MDMA abuse patients have been admitted with prolonged
neuropsychiatric disorders, convulsions, acute renal failure and hepatotoxicity. Thus
ingestion ofMDMA, acutely or chronically, can lead to a wide range of unwanted side
effects, in some cases death. The MDMA drug culture is associated with raves and all
night dance parties. 40 years ago amphetamine aggregation toxicity was first reported
in mice. If this was applicable to MDMA toxicity, raves and dance parties produce all
the conditions required for induction or enhancement of toxicity i.e. crowded
conditions, high ambient temperatures, loud noise and dehydrated subjects. The
controlled administration ofMDMA in rodents and other animals results in long term
neurotoxic decreases in 5-HT content in several brain regions, which reflects
neurodegeneration of 5-HT terminals. Some studies have observed 5-HT axons
undergoing regenerative sprouting following MDMA injury, although it has not been
determined whether they re-establish the original innervation pattern. One study by
Fischer et al., (1995), looked at 5-HT innervation patterns in rats and squirrel monkeys
lesioned with MDMA 12-18 months previously. 5-HT axon projections were studied
neurochemically, autoradiographically and immunocytochemically, and in both species
substantial 5-HTergic axonal sprouting was observed after MDMA toxicity. However
the pattern was highly abnormal, with distant targets (e.g. dorsal neocortex), remaining
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denervated, while some proximal targets (e.g. amygdala, hypothalamus) were
reinnervated or hyperinnervated. Such lasting changes may result in a lasting
reorganisation of ascending 5-HT axon projections, which may have implications in the
abuse of MDMA in humans. Unequivocal data demonstrating that similar changes
occur in human brain do not exist, but limited and indirect clinical evidence give cause
for concern. In a controlled study in humans (McCann et al., 1994), in which 30
MDMA users and 28 controls were admitted to a controlled inpatient setting for
measurement of biological and behavioural indexes of central 5-HT function,
concentrations of monoamine metabolites in cerebrospinal fluid, prolactin responses to
L-tryptophan, nociceptive responses to ischemic pain, and personality characteristics in
which 5-HT has been implicated (i.e. impulsivity and aggression) were all measured in
both groups. The subjects with a history ofMDMA abuse had lower levels of CSF 5-
HIAA as compared to controls. Levels of prolactin response to L-tryptophan and
ischaemic pain response were not significantly different between the groups, however
MDMA users had significantly lower scores on personality measures of impulsivity and
indirect hostility. The CSF findings suggest that 5-HT neurotoxicity may be a potential
complication ofMDMA abuse, and the differences observed in personality tests further
support the view that 5-HT systems are involved in modulating impulsive and
aggressive personality traits. Another attempt to study the potential effects ofMDMA
abuse in the human brain was to use rhesus monkeys and examine the effects of
repeated systemic administration ofMDMA (2.5-10 mg/kg twice daily for four days),
on selected neurochemical and behavioural measures. After four days CSF
concentrations of 5-HIAA and brain concentrations of 5-HT and 5-HIAA were
decreased significantly. At the high doses of MDMA a selective decrease in 5-HT
uptake sites, reflecting destruction of brain 5-HT terminals, was observed. The
monkeys were monitored for fourteen days after high dose ingestion for four days in a
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subsequent study, to determine if the changes observed in the previous study were
pharmacologic or truly neurotoxic. Throughout the fourteen days CSF 5-HIAA
remained significantly decreased as opposed to control animals. At the end of the
fourteen days, significant decreases in the concentration of 5-HT, 5-HIAA and 5-HT
uptake sites were observed in cerebral cortex and striatum, but not in hypothalamus or
spinal cord. Noradrenergic and dopaminergic measures in CSF and brain remained
unaffected. The authors suggested from this study that the potent and selective toxicity
produced by ingestion of MDMA on a chronic basis seen may also be produced in
humans (Insel et al., 1989).
MDMA thus causes wide spread toxicity in various species. Numerous studies in rat
brain have revealed that MDMA has potent selective neurotoxic properties on 5-HT
neurones. Exposure to MDMA in the rat has resulted in profound decreases in the
concentrations of 5-HT and its metabolites, the depletion of 5-HT uptake sites and a
marked reduction in the density of 5-HT immunoreactive axon terminals (Battaglia et
al., 1987, 1987, 1988). Deficits in 5-HT markers in rat have been shown to last up to
six hlonths after ingestion ofMDMA (Battaglia et al., 1988). Anatomically in rat klain
tke effects dfMDMA are manifest in the tferftllridl fields of 5-tfTergic neurones Whilst
the cell hbclies of the dorsal and median raphe nuclei remain relatively unaffected
(Atblliver,ld&7, O'Mearn et al., 1988). FtoWeVer within sdhie terminal fields, itiost
ittipbrtantiy hPbcOftex dhd hippocampus, me loSS Of 5-HT fibres is not homogetidUs,
with sortie subregibns of these structures beilig profoundly affected whilst others are
relatively Spdffed (b'ffcarrt et al., 198&).
But what df tke mechanism of action ofMbMA. 5-ifT transport has been implicated
in the mechanism of action of a number of amphetamine derivatives including p-
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chloroamphetamine and fenfluramine. These indirectly acting sympathomimetic amines
exert their effects by releasing endogenous biogenic amines from nerve terminals, and
in fact release 5-HT preferentially both in vivo and in vitro. (Fuller et al., 1965;
Schmidt et al., 1987). MDMA (3,4-methylenedioxymethamphetamine; MDMA), as is
suggested from its chemical name, is a ring substituted derivative of methamphetamine,
and as such exerts effects on monoaminergic systems in brain comparable to those of
amphetamines. The 5-HT transporter has been implicated in the mechanism of action
of amphetamine based drugs as inhibitors of 5-HT transport block the effect of these
drugs on acute 5-HT release and destruction of 5-HTergic terminals (Schmidt et al.,
1987; Fuller et al., 1975), suggesting that the 5-HT transporter either mediates the
entry of neurotoxic amphetamines, like MDMA, into 5-HTergic terminals or
participates in sequelae leading to 5-HT release and depletion or both. Calcium ions
are not required for amphetamine induced 5-HT release, suggesting that exocytosis is
not involved. The likely mechanism of action is via reversal of the transport systems
that normally catalyze accumulation of 5-HT to high levels within the neuron and
synaptic vesicle. In addition to releasing 5-HT, amphetamine derivatives also lead to a
long-term depletion of 5-HT (Ricuarte et al., 1985), which correlates with
morphological damage to 5-HT nerve endings (Molliver & Molliver, 1990). 5-HT
release may be only one of many processes contributing to neurotoxicity. Recently
evidence has accumulated implicating dopamine release in the action of neurotoxic
amphetamines, in fact dopamine receptor blockers prevent MDMA neurotoxicity
(Johnson & Nicols, 1991; Schmidt et al., 1985). Thus other potential mechanisms of
neurotoxicity involve an action of released dopamine on serotonergic terminals, also
dissipation of ion gradients by transporter-mediated amphetamine cycling and
unspecified intracellular actions of the amphetamines and their metabolites (Fuller,
1980; Stone et al., 1988; Schmidt et al., 1990; Rudnick & Wall., 1992).
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The previous perception ofMDMA as a safe drug of abuse has been revised in the light
of recent press coverage of deaths linked to MDMA abuse. Uncertainty remains
however as to whether the deaths and toxic side effects are solely due to MDMA
ingestion, or are due to contaminants in the illicit MDMA bought at raves etc., and also
to what the individual has also ingested that evening (i.e. alcohol, speed, cannabis etc.).
What is not in question is that in animal studies to date MDMA produces long lasting
toxic effects in the brain, but there has been no evidence that any lasting functional
defecit in the human brain occurs.
The results from our study show marked changes in aldosterone and PRA levels after
MDMA ingestion. However, this can not be linked to effects that may be seen in
humans after ingestion of MDMA for example at a rave. Most MDMA tablets are
mixed with various other compounds, the actual dose ofMDMA ingested ranges from
tablet to tablet. Further studies are needed within rat brain, and with differing
concentrations ofMDMA to enable a clearer picture ofwhat actually happens in vivo.
The 5-HT transporters are a major target for antidepressant medications and with the
localisation of the transporter within the adrenal cortex, it remains a possibility that
modulation of adrenal catecholamine or steroid production may be a property of these
agents. Within the CNS, transporter blockade results in elevated 5-HT exposure to
receptors and a downregulation of the receptor (Artigas et al., 1996). Further studies
are required to determine whether antagonsim of the adrenal 5-HT transporter may
result in heightened responsiveness and/or downregulation of adrenal 5-HT receptors,
leading to alterations in steroid hormone output.
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Soon after its chemical identification the structural similarities between 5-HT and
lysergic acid diethylamide (LSD) led to the logical speculation that substances related
to 5-HT may cause mental aberrations. Coincidentally, physicians working in
sanitariums for tuberculosis noted that iproniazid, an antitubercular drug with
monoamine oxidase inhibitory properties, improved mood in many patients. Also in the
1950's, it became evident in patients treated with reserpine, an antihypertensive agent
which depletes monoamine stores, depression was an unwanted side effect to therapy.
So nearly 50 years ago the first idea that 5-HT was important in psychiatric illnesses
was viewed.
Depression is a heterogenous disease state characterised by complex alterations in
several CNS neurotransmitter and receptor systems. All antidepressants are thought to
act by causing postsynaptic adaptive changes within these systems. Thus, the
mechanism of action of selective 5-HT reuptake inhibitors (SSRIs) cannot simply be
explained in terms of inhibition of 5-HT reuptake.
Within the CNS the vast majority of 5-HTergic nerve terminals originate in neuronal
cell bodies of the raphe nuclei in the brainstem. These 5-HTergic perikarya project in a
topographic fashion to neuroanatomically discrete areas, resulting in a diffuse but
heterogenous innervation throughout the brain (Azmitia, 1987). 5-HT acts
predominantly as an inhibitory neurotransmitter in the CNS. After release from
presynaptic 5-HT containing terminals, 5-HT present within the synapse is inactivated
by uptake into the presynaptic terminal by the 5-HT transporter. Once taken up, 5-HT
may be degraded by MAO to 5-HIAA, or repackaged into secretory vesicles by the
vesicular monoamine transporter (Chapter 1).
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Specific inhibitors of monoamine transporters have been important experimental tools
in elucidating physiological roles ofmonoaminergic neurons. For example, SSRIs have
helped to establish a role of brain 5-HT neurons in influencing some types of behaviour,
the choice and amount of food ingested, sleep and endocrine regulation (Fuller et al.,
1991). The tricyclic antidepressant drugs have long been thought to owe their
therapeutic efficacy to inhibition of monoamine uptake, particularly of 5-HT and
noradrenaline. Most of these drugs are relatively non-selective in their uptake
inhibition, and also they have high affinity for numerous neurotransmitter receptors,
including muscarinic cholinergic receptors and Hi histaminergic receptors (Richelson &
Pfenning, 1984). In recent years, more selective reuptake inhibitors have been
developed. These agents are more selective in their specificity of uptake inhibition as
well as in their lack of affinity for neurotransmitter receptors. A growing list of
structurally diverse SSRIs are now available and are effective antidepressant drugs
(Fuller, 1993). Also SSRIs are effective in the treatment of bulimia, obesity and
obsessive-compulsive disorder (Fuller et al., 1994). The full range of therapeutic roles
for the SSRIs is still to be elucidated. SSRIs that lack affinity for neurotransmitter
receptors may have advantages in clinical use over the tricyclics. They lack
anticholinergic and other side effects. Does selective inhibition of the transport of one
particular monoamine offer clinical advantages in the treatment of depression over the
inhibition of transport of more than one monoamine? This remains to be determined.
Perhaps in the future it may be possible to identify patients most likely to respond to a
5-HTergic, a dopaminergic or a noradrenergic drug therapy. In addition to mental
depression, transport inhibitors may be useful in treating other disease states, with the
SSRIs having the most widespread therapeutic use.
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Some neurotoxins appear to rely on transporters to gain entry into the cell cyptoplasm
where they exert their nerve killing action. The possibility that neurodegenerative
diseases such as parkinsonism may be triggered by such a process remains an attractive
hypothesis. Studies with non-toxic transport inhibitors, imipramine and fluoxetine,
found that they blocked the toxicity of transported toxins in each case (Rudnick et al.,
1992). Studies like these hold the possibility of preventative treatment to slow or stop
the progress of neurodegenerative diseases such as parkinsonism that might be
attributable to such transported neurotoxins. The drug of abuse cocaine exhibits
apparent competitive inhibition of transport of dopamine, but is not a transported
substrate. Identification of the regions of the dopamine transporter which recognises
cocaine but does not interfere with dopamine-recognition sites may allow a drug
addiction medication to be found, a molecule that would prevent cocaine binding
without interfering with transport function. The new transporter clones not only
provide templates for drug screening, they may also act as guides in the discovery of
novel neurotransmitters and neuromodulators. With the rapid growth in identified
clones, an equal number of 'orphan' clones has been discovered, with no currently
identified transport substrates. These 'orphans' may uncover new chemical
neuromodulators or new uses for existing compounds. Rapid developments in
molecular understanding of transporters are now poised to enable dramatic advances in
our understanding of synaptic function and in drug design.
In conclusion, the 5-HT transporter has been localised within the rat adrenal medulla.
Staining was also apparent in areas of the cortex, associated with the vasculature.
Pharmacological studies with the 5-HT uptake inhibitors, citalopram and DMI, and the
drug of abuse MDMA, would support a role of the 5-HT transporter within the cortex,
although this needs further clarification. The drug of abuse, MDMA, produced
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elevations in aldosterone and PRA levels in the plasma of rats. These may cause the
side-effects seen with ingestion ofMDMA, or may be secondary to acute hypovolaemia
and hyponatraemia. Further studies will include, studies on the uptake of tritiated 5-
HT into isolated ZG cells and whole capsular tissue, more extensive
immunohistochemical studies and physiological studies within the whole rat to
elucidate a role for the transporter within the gland, and its possible role in depression.
Sodium loading and depletion studies would be interesting to see if the transporter
molecule is regulated within the adrenal by sodium content.
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Chapter Seven
General Discussion and Future Studies.
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7.1. General Discussion
The main aim of this thesis was to establish a role for 5-HT in the control of
aldosterone secretion. 5-HT is well known for its roles as a neurotransmitter and in the
blood clotting cascade but the steroidogenic action of 5-HT in the adrenal gland is an
area of interest that still needs to be defined.
In attempting to clarify a physiological role for 5-HT in aldosterone secretion, it is
necessary to address a few questions. Is 5-HT able to stimulate aldosterone directly?
Does the sensitivity of this aldosterone response to 5-HT increase in states of sodium
depletion? If 5-HT does influence aldosterone secretion, what is the physiological
source of 5-HT reaching the ZG and can this source also be regulated by salt intake?
Are there specific receptors for 5-HT within the rat ZG? Does the 5-HT transporter
have a role to play in the ZG?
Classically, 5-HT has always been thought to be the major indoleamine involved in the
modulation of aldosterone secretion from the zona glomerulosa, a fact that has not
been proven. To resolve this, numerous indoleamines, both naturally occurring and
synthetic congeners, were studied in isolated rat zona glomerulosa cells for their ability
to induce aldosterone secretion, as compared to 5-HT. The rationale behind this study
was two fold, firstly to determine how specific 5-HT-stimulated steroidogenesis is in
relation to other structure-related indoleamines and to define more clearly the
structure-activity requirements for this stimulation in the ZG cells, and secondly to
determine if the metabolites, precursors or intermediates of the 5-HT biosynthetic and
metabolic pathways could give rise to a steroidogenic response.
Of the compounds tested, 5-methoxytryptamine, tryptamine, N-methyltryptamine, 5-
methyltryptamine, 6-methoxytryptamine and 5-hydroxytryptophan stimulated
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aldosterone secretion, to various degrees, from the zona glomerulosa. Of those
compounds tested that produced stimulation of aldosterone comparable to that
produced by 5-HT, cAMP output was also investigated.
The study allowed specific structural requirements for stimulation of aldosterone
secretion to be characterised, namely that the 5-hydroxyl grouping was not required for
full agonist activity but ring substitutions at other positions compromise agonist
activity. The basicity of the terminal amine group is also important in receptor binding.
Compounds lacking both a basic terminal amine grouping and an hydroxy, methyl or
hydroxymethyl grouping at C5 lack aldosterone stimulating activity. This study will aid
in the search for specific agonists and antagonists, to be used for research into the zona
glomerulosa 5-HT receptor. The role of 5-methoxytryptamine, a naturally occurring
indoleamine, within the adrenal gland deserves further investigation.
Unlike the cardiovascular system and CNS, where specific receptors have been
identified and categorised, specific 5-HT receptors within the rat zona glomerulosa
have still to be fully characterised. The second study of this thesis aimed at
characterising these receptors by utilising an array of 5-HT agonists and antagonists.
The antagonists ketanserin and mesulergine were found to inhibit 5-HT-induced
aldosterone secretion, and the agonists 5-methoxytryptamine and 5-
carboxamidotryptamine, produced identical stimulation of aldosterone from rat zona
glomerulosa as that produced with 5-HT. This effect was also found to be affected by
sodium status.
These results taken together with previous studies and preliminary studies with a 5-HT7
probe in sections of rat adrenal gland would suggest the presence of a 5-HT7 receptor
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in rat zona glomerulosa, although the presence of other 5-HT receptors can not be
ruled out. The presence of the 5-HT7 receptor in the rat ZG was confirmed by Contesse
et al., (1999). With the advent of new and more selective antagonist radioligands such
as ["HJ-SB-2669970 (Thomas et al., 2000), this receptor site may be more fully
characterised and the regulation of these receptors within the adrenal cortex may be
more fully investigated.
For 5-HT to have a physiological role in aldosterone secretion, a local source of 5-HT
would be required. In consideration of this, the role of the enzyme L-AAAD in the
local production of 5-HT and dopamine was investigated in rat adrenal zona
glomerulosa in animals maintained on varying sodium diets. The presence of L-AAAD
was located, via immunohistochemistry, in the zona glomerulosa, zona fasciculata and
the medulla. Conversion of 5-HTP to 5-HT and L-DOPA to dopamine was observed
in capsular and medullary tissue preparations; this was inhibited by carbidopa. 5-HTP
significantly stimulated aldosterone secretion, from capsular tissue. This effect was
more apparent in animals on a low salt diet and less apparent in high salt diet animals
than animals maintained on a normal salt diet. The opposite was true for studies with
L-DOPA. The effect of sodium status would suggest that the enzyme is regulated by
salt intake. No significant effect ofL-DOPA and of 5-HTP on corticosterone secretion
from tissue preparations was observed, which could indicate that dopamine and 5-HT
modulate aldosterone secretion through an action on aldosterone synthase. The results
from this study provide evidence for a role for L-AAAD in converting circulating L-
DOPA and 5-HTP to dopamine and 5-HT. This conversion would then act to either
inhibit or stimulate aldosterone secretion from the rat zona glomerulosa. In particular
the concentrations of 5-HTP measured in rat blood were similar to those levels found
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to produce aldosterone secretion both in rat adrenal capsules and rat glomerulosa cells.
So in effect a small regulatory system for aldosterone secretion would seem to exist
within the adrenal gland of the rat, possibly via a feedback loop mechanism.
The presence of L-AAAD within the ZF of the rat adrenal gland requires further
attention. This may be important in corticosterone modulation. Another study would
be to look at 5-HT within the ZF, to elucidate if the indole has any effect within this
region. The putative presence of the 5-HT transporter within the adrenal cortex has
been determined, but as yet no evidence has been shown for the existence of a
transporter for dopamine or L-DOPA. Competition experiments using an inhibitor of
this system, 3-o-M-DOPA may be able to determine the presence of such a system
(Soares-da-Silva et a/., 1994). The possibility of changing intracellular pH as a
mechanism of regulation of L-AAAD could also be investigated. The use of pH-
sensitive fluorescent probes, such as BCECF, on cells taken from rats on differing salt
diets would indicate if pH was affected by salt diet. The effect of manipulating the
intracellular pH of isolated ZG cells on aldosterone biosynthesis, through the use of
such agents such as NH4C1 and Na" proprionate, could then be investigated.
The results of this study suggest that the enzyme L-AAAD, present within the rat
adrenal cortex, may form part of a paracrine or autocrine mechansim for the
modulation of aldosterone secretion by 5-HT and dopamine.
The role of the 5-HT transporter was studied within the rat adrenal gland. The
transporter molecule was visualised throughout the rat adrenal medulla via
immunohistochemistry. The 5-HT uptake inhibitors citalopram and DM1 were
incubated with or without 5-HT in isolated rat zona glomerulosa cells and the resulting
aldosterone secretion was measured. Results varied and this was thought to be due to
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the collagenase digestion process destroying the transporter, therefore whole capsular
tissue was studied in a superfusion system and aldosterone secretion measured. In all
cases, both reuptake inhibitors increased the aldosterone output from capsular tissue.
The drug of abuse MDMA was also used in this system; this compound also caused an
increase in aldosterone secretion. In Vivo studies with MDMA produced interesting
results with an increase in plasma aldosterone and PRA.
From this study, evidence has been found for the existence of the 5-HT transporter
molecule within the rat adrenal gland. MDMA may induce a rise in aldosterone
concentration within the plasma by a direct action on the 5-HT transporter within the
adrenal gland.
In conclusion, the 5-HT transporter has been localised within the rat adrenal medulla.
Staining was also apparent in areas of the cortex associated with the vasculature. This
may be due to trapped platelets, or to the presence of chromaffin cells within the cortex
(Bornstein et al., 1992). Schroeter et al., (1997) reported the presence of the 5-HT
transporter within the rat adrenal medulla and found very intense immunostaining for
the transporter, within the chromaffin granules, at the border between the cortex and
the medulla. They postulate that these cells are readily positioned to regulate
corticomedullary reactions. Pharmacological studies with the 5-HT uptake inhibitors,
citalopram and DMI, and the drug of abuse MDMA would support a role of the 5-HT
transporter within the cortex, although this needs further clarification. The drug of
abuse, MDMA, produced elevations in aldosterone and PRA levels in the plasma of
rats. These may cause the side-effects seen with ingestion of MDMA or may be
secondary to acute hypovolaemia and hyponatraemia. Further studies will include the
uptake of tritiated 5-HT into isolated ZG cells and whole capsular tissue and more
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extensive immunohistochemical studies and physiological studies within the whole rat
to elucidate a role for the transporter within the gland and in depression
This thesis has provided strong evidence for a physiological role of 5-HT in the control
of aldosterone secretion in the rat. 5-HT can be produced locally within the adrenal
cortex and induce aldosterone secretion and this action may be switched on in cases of
low sodium status. Further studies are required to fully characterise the 5-HT receptor,
to elucidate a role for the transporter within the gland and to understand more fully the
importance of 5-HT and indeed dopamine, in the physiology and pathophysiology of
the adrenal cortex.
In conclusion, 5-HT acts in a multifunctional capacity to maintain normal
mineralocorticoid secretion. 5-HT may play a role in the regulation of glucocorticoid
secretion during stress, inflammation and allergic phenomena. The interactions seen
between cortical and medullary tissue may provide crosstalk between the immune
system and the hypothalamo-pituitary-adrenal axis. 5-HT may also play a role in the
physiopathology of aldosterone disorders such as primary hyperaldosteronism. Further
investigations are required to clearly establish the physiological role of the amine but
these studies provide a small insight into the potentially large and now unfolding area of
research into 5-HT and its role in adrenal homeostasis.
And finally, the amine 5-HT is such a diverse agent with many functions, summed up
quite aptly by Bean & Funk (1959)
This man was addicted to moanin';
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Confusion, oedema and groanin';
Intestinal rushes, great tri-coloured blushes;
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